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ABSTRACT
A number of physiologic processes require the expression of smooth muscle alpha
actin (SMαA) to mediate cellular contraction. Stable expression of SMαA in
differentiated vascular smooth muscle cells is associated with a contractile phenotype that
is essential for regulation of blood flow and pressure. The transient expression of SMαA
in myofibroblasts during wound repair facilitates wound closure. Hence, it is no surprise
that dysregulation of SMαA gene expression in both cell types can have pathological
consequences. Indeed, aberrant SMαA gene regulation has been implicated in diseases
such as atherosclerosis and fibrosis. Therefore, a better understanding of the molecular
mechanisms that regulate SMαA gene expression is necessary to uncover the factors
involved in modulating the phenotype of vascular smooth muscle cells and fibroblasts in
diseases affecting blood vessels and connective tissue.
Previous studies have shown that the SMαA gene is regulated by a combination of
transcriptional activators, repressors, and cofactors. Two members of the purine-rich
element binding protein family known as Purα and Purβ have been implicated in the
repression of SMαA gene expression. Both proteins bind to single-stranded, purine-rich
DNA sequences in the SMαA gene promoter with high affinity and specificity. However,
published loss-of-function and gain-of-function analyses suggest that Purβ is the
dominant repressor in vascular smooth muscle cells and fibroblasts. Thus, the principal
objective of this dissertation project was to define the specific molecular mechanism(s)
by which Purβ represses the SMαA gene. This undertaking was made possible by the
prior identification of a functional core region in the center of the protein containing three
regions of internal homology termed repeats I, II, and III. Amino terminal repeats I and II
form an intramolecular DNA-binding domain, while two carboxy terminal repeats III
form an intermolecular dimerization domain. Further analysis revealed that the
dimerization domain is also capable of interacting with purine-rich single-stranded DNA
and is absolutely necessary for the full SMαA gene repressor activity of Purβ.
In this dissertation, experimental findings are presented indicating that Purβ
binding to single-stranded DNA is mediated by both ionic and hydrophobic interactions.
Site-directed mutation of specific positively-charged amino acid residues in each of the
three repeats resulted in reduced repression of the SMαA gene promoter owing to
diminished DNA binding affinity. Mutation of a positionally-conserved arginine residue
in the third repeat had the most significant effect on the function of Purβ. In addition,
biochemical characterization of rare single nucleotide polymorphism-encoded variants of
Purβ revealed that other amino acid changes in the third repeat affect protein-protein
interaction, but not DNA-binding activity. Lastly, evidence is shown indicating that Purβ
inhibits the potent smooth muscle-restricted co-activator myocardin via a novel proteinprotein interaction based mechanism. Interestingly, specific point mutations and
variations in the third repeat impair the ability of Purβ to repress myocardin cofactor
function. Collectively, these studies demonstrate that the third repeat/dimerization
domain of Purβ is essential for full repression of the SMαA gene as specific amino acid
residues in this region mediate both protein-DNA and protein-protein interactions.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW
1. Smooth Muscle Alpha Actin: a Contractile Isoform of the Actin Family
Actins are one of the most abundant proteins expressed in the cell and are wellrecognized for their role in generating force (1). Both protrusive and contractile force are
generated through different mechanisms each involving the activity of actin oligomers
known as actin filaments. Polymerization and crosslinking of actin monomers to the end
of an actin filament mediates protrusion as seen in cell migration (2). Contraction occurs
when actin filaments slide along myosin fibers in the contractile apparatus of the cell (2).
Together these forces enable many cellular events including cell migration, changes in
cell morphology, cell adhesion, and intracellular motility in a variety of cell types (3).
In total, there are six actin isoforms; beta and gamma non-muscle isoforms, three
alpha isoforms expressed in cardiac, skeletal, and smooth muscle, and a gamma smooth
muscle isoform (1, 4). Beta and gamma non-muscle actins are ubiquitously expressed and
contribute to the cytoskeleton. Muscle specific isoforms are primarily associated with
contraction in their respective tissue-type, although low levels and temporary expression
are sometimes observed in other cell types. This is perhaps best represented in an actin
isoform of particular relevance to this dissertation, smooth muscle alpha actin (SMαA),
which is the predominant contractile protein associated with the differentiated vascular
smooth muscle cell phenotype (5, 6). Additionally, transient and low level expression of
SMαA has also been observed in other cell types such as in the early differentiation of
skeletal and cardiac myocytes during their development (7, 8) and in myofibroblasts
1

during wound healing (9). However, independent of the tissue and expression level,
SMαA has an essential role in maintaining cellular homeostasis (10-13).
As a variety of life-sustaining processes are mediated by careful regulation of
SMαA expression, it is no surprise that dysregulation of SMαA gene expression is
directly linked to many pathological states, including atherosclerosis and fibrosis (10-12,
14). Therefore, this chapter will summarize the cellular and biochemical roles of SMαA
in both normal and disease states and discuss the transcriptional and post-transcriptional
mechanisms regulating SMαA gene expression. In particular, the functional role of
purine-rich element binding protein B (Purβ) in the repression of SMαA gene expression
will be examined. Special emphasis will be placed on the known structural features of
Purβ that enable its unique nucleic acid and protein binding properties. Additionally this
chapter will discuss how certain gaps in knowledge about the details of Purβ structurefunction led to empirical studies described in this dissertation.

2. SMαA Dysregulation in Disease
2.1 Vascular Smooth Muscle Cells (VSMCs) and Heart Disease
Cardiovascular disease is the leading cause of death worldwide claiming 17.7
million lives per year (15). While the United States contributes to about 3.5% of these
deaths, cardiovascular disease is also the primary cause of death nationwide responsible
for 1 in 4 deaths (16) (Figure 1-1). The disease encompasses a variety of conditions,
although the primary contributors are linked with atherosclerosis (i.e. coronary artery
disease, stroke, peripheral artery disease, etc.) and are responsible for 80% of global and
2

Figure 1- 1. Cardiovascular disease associated deaths in 2016.
A query of the GDB Compare database depicts cardiovascular disease associated deaths
of individual countries as a percent of the total global deaths due to cardiovascular
disease (19).
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60% of nationwide cardiovascular disease related deaths (15, 17). Within these disease
states, the rupture of an arterial lesion induces thrombosis (18). The formation of a blood
clot results in potentially lethal ischemic injury by occluding the artery and preventing
blood from supplying neighboring tissue with oxygen and nutrients (20). While the clot
may ultimately cause death, the root of this pathology lies not with clot formation, but
rather in lesion formation and development.
Lesion formation and development is complex, involving multiple cell-types,
signaling pathways, and biomolecules. Lesion formation often begins at a young age and
develops over a period of years (21-23). The early stages of the disease are characterized
by changes in the intimal layer of the blood vessel whereby the endothelium becomes
permeable and the underlying ECM changes in structure to enable modified low density
lipoprotein entry and retention (24, 25). In conjunction with endothelial cell damage, an
upregulation of leukocyte adhesion molecules in the endothelium recruits leukocytes,
which upon binding also migrate to the subintimal space where they mature into
macrophages (18). Macrophages in the vasculature phagocytose oxidized low density
lipoprotein to form mature lipid-laden foam cells and release pro-inflammatory mediators
that induce chronic inflammation at the lesion site (26). The accumulation of foam cells
results in the formation of the fatty streak, to which other cells are recruited including T
lymphocytes and vascular smooth muscle cells (18). These and other events induce the
formation of the advanced lesion, which is characterized by the progressive accumulation
of foam cells, macrophages, lipid, and cellular debris from apoptotic and necrotic cells to
form a necrotic core. The core is covered by a fibrous cap composed of vascular smooth
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muscle cells, which secrete collagen, elastin, and glycoproteins(26) (Figure 1-2). Lesions
having a thin fibrous cap where there are few VSMCs and low collagen constitute the
unstable or vulnerable plaque (26, 27). This type of cap is often the result of VSMC
death, accumulation of macrophages, and the release of metalloproteases and other
proteolytic enzymes. Ultimately, the unstable plaque can rupture releasing coagulation
factors into the lumen of the vessel, resulting in clot formation and potentiating death.
While many cell-types have been implicated in atherosclerosis, VSMCs are
notable due to their phenotypic plasticity. In the healthy physiologic state, VSMCs reside
in the medial layer of the vessel wall where they modulate blood flow and pressure
through contraction via an internal contractile apparatus (28). However, in the context of
atherosclerosis, VSMCs transition from a quiescent and contractile state to a highly
migratory and proliferative synthetic state enabling their contribution to both the necrotic
core and the intimally-based fibrous cap as previously described (29). This change is the
result of phenotypic switching which effectively alters many physical properties of the
cell (26, 28-30). Among the most notable are alterations in cell morphology whereby
VSMCs lose an elongated spindle-like morphology and transition to a large rhomboidlike morphology (28). This is accompanied by a reduction in microfilaments associated
with contractile ability, ion channels, and signal-transducing molecules and an increase in
organelles within the cell (28). However, it is important to note that phenotypic
modulation of VSMCs is not bimodal, rather, the process enables activated VSMCs to
adopt a range of phenotypes and functions (31). For instance, VSMCs can express
markers of mesenchymal stem cells, myofibroblasts, and macrophages. One study found

5

Figure 1- 2. Formation of the Advanced Lesion in Atherosclerosis.
The formation of the advanced lesion is marked by the development of a necrotic core
containing foam cells, macrophages, necrotic cells and cellular debris. The core is
covered by a fibrous cap containing VSMCs and thin caps are associated with rupture.
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that 30% of SMCs are macrophage-like, 7% mesenchymal stem cell-like, and 12% are
myofibroblast-like in a mouse model of atherosclerosis, demonstrating that SMCs acquire
multiple phenotypes in atherosclerosis (32) (Figure 1-3).
As VSMCs are capable of adopting range of phenotypes, recent studies have
evaluated the contribution of macrophage-like VSMCs to the atherosclerotic lesion.
Several reports found that a number of cells seen in advanced lesions containing the
macrophage marker CD68+ were of VSMC descent (29, 36). One study showed that
almost 20% of CD68+ cells in the advanced lesion of human patients were of SMC not
myeloid lineage (29). Another report suggests that about 40% of CD68+ cells are SMCnot leukocyte-derived (36). In addition to expressing macrophage markers, macrophages
with VSMC lineage are also capable of accumulating lipid and becoming foam cells (23,
37, 38). In fact, one report states that SMCs contribute to more than half of foam cells in
the lesion (36). Although another study showed that 40% of foam cells within the
necrotic core of an advanced lesion had both SMC and macrophage markers making the
cell origin ambiguous (29, 36). Additionally, some reports have suggested that VSMC
derived macrophages exhibit reduced phagocytic activity which may contribute to the
low clearance of cell debris in the necrotic core (29, 39). Collectively, these lineage
studies suggest that the maladaptive role of VSMCs is in fact widespread, complex, and
not entirely understood.
The loss of contractile VSMC markers appears to have a significant role in
phenotypic switching that occurs during atherosclerosis independent of the “end point”
phenotype. The markers of the quiescent differentiated VSMC include SMαA, smooth
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Figure 1- 3. Phenotypic switching of VSMCs in Atherosclerosis.
VSMCs are known for their phenotypic plasticity and in atherosclerosis VSMCs are
reported to obtain a myofibroblast-like phenotype, macrophage-like phenotype,
mesenchymal stem cell-like phenotype, and a synthetic phenotype. Each of these cell
types contribute to either the growing necrotic core or the fibrous cap. (Images based on:
(33-35))
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muscle myosin heavy chain, myosin light chains, calponin, transgelin, caldesmon,
vinculin, and tropomyosin (28, 30). While no one marker is an adequate indication of the
quiescent, contractile state, the expression of SMαA is of particular interest. During
development, SMαA (encoded by the ACTA2 gene) is the first marker of the
differentiated VSMC that is expressed (28, 40, 41). Additionally, SMαA contributes to
about 20% of total protein within the cell and is the predominant actin isoform expressed
in VSMCs (5, 28, 42). Furthermore, it is required for generating strong contractile force,
a feature that is necessary for VSMCs residing in the medial layer of the vasculature (28,
42). Therefore, an analysis of the factors regulating expression of the ACTA2 gene may
provide insight into the molecular mechanisms that promote VSMC phenotypic switching
and enable the development of effective therapeutic strategies to limit the progression of
atherosclerosis.

2.2 Myofibroblasts and Wound Healing Dysfunction
The wound healing process has been described as having four phases: the
hemostasis, inflammatory, proliferative, and scar formation phase (43, 44). Immediately
following injury, the hemostasis phase is induced as blood coagulation factors become
activated. This results in the formation of a fibrin-fibronectin matrix at the wound site,
which in addition to limiting blood loss, provides a temporary barrier from pathogens,
and provides a matrix for cell adhesion (44). The inflammatory phase is initiated as cells
neighboring the wound site and clot-associated platelets secrete growth factors and
chemokines to recruit inflammatory, endothelial, and fibroblast cells to the fibrin matrix
9

(43, 44). This is followed by the de novo formation and contraction of granulation tissue,
a hallmark of the proliferative phase (34). Granulation tissue, composed of small vessels,
fibroblasts, myofibroblasts, and inflammatory cells, replaces the provisional fibrin matrix
with a stable matrix of collagen, fibronectin, and other proteins (34, 44). In addition, the
granulation tissue replaces injured tissue and provides contractile force to bring wound
edges together (34). Finally, a scar is generated as fibroblasts, myofibroblasts, and
macrophages of the granulation tissue undergo apoptosis (44, 45).
While the formation and contraction of granulation tissue is essential to the
physiologic wound healing state, it is also the primary contributor to several pathologies.
In diseases such as fibrosis and hypertrophic scarring, granulation tissue remains
persistently active supplying additional contraction and ECM components despite wound
closure (46-50). As a result, organs can become disfigured, impaired, and dysfunctional
potentially resulting in death. Within this “endless healing” state, one of the most
influential cell-types is the myofibroblast (34, 48, 50). This is because myofibroblasts are
one of the primary cell types in granulation tissue and are thought to be responsible for
generating the contractile forces needed for wound closure (34). This function is
accomplished through the contractile apparatus within the cell which transduces
intracellular force to the surrounding environment (34). The myofibroblast stabilizes
these forces by secreting ECM proteins such as collagen types I and II (34, 50). As these
cells have an essential role in granulation tissue, a better understanding of their activity
and origin may provide insight into the processes involved in wound healing pathologies.
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Historically, it has been accepted that myofibroblasts originate from the
differentiation of connective tissue fibroblast cells (51). However, many have questioned
whether fibroblast-derived myofibroblasts are the sole contributors to myofibroblasts
observed in granulation and fibrotic tissue (50-52). Studies have reported that
myofibroblasts differentiate from localized cells including smooth muscle cells in
coronary atheromatous plaques (50, 53), keratocytes in the eye (54, 55), perisinusoidal
cells in the liver (56), and pericytes (57). Additionally, the myofibroblast may be derived
from resident and circulating mesenchymal stromal/stem cells, circulating fibrocytes, and
cells of bone-marrow origin (58, 59). While still a highly contested topic, studies have
also suggested that myofibroblasts are derived from epithelial and endothelial-tomesenchymal transition (EMT) (60, 61). Although, many of these alternative sources of
myofibroblasts are still somewhat controversial in regards to their contribution to the
granulation tissue (50, 51).
In spite of the uncertainty surrounding the origin of myofibroblasts in granulation
tissue, the general consensus is still that the majority of myofibroblasts are derived from
localized fibroblast cells (51, 62). With this in mind, the rest of this section will focus on
myofibroblast differentiation from fibroblast cells. In the physiologic state, fibroblasts
reside in the connective tissue where they maintain the integrity of the tissue. However,
following injury, local fibroblasts migrate to the wound and are subjected to mechanical
tension (34). This induces the proto-myofibroblast state which is marked by the
appearance of  and γ nonmuscle actin and the secretion of ECM proteins including
collagen types I and III (34, 50). In the presence of the EDA splice variant of fibronectin
11

and TGF1, the differentiated myofibroblast phenotype is induced and, independent of
cell lineage, is marked by the expression of the contractile protein SMαA (34, 50).
Moreover, inclusion of SMαA into stress fibers within the contractile apparatus
significantly increases the contractile ability of the cell (34, 50). In addition, SMαA
expression is essential for the differentiated myofibroblast remodeling activity (50). As
SMαA protein mediates the activity of the differentiated myofibroblast, further study of
SMαA gene regulation may enable the development of effective therapeutic strategies to
thwart the development of wound healing disorders.

3. Regulation of SMαA Gene Expression
3.1 Transcriptional Regulation
With striking sequence similarities between the human and mouse genes, many
studies have used the murine SMαA gene (Acta2) to characterize transcriptional
regulation of the gene. Expression of the mouse Acta2 gene is regulated by a promoter in
the 5’ flanking region of the gene. Early mapping studies suggested that the functional
promoter includes -1074 base pairs relative to the transcriptional start site and extends
past the start site to include a 2.5 kbp intron. This sequence of DNA contains MCAT,
THR, and TCE elements as well as E boxes, CArG boxes, and a TATA box (63-68).
These cis-regulatory elements are associated with a variety of different activities and will
be discussed below.
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3.1.1 Cis Elements within the Acta2 promoter
E boxes are positive regulatory elements that share a signature motif of CANNTG
and regulate the transcription of muscle, neuron, and pancreas-associated genes (69).
Typically these genes contain multiple E boxes which are the binding sites for
transcription factors with the DNA binding domain described as a basic helix-loop-helix
(70). Among such proteins is E47, which binds to DNA as a dimer and interacts with
both the DNA backbone and DNA bases enabling sequence specific recognition (70).
Another group of E box binding proteins are myogenic regulatory factors (MRFs), which
are known for their role in development and in the differentiation of muscle cells.
Currently four MRFs have been identified: MyoD, MRF-4, Myf-5, and myogenin (69).
Interestingly, in addition to muscle cells, these proteins are also expressed in
myofibroblasts where they are reported to be active and capable of binding to E-boxes
(71). Hence, MRFs may mediate Acta2 transcription in both VSMCs and myofibroblasts
potentially influencing both atherosclerosis and wound healing disease states.
Within the context of the Acta2 promoter, there are 7 E-boxes: E box 1 and 2
reside before -330, E boxes 3 and 4 between -724 and -850, and E boxes 5-7 between 850 and -1074 (63, 64, 72, 73). In vivo transgenic mouse experiments using a promoter
in which E boxes 1 and/or 2 were mutated upstream of a LacZ reporter resulted in
reduced Acta2 transcription, demonstrating that these boxes are likely involved in the
regulation of Acta2 transcription. This finding is also consistent with other musclespecific gene studies, which show that activity is highest when transcription factors can
bind to multiple E-boxes (73).
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Muscle-CAT (MCAT) cis elements are key transcriptional activating elements in
a number of cardiac, skeletal, and smooth muscle specific genes including -tropomyosin
(74), -myosin heavy chain (75), -myosin heavy chain (76), skeletal alpha actin (77),
and SMαA (78, 79). Some of these genes have multiple MCAT boxes while others have
one, a feature that is dependent on both the gene and the host species. The mouse Acta2
promoter contains three inverted muscle CAT motifs. The MCAT element most distal
from the transcriptional start site is the least studied and resides between bp -643 and 638. The other two sites are located at -318 to -312 (MCAT2) and -182 to -176
(MCAT1). Each MCAT element has a consensus sequence of CATTCC, which contains
the binding site for transcription enhancer factor (TEF aka TEAD) family of proteins and
enables transcription of the gene (80).
Cell culture and transgenic mice studies have shown that MCAT has an essential
role in activating Acta2 transcription in both the presence and absence of TGF1
signaling (81, 82). Additionally, these experiments demonstrate that MCAT enhancer
activity is influenced by tissue-type as mutations to MCAT elements result in no
difference, an increase, or decrease in transcription in different cell types (78).
Transgenic mice containing an Acta2 promoter-enhancer-Lacz reporter gene were
evaluated when mutations were made to both MCAT elements 1 and 2 (82).
Interestingly, these mutations had no effect on Acta2 transcription in adult VSMCs, but
they eliminated Acta2 transcription in myofibroblasts of the granulation tissue (82).
Further study showed that in early development of the embryo up to day E12.5, Acta2
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transcription is dependent on MCAT 1 and 2. This suggests that some tissues have a
temporal requirement for the MCAT cis elements in Acta2 regulation.

The CArG box is a key functional sequence within the center of the serum
response element of the c-fos promoter (83). Studies have also shown that CArG
elements are required for the transcription of many muscle-specific genes (83). This
includes markers of the differentiated SMC phenotype, namely the contractile proteins
smooth muscle myosin heavy chain, caldesmon, telokin, and SMαA each of which have
two or more CArG boxes. The Acta2 gene contains five CArG boxes with four existing
in the 5’ flanking region of the gene, CArGD (-195 to -204), CArGC (-163 to -172),
CArGB (-111 to -120), CArGA (-61 to -70), and one intronic CarG (65). While the
consensus sequence is [CC(A/T)6GG], the CArG boxes of the Acta2 gene are degenerate
with varying bases in the middle of the consensus sequences (84, 85). This feature is
commonly observed in genes encoding smooth muscle specific proteins and enables
smooth muscle specific gene regulation (86). Independent of muscle-type, serum
response factor (SRF) binds to both c-fos derived consensus CArG elements and
degenerate CArG elements (86). So it is thought that the smooth muscle specific
coactivator, myocardin, and epigenetic modifications to CArG-containing chromatin
mediate smooth muscle specific expression (85, 86).
To identify CArG elements that are essential in Acta2 transcription, Acta2
promoter constructs extending to -125 bps were generated upstream of a reporter and
evaluated in SMCs. Results of the assay showed CArGA and B are required for full
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expression (72). Separate studies showed that mutation of an intronic CArG box
obliterated expression, suggesting that the intronic CArG also functions as an essential
enhancer (87). While the role of CArG is best defined in muscle cells, studies have also
evaluated the role of CArG in the Acta2 gene in myofibroblasts of the granulation tissue
and found that mutation of the intronic CArG box inhibited Acta2 transcription as well.

TGF1 hypersensitivity region (THR) and TGF1 control element (TCE) are
required for basal expression of the Acta2 gene and are essential for TGF1-mediated
upregulation of gene expression (67, 88). THR has a consensus sequence of
CAGGCCTCTGG and is located at -162 to -152 (68, 88). The TCE consensus sequence
is TGGGAGGGG and is located between base pairs -52 to –44 (67). TCE is the binding
site for transcription factors Sp1 and Sp3 (89). In myofibroblasts of the granulation
tissue, TCE in combination with the intronic CArG element are required for Acta2
transcription. Similarly, in VSMCs TCE in combination with CArG boxes induces Acta2
transcription in the presence of TGF1 (67).

Perhaps the most well-known cis-element is the TATAA box. The TATAA box
is often 25-35 bp before the transcriptional start site and has a consensus sequence of
TATAAA and TATATA. The transcription factor, TFIID binds to the TATA box in the
minor groove of DNA with nanomolar affinity (90). This induces DNA bending and the
assembly of the pre-initiation complex of RNA polymerase II (91-93). Collectively, these
events facilitate the transcription of the gene at the transcriptional start site. Importantly,
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the transcriptional start site of the mouse Acta2 gene is reported at the first G in the
GGGACAC sequence, which we will use in the context of this dissertation (65).
However, other sources report that the transcriptional start site begins one nucleotide later
at GGACAC.

Transfection of vectors encoding the full length Acta2 promoter upstream a
reporter results in low levels of reporter expression in both fibroblasts and smooth muscle
cells (63, 81, 94, 95). To identify the minimal promoter, mapping studies were
performed using multiple truncated forms of the promoter upstream of a reporter which
were then transfected into cells (63, 65, 81, 95). The promoter construct extending from 191 to +46 (VSMP4) relative to the transcriptional start site had highest expression far
exceeding all other constructs in both fibroblasts and VSMCs (63, 81, 95). This sequence
contains an MCAT element proximal to the 5’ end followed by two CArG boxes known
as CArGB and CArGA, respectively.

A 2 base pair transversion mutation within in the

center of the MCAT element significantly reduced activity, suggesting that MCAT is an
essential enhancer in the Acta2 promoter and that these central base pairs have a
significant role (81, 88). Additionally, mutation of CArGB and CArGA lead to a
reduction in activity with lower levels of transcription observed in the CArGB mutant
(80, 81, 88, 95). This suggests that MCAT, while necessary, is not sufficient to induce
transcription and requires both CArG boxes, with CArGB having a greater effect than
CArGA in both fibroblasts and smooth muscle cells (81). Subsequent experiments also
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evaluated the role of TCE and THR in the minimal promoter and found that mutations in
either cis-element impaired the activity of the minimal promoter (88).
Interestingly, an addition of 4 base pairs to the 5’ end ablates expression of
VSMP4 in both fibroblasts and VSMCs (63, 81). This suggests that base pairs -195 to 191 are important contributors to the negative regulation of the Acta2 gene perhaps
enabling the binding of a transcriptional repressor. The base pairs between -195 to -191
are GGGA. Mutation of the sequence to GTTA along with other residues such as purines
at the 3’ flanking region of the MCAT element appear to restore minimal promoter
activity in fibroblast cells (81). However, in smooth muscle cells these mutations only
partially restore the minimal promoter activity (81). Together these findings suggest that
the bases GGGA are essential in the negative regulation of the Acta2 gene, but suggest
that different mechanisms govern repression in different cell types.
As TGF1 signaling potently induces activation of genes encoding contractile
proteins, additional experiments evaluated the activity of the minimal promoter following
exposure of cells to TGF1. Consistent with previous findings, TGF1 was able to
induce robust transcriptional activity of the minimal promoter (88). To identify the
contribution of individual cis-elements, promoters with mutations in CArGA and B,
MCAT, THR, and TCE were generated and evaluated in a promoter-reporter system (67,
88). As perhaps expected, each of the mutated promoters were impaired in their response
to TGF1 exposure, suggesting that each element is required for full promoter activity in
both the presence and absence of TGF1 (67, 88). However, one particularly notable
finding was that mutation to the THR element resulted in minimal TGFB1 activation,
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suggesting that this one element is the most important in TGF1-mediated induction of
gene expression (88).

3.1.2 Transcription Factors that regulate Acta2 expression
Trans-acting Activators
In light of promoter mapping studies, it is not surprising that the Acta2 gene is
regulated by combinatorial interactions of activators and repressors (Figure 1-4). These
proteins mediate activation and repression of gene expression through direct association
with DNA target sites and through association with other proteins. Transcriptional
activators include TEF-1, SRF, Myocd, Sp1/3, and Smad2/3, which will be discussed
below.

Transcription Enhancer Factor 1 (TEF1)
The TEF family members are regulators of muscle-specific genes and have an important
role in muscle development and disease (79). These transcription factors bind to double
stranded MCAT elements in the DNA with the sequence of 5′-CATTCC-3′ (96). DNA
binding is mediated by the TEA domain which is composed of a three helix bundle with a
homeodomain fold (79, 97) (Figure 1-5). This feature is shared by all four members of
the TEF-1 family: TEF-1 (NTEF-1/Tead1), RTEF-1 (TEF-3/ETFR-2/FR-19/Tead4), ETF
(TEF-4/Tead2), and DTEF-1 (TEF-5/ETFR-1/Tead3) with their alternate names in
parenthesis (79). TEF-1, DTEF-1, and RTEF-1 are found in a variety of tissue types,
while ETF is restricted to a subset of embryonic tissues (98). Protein activity is dependent
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Figure 1- 4. Regulation of Acta2 transcription.
The Acta2 promoter is regulated in a dynamic manner through combinatorial interactions
of activators and repressors. Additionally, these transcription factors modulate activity
through direct binding to cis-elements in both the promoter and coding region of the
gene.
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Figure 1- 5. Activators of the Acta2 gene.
Some of the most notable activators of the Acta2 gene are TEF family proteins (PDB:
5NNX), Smad 2/3/4 (Smad3 PDB: 1MHD), serum response factor (PDB: 1SRS),
myocardin, and specificity proteins. Each of these proteins is unique in both function and
structure and this figure highlights some of the structural differences between these
proteins.
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on the tissue type with RTEF-1 inducing transcription in myofibroblasts and embryonic
SMCs, but not in adult differentiated SMCs (82). Quantitative chromatin
immunoprecipitation revealed that RTEF is the pre-dominant protein bound to MCAT in
the Acta2 promoter in myofibroblasts (82). While TEF-1 appears to be the major protein
bound to MCAT elements in differentiated SMCS (82). Furthermore, when the SMαA
protein is not expressed there is an absence of TEF family members binding to the Acta2
gene, suggesting that the binding of TEF proteins are important for Acta2 transcription
(82).
In addition to DNA binding, TEF family members have also been shown to
mediate Acta2 transcription through association with a number of different proteins (79).
One recent study has suggested that TEF1 is capable of disrupting Myocd binding to SRF
effectively acting as an inhibitor of Acta2 transcription (96).

Serum Response Factor (SRF)
SRF was first discovered and named for its ability to induce c-fos gene expression
in the presence of serum (99). Since then SRF has been detected throughout the body
with high expression in muscle and has been shown to influence gene expression in a
number of cell types (100, 101). SRF modulates the transcription of genes that regulate
cell proliferation (100-102), neuron migration and circuit assembly (103, 104) and
development and maintenance of SMCs and cardiac cells (100, 105, 106). SRF is
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associated with activation of both muscle-specific and growth factor inducible genes (99).
SRF is one of four founding members of the MADS family (MCM1, AG, DEFA,
and SRF). Each member contains an N-terminal MADs box that is composed of 56
amino acids with 9 identically conserved amino acids. The MADS box enables highly
specific protein-DNA interactions and differences in the 47 non-identical amino acids of
the MADS box facilitates unique DNA binding specificities (107). The C terminus
enables SRF dimerization prior to binding to double-stranded CArG boxes of DNA (99).
However, dimeric SRF has low transcriptional activity, therefore formation of higher
order complexes leads to potent co-transactivation of contractile protein genes (81, 108,
109).
To date there are 4 isoforms of SRF: SRF-M, SRF-L, SRF-S, and SRF-I (110).
SRF-L was the first isoform to be identified and is considered to be the full length
protein. The other isoforms are products of alternative splicing, in which SRF-M has
exon 5 spliced out, SRF-S has exons 4 and 5 spliced out, and SRF-I has exons 3, 4, and 5
spliced out (110). In each case, this results in the loss of some of the C-terminal
transactivation domain (110). Within the context of adult muscle tissues, SRF-I is
irrelevant as it is only expressed in the embryo and there acts as the dominant negative
form of SRF. In both differentiated smooth muscle and skeletal muscle, SRF-M and L
are expressed at similar levels and transactivate contractile protein encoding genes such
as SM22alpha/transgelin, with L having higher activity than M (110).
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Myocardin (Myocd)
Initial identification and characterization of Myocd revealed that Myocd is a
relatively large protein composed of 807 amino acids (111). The protein contains a
centrally located leucine-zipper motif, which mediates Myocd dimerization (112). The Cterminus is also necessary for high transcriptional activity, which is observed with a
terminal 300 bp deletion (111). The N-terminal domain contains both a basic and
polyglutamate region, which is thought to mediate the binding of Myocd to the MADS
domain of SRF (113). Additionally, the N terminus contains a SAP domain, which is a
common feature in transcription factors that enables changes in gene architecture (111).
Later studies revealed that there are a total of five isoforms of Myocd (114). The
original isoform is known as variant 5 (V5) and is found in embryonic and adult smooth
muscle cells (SMC) (115, 116). The other isoforms are products of alternative splicing
and include the addition of 128 amino acids to the N terminus of the protein and the
insertion of 48 amino acids from exon 10a (114). Myocd V1 and V2 are cardiac isoforms
with an MEF2 binding domain and extended N terminal domain (114). V1 has a 48
amino acid insertion from exon 10a while V2 does not (114). Myocd V3 and V4 are
SMC isoforms and have amino acids encoded by exon 2a, which also encodes an inframe stop mutation truncating proteins by 79 amino acids at the N terminus compared to
the full-length protein (114). V3 is more abundant than V4 and encodes the 48 amino
acids from exon 10a while V4 does not have this sequence element.
As Myocd expression is restricted to cardiac and SMC, Myocd enables cardiac
and smooth muscle-specific gene activation (112). In fact, Myocd is believed to be the
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dominant cofactor in mediating the differentiation of VSMCs. Studies have shown that
overexpression of Myocd in SMCs results in reduced cell growth and induced expression
of marker genes of the contractile phenotype including Acta2 and smooth muscle myosin
heavy chain (Myh11) (117, 118). Furthermore, Myocardin invokes a potent
transcriptional response in multiple CArG-containing target genes, which has led to it
being described as “the master regulator of the smooth muscle gene expression” (111,
112). While Myocardin activation is linked with CArG boxes in contractile genes,
studies have shown that Myocd does not bind to CArG elements directly (111). Instead,
Myocd binds to the trans-activator SRF to induce potent co-activation (112).
Furthermore, Myocd dimerization elicits cooperative gene activation.

Specificity Proteins (Sp)
There are four members of the specificity protein (Sp) family termed, Sp1, Sp2,
Sp3, and Sp4. These proteins enable a variety of processes including cell cycle
regulation (119), activation of housekeeping genes (120), chromatin remodeling,
transcriptional activation, and proliferation (119). Sp1 and Sp3 are ubiquitously
expressed and modulate these activities in a range of tissues, while Sp4 is restricted to
neuronal tissue, and Sp2 is observed in cultured cells (120). Therefore, Sp1 and Sp3 are
the most relevant isoforms in studying Acta2 regulation in both VSMCs and
myofibroblasts. Sp1 binds to GC boxes with a DNA binding domain consisting of three
zinc fingers at the carboxy terminal end (119, 120). This binding is associated with strong
transcriptional activation and a synergistic effect is observed when Sp1 binds to multiple
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sites (121). Conversely, reports have indicated that Sp3 varies in function and can act as
a strong activator (122-124) or repress activation by Sp1 (125-127). This range in
activity is believed to be due to a number of different factors including the structure and
arrangement of DNA binding sites with weak activation being associated with Sp3
binding to multiple sites (128). Additionally, the cell type and environment may also
contribute to the differential roles of Sp3 (120). Finally, as Sp3 functions as a weak
activator, repression is attributed to competition with Sp1 for binding sites in the
promoter (120, 126).
Sp1/3 are necessary for Acta2 transcription in myofibroblasts (88, 89) and bind to
a site required for TGFB1 signaling, the TCE element (88, 89). Overexpression of Sp1
appears to facilitate higher transcription than overexpression of Sp3 with the Acta2
VSMP4 promoter construct and overexpression of Sp3 may limit Sp1 binding to DNA
(88). Lastly, Sp1 and Sp3 association with Smad proteins increases the transcription of
Acta2 (88).

Small Mothers Against Decapentaplegic (Smad) proteins
During wound healing, TGF1 signaling induces the potent activation of Acta2 in
myofibroblasts. Mechanistically, TGF1 binds to type 2 transmembrane serine/threonine
kinase receptors (129), which recruits type 1 receptors to form a multimeric
transmembrane complex. This complex then associates with cytosolic receptorregulated Smads, namely Smads2 and 3 (129-131). Dimeric forms of these R-Smads
associate with monomeric Smad4 to form a ternary complex that translocates to the
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nucleus and interacts with specific sequences of DNA to enable positive and negative
regulation of genes (129, 131). Studies have shown that Smad3 and Smad4 bind to
recognition sites containing 5′-AGAC-3′ through a N-terminal Mad-homology (MH)
domain termed MH1 (131-134). However, Smad proteins bind to DNA with low
affinity, requiring Smads to associate with other transcription factors to mediate high
affinity interactions with DNA (129). Similar to DNA binding, protein interaction is
mediated by a second MH domain termed MH2 at the C-terminal end (131).
In the regulation of Acta2 expression, several putative Smad2/3/4 binding sites
have been suggested within the THR cis-element (89). Overexpression of Smads2 or 3 in
combination with Smad4 increases transcription, though expression of all three result in
higher transcriptional activity of VSMP4 in fibroblasts (88). Additionally, a combination
of both Smads and Sp1 increases transcription of VSMP4, although the effect is not
additive (88). Conversely, when Sp3 is combined with Smads, transcriptional activity is
lower (88).

Trans-acting Repressors
Three distinct, single-stranded nucleic acid-binding proteins have been identified
as repressors of Acta2 transcription in both fibroblasts and VSMCs. These repressor
proteins include Pur, Pur, and MSY1, which preferentially bind to either purine- or
pyrimidine-rich single-stranded DNA (ssDNA) sequences in the Acta2 promoter. Many
studies have characterized their binding and repressor activity in relation to ssDNA
sequences flanking and central to the MCAT cis element and linked them to the marked
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repression of the minimal promoter with the addition of 4 base pairs. Though repressor
binding is not limited to this location and has been observed at other regions of the gene.
As these proteins are not redundant in function, their unique structural and functional
features will be highlighted below.

Mouse Y-box binding protein 1 (MSY1)
MSY1 is a class I of III Y box protein and depending on the organism is given
different names; MSY1 (mouse), YB1 (human) (135). Independent of species, the
proteins share a similar structure and function. Structural features include a cold shock
domain, a disordered A/P rich N terminus, and a disordered C terminus with localized
regions of positive and negative charge (135). Among the many biological roles of
MSY1 are contributions to cell proliferation, differentiation, and stress response. These
functions are enabled by the molecular activity of MSY1, namely binding to pyrimidinerich ssDNA and RNA, which enables contributions to DNA replication, transcriptional
repression, DNA repair, pre-mRNA splicing, and mRNA translation (135). In the
repression of the Acta2 gene, MSY1 binds directly to DNA in regions surrounding the
MCAT element (bp-194 through -1165) and interacts with other proteins. However, in
the presence of TGF1 or Smads 2/3/4, YB1 dissociates from the Acta2 promoterenhancer (136).
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Pur Protein Family
The purine-rich element binding proteins are a family of nucleic acid binding
proteins that preferentially interact with purine-rich ssDNA or RNA. The family consists
of 4 members; Pur, Pur, PurγA, and PurγB, which are encoded by different genes on 3
different chromosomes at 3 different loci in humans (PURΑ: 5q31 (137), PURΒ: 7p13
(138), PURG: 8p11 (139, 140)). Within the family, some unusual patterns of gene
expression have been observed specifically in regards to Pur and Purγ transcription.
Purα is regulated by 3 promoters with distinct and widely-separated transcriptional start
sites (141). While Purγ has one transcriptional start site, the production of PurγA and B
is atypical. The transcription of PurγB proceeds through the PurγA termination site and
PurγB mRNA is spliced to remove an intron encoding C-terminal residues of PurγA
(139).
Primary sequence alignment of human Pur proteins indicates that the average
length of these proteins is 326 amino acids and that 126 amino acids are identical and 61
amino acids are similarly conserved. Additionally, each member contains repeating acidic
and basic sequences and three distinct regions of internal homology within the center of
the primary sequence. Glycine, the most abundant amino acid in each member of the
family, contributes to a glycine rich N-terminus present in all four proteins. The Cterminus is less conserved and an amphiphatic helix, known as the Psycho motif, is found
in all proteins, except for PurγB (142).

Following the Psycho motif, is a glutamate-

aspartate rich tail that is only shared by Purα and Purβ (142).
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Functionally, all four proteins have been shown to regulate the transcription of a
number of different genes. Pur proteins act as transcriptional regulators by binding to
purine-rich nucleic acid and by interacting with other proteins, though DNA binding
ability has been best characterized. One of the early studies characterized a DNA binding
site, namely a region 1.6 kb upstream the human c-myc gene, close to a zone of initiation
for DNA replication (143). This region contains a consensus sequence of
GGNNGAGGGAGARRRR and has been named the PUR element (143). Additional
evaluation revealed that PUR elements are present at origins of replication and gene
flanking regions from yeast to humans (143). Since then the Pur proteins have been
shown to bind to other purine rich sequences in both ssDNA and RNA including regions
in the Acta2 promoter, alpha myosin heavy chain promoter, and mRNA associated with
both genes (144, 145).

Purine-rich element binding protein A (Pur)
In one of the early studies of Acta2 regulation, proteins associated with the VACssBF2
(vascular actin single-stranded binding factor 2) complex were reported to bind to purinerich ssDNA near the MCAT cis-element (66). These proteins were later identified as
Pur and Pur (146, 147). Since that time, Pur has become the most studied and well
characterized protein within the Pur family in terms of biological function, protein
structure, and biochemical activity (140). Purα is ubiquitously expressed across human
tissues with highest expression in the brain and endocrine tissues (148, 149). Similarly,
mouse gene knockout models have indicated that expression of Pur is essential in the
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development of the post-natal brain (142, 150, 151). To date, two knockout studies have
been performed, the first demonstrated that the homozygous knockouts died 21 to 25
days following birth, after developing tremors, limited mobility, and uncoordinated
movement (151). Evaluation of the nervous system revealed that the numbers of Purkinje
cell neurons, cerebral neurons, and hippocampal neurons were reduced. Further study
also showed that there was a decrease in the number of synaptic connections in the
hippocampus (142, 151). The second study showed that mice presented with a persistent
tremor and fewer numbers of Purkinje cells in the cerebellum, although these mice died
at six months of age (142, 150). These studies both demonstrate that Pur is essential to
neuronal development in the mouse.
Human Pur is 322 amino acids long with a molecular weight of 34, 884 Daltons.
The primary sequence of Pur contains a notably glycine rich N-terminus with 30 of 60
residues being glycine and with an uninterrupted stretch of 20 out of 23 glycines (140).
The regions of internal homology include residues 61-122, 142-203, 204-279 in the
mouse species. Additionally, the acidic regions span residues 107-131 and 195-220 and
basic regions span residues 66-88, 148-170, and 224-245 with the psycho motif residing
between residues 295-332 (142, 152). Unique to Purα is the presence a glutamine-,
glutamate-, and aspartate- rich C-terminus.
Pur often functions to negatively regulate the expression of a gene. This has
been well characterized in the context of Acta2, but is also evident in the modulation of
amyloid-B protein precursor, CD43, alpha myosin, fas, gata2, and somatostatin (153).
Additionally Pur has the ability to negatively regulate its own expression (153). This
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activity can be attributed to association of Pur with DNA, RNA, and other proteins.
Among the proteins that Purα has been reported to bind, there are several transcriptional
factors that regulate contractile protein expression such as Sp1 (154), YB-1 (155), Smad
proteins, as well as cell cycle regulators such as the retinoblastoma protein (156) and
E2F-1 which regulates cell proliferation (157). However, while many of these
interactions are involved in repression of gene expression, Pur has also been linked with
upregulation of gene expression. Pur has been reported to act as a transcriptional
activator in the regulation of genes encoding myelin basic protein, B2-integrin, placental
lactogen, CD11c beta-2 integrin, TGF1, neuron-specific FE65 protein, and PDGF-A
(153).

Purine-rich element binding protein B (Pur)
Like Pur, Pur is a well-established transcriptional regulator directly involved in
the negative regulation of Acta2 transcription. An analysis of Pur and Pur primary
sequence reveals that both proteins share a 71% sequence identity (147). Among the
differences is the location of acidic and basic regions which are similar, but not identical
(146). The basic regions of Pur reside between amino acids 38-87, 136-186, 237-263
and are interrupted by acidic regions from amino acids 88-135 and 187-236 (158). Other
differences involve the glycine-rich N-terminal domain, which has 11 out of 31 residues
being glycine, far fewer than Pur. However, glycines are still the most abundant amino
acid in Purβ, with many glycine stretches residing in the central regions of the protein.
Lastly, the glutamine-rich stretch is missing from the C-terminal GED stretch (140).
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Pur mRNA is expressed throughout human tissue at modest levels, with highest
expression being localized to the brain and endocrine tissue (148, 149). Within the
published literature, Purβ knockouts have not been reported making physiologic
contribution difficult to determine. To date, Purβ has been linked to two disease states;
cancer and heart failure. In cancer, Pur ssDNA-binding activity is enhanced in
malignant cells isolated from patients with acute myelogenous leukemia (159).
Separately, another report found that Pur and not Pur was elevated in an individual
with heart failure (144). Despite these intriguing findings, the specific role of Pur in
cancer and heart disease is not known.

Purine-rich element binding protein G (Purγ)
PurγA and PurγB are the least studied members of the Pur protein family (142).
Primary sequence alignments reveal that PurγA and PurγB are 85% identical and 87%
similar to each other. The major difference between the two proteins is at the C-terminal
end, which is due to a unique post-transcriptional processing mechanism that involves
differential termination and polyadenylation as described above (139, 142). Compared to
Pur, PurγA and PurγB are 56% and 48% similar respectively. However, both proteins
retain many of the primary sequence features shared by Pur and Pur. This includes
repeating acidic and basic regions and three regions of internal homology, though neither
aligns perfectly with Pur and Pur. The glycine-rich N terminus is also conserved
although the proportion of glycine residues is lower than Pur with 13 out of 57 amino
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acids being glycine. Lastly, only PurγA contains a Psycho motif near the C-terminus and
neither PurγA or PurγB contains a glutmate-aspartate rich C terminal end.
Biologically, Purγ mRNA expression appears limited across tissues with highest
expression observed in the brain, reproductive tissues, and smooth muscle (148, 149). Of
these, Purγ expression has been best characterized in the development of pre-natal brain
from e14 through day p1 (142). Other studies have evaluated PurγA in pathological
states, as expression is associated with the formation of tumors (142).

3.2 Post-Transcriptional Regulation
Several studies have suggested that SMαA expression is also positively and
negatively regulated through post-transcriptional mechanisms. One instance of positive
regulation is in Dupuytren contracture. While physiologic and pathogenic
myofibroblasts have equivalent SMαA mRNA levels, SMαA protein is higher in the
disease state theoretically due to mRNA modulation (160). Conversely, negative
regulation has been observed under a variety of circumstances including one study which
found that glucocorticoids, a class of corticosteroids, modulate SMαA expression in
airway smooth muscle cells in part by preventing translation of mRNA (161). Another
group suggested that SMαA mRNA is modulated by other proteins within the cell,
reporting that disorganization of actin filaments is linked with downregulation of SMαA
protein (162). Similarly, platelet derived growth factor is thought to destabilize SMαA
mRNA, limiting protein expression (163).
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In spite of these findings, it is not known whether there is a balance between both
post-transcriptional and transcriptional regulatory mechanisms or if one dominates. One
study suggests that the occurrence of Acta2 gene regulation at the transcriptional or posttranscriptional level is mediated by the environment with transcriptional regulation taking
place in the aortic ligature in vivo and post-transcriptional regulation in cultured primary
cells (164). Another study found that multiple factors (Pur, Pur, MSY1) implicated in
the repression of the Acta2 promoter also bind to mRNA encoded by exon 3, suggesting
that Acta2 transcription and translation may be interconnected and utilize similar
regulatory mechanisms (145).

4. Purβ in SMαA Gene Regulation
While both Pur and Pur are similar in structure and function, studies have
suggested that Pur is the dominant repressor of Acta2 transcription in fibroblasts and
VSMCs.

4.1 Purβ Repression in Cells
To evaluate the cellular role of Pur, gene knockdown experiments were
performed in mouse embryonic fibroblast cells (165). Knockdown of Pur expression
using short hairpin RNAs resulted in an increase of SMαA mRNA and protein expression
(94, 165). Additional analyses included transient transfection of knockdown cells with
plasmid DNA constructs containing either full length or truncated Acta2 promoter
sequences upstream of a reporter gene. As expected, deficiency of Pur had no effect on
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the unrestricted VSMP4 promoter-enhancer in fibroblasts (94). However, promoter
constructs containing an intact 5’ Pur binding site were activated in Pur knockdown
fibroblasts by about 4 fold (94). Interestingly, the activity of the full length promoter
construct (VSMP8) -1074 was enhanced by about 2 fold in Pur knockdown fibroblasts
(94). However, knockdown of either Pur or Pur led to an equivalent increase in the
Acta2 promoter-reporter activity in VSMCs (94). These findings suggested that Pur
plays an important role in Acta2 repression and that mechanisms governing Pur/dependent regulation of Acta2 may be cell type-dependent.
Conversely, studies have also evaluated the effect of Pur protein overexpression
on SMαA expression. Overexpression of Pur in A7r5 VSMCs resulted in virtual
ablation of VSMP8 activity across a range of cell culture conditions which included
treatment with serum free medium, medium with fetal bovine serum, and medium with
TGF1 (94). Additionally, overexpression of Pur also greatly repressed the VSMP4
reporter in A7r5 cells. Furthermore, repression of VSMP8 and VSMP4 by Pur was
significantly greater (by 5 fold) than Pur in VSMCs.(94) However, in AKR2B
fibroblast cells, the effects of Purα and Purβ overexpression were nearly equivalent in
terms of repression of VSMP4. Taken together, both loss-of-function and gain-offunction studies, point to Pur as the dominant repressor of Acta2 transcription
particularly in VSMCs (158).
Pur has also been shown to repress or enhance the activity of other transcription
factors. Overexpression of Pur appears to repress the activity of trans-activators such as
TEF1 and SRF (158). Other experiments also demonstrated that combinations of Pur
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with MSY1 increased the level of repression of the VSMP8 promoter as compared to
Pur alone (158). As MSY1 repression at a number of different concentrations alone
was minimal, these studies suggested that Pur activity enhances the activity or enables
the full function of MSY1 (158). Taken together, these cell-based studies indicate that
Pur has a strong repressor role in a number of different cell types and is the dominant
repressor of Acta2 compared to both Pur and MSY1.

4.2 Purβ binding to the Acta2 promoter
An early seminal study identified a binding site for Pur termed the PUR
element with the consensus sequence GGNNGAGGGAGARRRR, which was located at
origins of replication and gene flanking regions in the genomes of yeast to humans (143).
Since then, Pur and Pur binding to DNA has been further characterized in several
different sites in various gene promoters. The common feature of Pur function remains
the preferential and high affinity binding to purine rich sequences of ssDNA. In fact,
methylation interference maps suggest that a series of guanines are points of contact by
Pur proteins (143). Within the Acta2 promoter, a number of such sequences are
interspersed throughout the promoter residing either in or near consensus cis-elements for
double-stranded DNA (dsDNA)-binding transcription factors.
Two Pur monomers bind to multiple purine-rich sites encompassing and internal
to a core MCAT cis-element in a sequential and cooperative manner (166). This
sequence element, dubbed PE32-F, resides in the Acta2 promoter between nucleotides 37

195 and -164 and contains a central consensus MCAT motif (italics) and two flanking
PUR elements (underlined) (PE32-F: 5’GGGAGCAGAACAGAGGAATGCAGTGGAAGAGA-3’). Binding to a “GGGA”
sequence at the 5’ end may be most significant as this is associated with potent repression
of the Acta2 promoter in fibroblasts and VSMCs. To further characterize the role of each
purine-rich stretch in PE32-F, these regions were mutated to pyrimidines and analyzed
using DNA binding competition assays. As expected, mutation of the PUR element at
the 5’ end to 7 thymines impaired Pur binding to the PE32-F element (166). Individual
mutation of the core MCAT motif and the 3’ PUR element had less of an effect,
highlighting the importance of the purines in the 5’ flanking region (166). However,
combinatorial “double” mutants of both the 5’ end PUR element with either the 3’ PUR
element or the central MCAT further impaired Pur binding to PE32-F and mutation of
both the 3’ and the central purine-rich sites led to a dramatic decrease in Pur affinity for
the probe, collectively confirming the contribution of these other purine-rich sites to Pur
binding (166). Additional support for their role was observed by the virtual absence of
Pur binding to a probe with mutation of all three regions (166). Taken together, these
findings suggested that purines in the 5’ flanking region of the probe are vital to binding,
and act in combination with the 3’ PUR element and perhaps the core MCAT element to
enable the high affinity binding of Pur.
Other reports have identified additional Pur binding sites in the Acta2 promoter.
These sequences include the SPUR motif, which encompasses the TCE cis element and
extends from base pairs -29 to -60 (89). Binding has also been characterized at the
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reverse single-stranded THR element, in which Pur binds with an apparent Kd of 18.3 ±
1.6 nM compared with Pur, which binds to THR with a Kd of 6.1 ± 0.9 nM (94). Other
suggested sites include regions in or near the THR and TCE cis-elements, around the
MCAT motif, and regions in or flanking CArG boxes A and B (166). Pur may also bind
around an upstream element (-218 to -210) as suggested by DNase footprinting assays
(166). Finally, in addition to binding to purine-rich regions surrounding canonical ciselements in the promoter, Pur also binds to purine-rich regions in the mRNA encoded
by the Acta2 gene. More specifically, Pur has been shown to bind to purine-rich
sequences corresponding to exon 3, where it is thought to repress translation of the
sequence (144).
In addition to binding to single-stranded purine-rich nucleic acid, Pur and Pur
also associate with dsDNA. In this context, these proteins facilitate helix destabilization
(167-169). This phenomenon was first observed in Pur after an incubation with an 18
bp double-stranded oligonucleotide, which resulted in the generation of separated ssDNA
strands (167). Further evaluation revealed that helix unwinding was independent of ATP
and observed in short double-stranded oligonucleotides, long linear double-stranded
oligonucleotides, and supercoiled DNA containing purine-rich sequences (167, 168).
This unwinding ability is thought to be dependent on stable interactions between the
protein and purine-rich DNA, which is supported by experiments that have mutated
amino acids implicated in DNA binding and resulted in impaired unwinding (168, 169).
Interestingly, ability of Pur to unwind dsDNA is not as effective as Pur, as Purβ was
unable to unwind linear dsDNA (168). However similar to Pur, Purβ was able to
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destabilize supercoiled DNA perhaps suggesting that mechanisms involved in the
destabilization of supercoiled DNA and the unwinding of linear dsDNA are not entirely
redundant (168).

4.3 Purβ association with other proteins in absence of DNA.
While Pur is best-known for high affinity binding to purine-rich ssDNA, Pur
also interacts with a number of different transcription factors. At the most basic level,
Pur self-associates to form homodimers in both the presence and absence of DNA (166,
170). Similarly, it has been suggested that Pur interacts with Pur to form heterodimers
(81, 171). These heterodimeric complexes have only been identified in the presence of
purine-rich ssDNA, therefore additional experiments are needed to determine if Pur and
Pur interact in the absence of DNA. Also, it is not known whether heterodimeric
complexes between Pur-PurγA and Pur-PurγB can form.
A well-characterized interaction is between Pur and MSY1 (171). Protein
interaction assays using purified recombinant proteins have shown that Pur binds with
high affinity to MSY1. Further evaluation suggested that amino acids 264-324 of Pur
are required for Pur-MSY1 interaction (145). However, it is possible that additional
amino acids are necessary as this finding was reported after analyzing truncation mutants
spanning amino acids 2-324, 2-263, and 2-236 (145). Furthermore, the proper folding of
each of the truncated proteins was not confirmed and if folding was altered it may have
influenced these results. Within the context of the cell, Pur retains high affinity for
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protein complexes containing MSY1. In fact, Pur has higher affinity for cell-derived
MSY1 than Purα in both fibroblast and VSMC nuclear lysate (94).
In addition to transcriptional repressors, Pur has also been reported to form
complexes with activators. These transcription factors include TEF1, SRF, Sp1, Sp3, and
Smad2/3 (81, 94). Although additional studies are needed to confirm whether Pur
interacts directly or indirectly with these proteins. Pulldown assays using fibroblast cell
lysate have detected interactions with each of the aforementioned proteins, except for Sp1
and Smad2 (81). Additionally, nuclear lysate based assays have also identified many of
these Pur-protein complexes (94). In this approach, recombinant Pur protein was
immobilized on a high binding 96 well plate, nuclear lysate was applied to the wells, and
protein complexes were immunodetected using various antibodies with epitopes against a
range of transcription factors. This approach also showed that Pur associates with
MSY1, TEF1, SRF, Sp3, Sp1, and Smad2/3. Furthermore, Pur had higher affinity for
MSY1, TEF1, and Sp3 in fibroblasts and higher affinity for MSY1, Sp1, and Sp3 in
VSMCs compared to Pur (94). Given the differences in relative affinity for TEF1 and
Sp1, protein affinity appears dependent on the cellular environment, which may influence
the mechanism of Pur-mediated repression in a given cell-type.

4.4 Purβ association to the Acta2 promoter in the presence of other proteins
As previously described, Pur and Pur bind with high affinity to purine-rich
regions both flanking and within the MCAT cis-element, while MSY1 binds to the
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corresponding pyrimidine-rich regions (81). Together these proteins are thought form a
strong repressor complex in both fibroblasts and VSMCs that represses Acta2
transcription (158, 172). As a result, there are several hypotheses regarding the
mechanism of Pur/Pur/MSY1 repression at the MCAT cis-element. These theories are
primarily based on a series of DNA pulldown assays and consider the role of activator
TEF1. As experiments found that TEF1 did not bind to Pur/Pur/MSY1 associated
with ssDNA, the first hypothesis suggests that Pur/Pur/MSY1 prevents TEF1 binding
to dsDNA and subsequent activation of Acta2 (81). The second hypothesis was derived
from studies that found that Pur/Pur/MSY1 are able to associate with dsDNA-bound
TEF1, and suggests that activation of Acta2 is prevented by the formation of this protein
complex (81). Lastly, a third hypothesis suggests that Pur/Pur may sequester TEF1
and limit DNA binding and activation. While these theories are not mutually exclusive,
they may oversimplify the mechanisms of Purα/β/MSY1 repression at MCAT in the
Acta2 promoter.
As previously mentioned, it has been reported that both Pur and Pur bind to ss
and dsSPUR DNA. In ssSPUR DNA and in ssTCE DNA, Pur and Pur binding is
accompanied by MSY1 (89). Moreover, TGF1 treatment has no effect on the binding of
all three proteins to ssSPUR DNA (89). In dsSPUR DNA, Pur and Pur both bind to
the DNA along with transcription factors Sp1 and Sp3 (89). Mutations in the dsSPUR
DNA reveal that the binding of one transcription factor does not depend on the other
transcription factor as some mutations that minimalize Sp1 and Sp3 binding have no
effect on Pur and Pur binding to dsSPUR and vice versa (89). Interestingly, after
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exposure of cells to TGF1, Pur/ binding to dsSPUR diminishes, while Sp1 binding
appears unaffected (89). Further analysis using immunoprecipitations suggested that the
presence of Smad2/3/4 impairs Sp1-Pur association (89). To evaluate the functional role
of these complexes, select transcription factors were overexpressed and Acta2 promoterreporter assays were performed. This revealed that Pur represses Sp1 and/or Smad2/3/4
activation in the minimal promoter and, in the presence of TGF1, Pur repression of
Smad2/3/4 activation was still observed (89). Finally, while Pur repression mirrored
Pur repression in these experiments, Pur was more effective in repressing Smad2/3/4
activation of VSMP8 than Pur (89).
A more recent study by Hariharan et. al. evaluated the binding of human
fibroblast-derived transcription factors to a long Acta2 promoter-derived DNA probe
encompassing the MCAT cis-element and SPUR motif in both the presence and absence
of TGF1 treatment (172). Prior to TGF1 treatment, fibroblast-derived Pur, Pur, and
SRF bind to the DNA and appear unaffected following treatment (172). As expected,
TGF1 treatment induced the expression of pSmad3 and the binding of pSmad3 to the
DNA probe (172). As other studies have commented on the dynamic nature of
transcriptional regulation, this study evaluated the effect of pre-loading transcription
factors to DNA probes and increasing transcription factor concentrations. In doing so,
this study found that Pur is capable of both displacing and limiting the binding of
transcription factors to the promoter (172). After pre-loading 100 pmol of purified Pur
to the Acta2 promoter probe, incubation with the same concentration of purified Pur
resulted in the displacement of Pur and Pur binding to the promoter at high levels
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(172). Interestingly, in the inverse experiment, Pur was not able to remove Pur that
had been preloaded to the promoter, however Pur was able to accumulate on the
promoter along with Pur. Further analysis revealed similar binding trends with other
proteins. High concentrations of purified recombinant Pur were also able to displace
SRF binding and Pur preloading limited SRF binding with and without TGF1
treatment of the cells (172). Pur preloading also limited pSmad3 binding to the
promoter with TGF1 treatment (172). Pur was not able to displace SRF or pSmad3
with SRF or pSmad3 preloading, instead Pur binds to the promoter with these
transcription factors. However, Pur preloading was found to limit the binding of SRF
and pSmad3 to the promoter but not as effectively as Pur (172). Taken together, these
binding studies depict a functionally unique property of Pur in comparison to Pur,
namely the ability to displace and limit the binding of other transcription factors.

5. Structural Features of Purβ that Dictate its Functional Activities
One of the long-standing goals in the field is to elucidate the specific molecular
mechanisms by which Pur represses SMαA expression. Given the well-established
relationship between protein structure and function, the lab has focused on identifying
unique structural features of Pur. Traditionally, crystal structures of transcription factors
have provided unparalleled information regarding protein structure and insights into the
mechanism of protein-DNA and protein-protein interaction. Yet to date a crystal
structure of Pur has not been solved. For this reason, a number of studies have used
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alternative techniques to identify the structural features of Pur that enable its ssDNAbinding and gene repressor functions. A biophysical approach has revealed the global
properties and dimensions of the protein. A combination of bioinformatics and webbased servers have enabled secondary structure predictions and the creation of 3dimensional homology models. Finally, essential domains and amino acid residues have
been identified by mutational studies. This section of the review will highlight these and
other findings.

5.1 Global Properties of the Pur Protein
Several studies have reported that Purβ exists in a monomer-dimer equilibrium in
both the presence and absence of DNA (166, 170). Monomeric NHis-tagged
recombinant mouse Pur has an apparent mass of 35.94 kDa and therefore an expected
dimeric molar mass of ≈70 kDa (170). However, due to dynamic interactions between
monomers and dimers the average molar mass of the dimer is slightly smaller at 67.7 ±
4.12 kDa in size exclusion chromatography experiments (170). Further analysis using
sedimentation velocity and equilibrium approaches indicated that Pur reversibly selfassociates with an equilibrium dissociation constant of Kd = 1.13 ± 0.27 μM (170).
The shape of dimeric Pur was determined from dynamic light scattering and
sedimentation velocity experiments. In both instances, an analysis of the hydrodynamic
radii suggested that the homodimer is non-spherical, asymmetric, and consistent with
either a prolate or oblate ellipsoid (170). Initial measurements used a degree of hydration
of 0.43 g H2O/Pur suggested ellipsoid dimensions of 23.57 x 3.36 nm (prolate) and
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12.90 x 1.60 nm (oblate). To adjust for dehydration that occurs during protein folding, a
10% reduction in hydration is recommended. Using these parameters, the corrected radii
are 23.91 x 3.28 nm and 12.94 x 1.54 nm for the prolate and oblate ellipsoid, respectively
(170). Given the above calculations, it would appear that Pur adopts an elongated
conformation in solution, similar to the shape of Pur as determined by small angle x-ray
scattering (173). Pur has been reported to form a skewed Z-like conformation, which
may or may not be shared by Pur (173).

5.2 Identification of the Functional Purβ Core Protein
Rumora et al. identified a functional core region of Pur following limited tryptic
digestion of full length Pur at concentrations in which the homodimer would form
(174). Electrospray ionization liquid chromatography mass spectrometry (ESI-LC-MS)
analysis identified the region as amino acids 29-305/306, which suggests that the 47
amino acids on the N and C terminus are solvent exposed (174). To determine if
dimerization of the protein is mediated by the N and C terminal residues, calibrated size
exclusion chromatography was performed. The elution volume of the protein core,
indicated that the core region mediates dimerization not the N- or C-terminal residues
(174). Furthermore, biochemical analyses using competitive DNA binding assays showed
that the core 29-305/306 protein had a slightly higher affinity for purine-rich ssDNA than
full-length Purβ, although subsequent experiments showed that the core had slightly
lower specificity than full-length Pur (174).
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Similar experiments were performed at a later date using a genetically-engineered
truncated version of Pur encompassing amino acids 41-303, which was re-named as the
Pur core protein (I-II-III) (165). As expected, these experiments demonstrated that the
core protein retained the ability to dimerize and was folded comparably to the full length
protein (165). However, unlike earlier studies the core exhibited comparable ssDNA
binding affinity and the ability to compete with the full-length protein for ssDNA binding
(165). This discrepancy may be due to subtle changes in the structure of the first protein
core induced by trypsin proteolysis in the earlier experiment. Regardless, each of these
studies identified a core region in the Pur protein that is stably folded and retains the
ability to bind specifically and tightly to purine-rich ssDNA.

5.3 Identification of Internal Repeats and Functional Characterization of Pur
Repeats
Perhaps one of the most important findings in recent years was the identification
of regions of internal homology in each member of the Pur family. These regions termed
PUR repeats were first observed by Graebsch et al. who identified three repeats within
Drosophila melanogaster (Dm) Purα, Pur repeat I (aa 42-106), Pur repeat II (aa 120-182),
Pur repeat III (aa 197-252) (173). Similarly, other Pur proteins share three repeats
including human Pur. Corresponding repeats between Dm Pur and human Pur share
64-71% similarity and 51% identity. The web-based server, HHrepID, also predicts 3
repeats in mouse and human Pur. Mus musculus (Mm) Purβ repeats span residues 43110 (repeat I), 127-208 (repeat II), and 211-294 (repeat III), indicating that all three
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repeats reside in the functional Pur core region. Comparison of corresponding repeats
between mouse Pur and mouse Pur reveal that these repeats are 67-76% similar and
58-67% identical. However, within the individual proteins, repeat homology is between
25-49% similarity and 13-30% identity for Pur, 41-55% similarity and 19-29% identity
for Dm Pur, and 39-49% similarity, 16-28% identity for human Pur. Together, these
studies suggest that repeats within a given protein may hold similar but not completely
redundant functions.
The secondary and tertiary structure adopted by each repeat has been determined
by high resolution x-ray crystallography of several Pur proteins. The x-ray crystal
structure of Borrelia burgdorferi (Bb) Pur protein, a bacterial protein with one repeat,
revealed that the repeat contains four anti-parallel beta strands followed by an alpha
helix, which runs parallel to the beta strands (152). Similarly, these features were also
observed in each repeat of Dm Pur (169, 173). In the absence of a crystal structure of
Pur, web-based modeling servers such as PSIPRED have been used to predict secondary
structure. Consistent with findings for other Pur proteins, these programs have predicted
that Pur repeats also consist of four antiparallel beta strands followed by an alpha helix.
As previously mentioned, early studies observed repeating acidic and basic
regions in the primary sequence of Pur proteins. Yet, the apparently haphazard
organization of the acidic and basic regions across species reflected poor sequence
conservation of these elements. However, a more systematic arrangement is observed
when acidic and basic sequences are analyzed in reference to the Pur repeats, as these
regions appear in proximity or within the repeats (152). Moreover, in both crystal
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structures and in secondary structure predictions, basic and acidic regions correspond to
the beta strands and alpha helices, respectively.
5.4 PUR Domains
Crystal structures of Dm Purα and Bb Pur proteins have revealed that pairs of repeats
form globular PUR domains (152, 173) (Figure 1-6). In the Bb Pur protein, the single
repeats dimerize to form a domain in which the alpha helix of one repeat intercalates
between the alpha helix and beta sheet of another repeat and vice versa (152). The alpha
helices run antiparallel to each other and are packed against the beta sheets. In total 33%
of the surface area of each repeat is buried within the domain and acts to stabilize the fold
through a large number hydrophobic interactions involving aromatic and aliphatic amino
acids (173). Two very similar folds are also observed in Dm Pur (169, 173). An
intramolecular PUR domain was composed of amino terminal repeats I-II and was the
first reported in crystal structure of Dm Pur (173). Since then, the crystal structure of
the intramolecular domain has also been solved in complex with ssDNA (169). Recently,
a crystal structure of two repeats III was solved and revealed that the dimerization
domain forms an intermolecular PUR domain (169).
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Figure 1- 6. The inter and intramolecular domains of Purβ.
Trypsinization studies identified a functional PurB core protein that contained 3 regions
of internal homology termed repeats. Amino terminal repeats I-II form an intramolecular
domain, while carboxy terminal repeats III form an intermolecular dimerization domain.
Intermolecular and intramolecular domains were derived from a homology model of
murine Purβ.
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The PUR domain shares a similar fold with the Whirly class family (173). Whirly
domains are typically found in nucleic acid-binding proteins that reside in the
mitochondria and chloroplasts of plants. These proteins primarily interact with ssDNA,
although some associate with RNA and dsDNA, to activate transcription, maintain
telomeres, aid in splicing, and repair DNA. The PUR domain formed by repeats I-II in
Dm Pur is most similar to the Whirly domain protein RNA binding protein-2 (MRP-2),
mitochondrial RNA-binding protein-1 (MRP-1), and plant transcriptional regulator PBF2 (P24), which all contain a bbbb-a, bbbb-a topology (173). Like the PUR domain, one
alpha helix is inserted between another alpha helix and beta sheet with the alpha helices
maintaining an anti-parallel orientation (173). However, unlike Pur, the beta sheets in
Whirly class proteins are rotated and are offset from one another (173). Additionally,
many Whirly class proteins form tetramers with the alpha helices associating to form an
inner circle with the beta strands extending in a pinwheel-like conformation. This too
deviates from the Pur protein quaternary structure in which Pur and Pur form
homodimers in an extended conformation.
To date, no study has been able to directly address whether Pur contains one or
more Whirly-like domains. However, the stable formation of both the intramolecular and
intermolecular PUR domains in Pur has been confirmed (165). A series of NHis-Pur
truncation mutants including individual repeats I, II, and III, combinations of repeats I-II,
II-III, and the core protein I-II-III were generated in a eukaryotic expression vector to
facilitate functional analysis of each construct in transfected cells (165). After harvesting
AKR2B fibroblast cells transfected with these vectors, protein expression was evaluated
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though Western bot analysis. Individual Pur repeats I and II were not detected in either
the soluble or insoluble lysate indicating that neither of these repeats was stably
expressed and each was quickly degraded by the cell (165). Individual Pur repeat III
forms the intermolecular dimerization domain and was expressed in the soluble lysate,
but did not localize to the nucleus suggesting that repeats I-II may contain the nuclear
localization signal (165). Additionally, repeats II-III were only detected in the insoluble
lysate suggesting that the mutant was not properly folded. This finding also demonstrates
that repeats are not interchangeable in the formation of PUR domains. As the remaining
mutants (repeats I-II and repeats I-II-III) were observed in soluble lysate and nuclear
extract, the functional activity of each protein was evaluated using an Acta2 promoterluciferase reporter system. Results showed that Pur repeat I-II is slightly impaired in its
repressor activity compared to full length Pur (165). Therefore, one may conclude that
Pur repeat I-II is necessary for repression, but not entirely sufficient. As the core protein
(repeats I-II-III) is comparable in repressor activity to full length Pur, one may infer that
the presence of the third repeat is necessary for full repression of the Acta2 promoter.
To further characterize both the intramolecular and intermolecular domains, each
subdomain was expressed in E. coli, purified, and biochemically analyzed. Circular
dichroism spectroscopy suggested that each truncation protein was properly folded (165).
Calibrated size exclusion chromatography revealed that Pur repeat III facilitates the
formation of dimers, while Pur repeat I-II is only found in the monomeric state, which is
similar to observations in Pur (165).
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The finding that Purβ forms a stable intramolecular domain with repeats I-II and a
stable intermolecular domain with two repeats III, validated a homology model that was
previously generated using the intramolecular PUR domain from Dm Purα as a template
for each subdomain (165). In addition to the three PUR subdomains, flexible N and C
termini that are also shared with Pur, but have not been crystallized, were depicted in
the model. Unique to Pur are longer loop and linking regions connecting certain
secondary structural elements and domains, respectively. Based on the model and Pur
crystal structure, most basic and acidic residues are solvent-exposed and localized to beta
strands and alpha helices, respectively (165). In the later chapters of this dissertation, a
new and improved Pur homology model is reported using a similar approach.

5.4.1 DNA Binding
The binding properties of Pur repeat I-II, III, core I-II-III, and full length Pur
were evaluated in the context of ssDNA binding assays. In these experiments, varying
concentrations of recombinant Pur protein was applied to 96-well plates containing a
fixed concentration of immobilized biotinylated purine-rich ssDNA from the Acta2 gene
(PE32-bF) (165). Following immunodetection of solid-phase protein-ssDNA complexes,
binding curves were generated and revealed that full length and core Pur proteins
exhibited comparable ssDNA binding activity (EC50: 0.16 ± 0.05 nM, EC50: 0.22 ± 0.05
nM, respectively) (165). In contrast, each PUR domain separately demonstrated lower
affinity for purine-rich ssDNA with Pur repeat I-II (EC50: >100 nM) being more
deficient than Pur repeat III (EC50: 1.80 ± 0.74 nM) (165). Similarly, in competition
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assays where the Pur core and subdomain proteins compete with the full-length protein
for binding to purine-rich ssDNA, Pur I-II is least effective and Pur III is more
effective in competing for full-length Pur binding to ssDNA (165). These findings
suggested that the Pur repeat III dimerization domain may be an essential contributor to
full length Pur binding to ssDNA.
When comparing the reported subdomain ssDNA binding activity of Pur and
Pur, it was surprising to find that Pur repeat III has higher apparent binding affinity for
ssDNA than Pur repeat I-II in Pur. Previous studies have shown that Pur repeat I-II
binds to purine-rich regions in the c-myc sequence element with comparable affinity and
specificity to full length Pur (173). Additionally, Purα repeat III has 30 times weaker
affinity for purine-rich ssDNA than Pur repeats I-II (173). However, while these binding
differences were unexpected, the idea that a Pur dimerization domain binds with high
affinity to single-stranded nucleic acid is not new. The bacterial protein Bb Pur, a single
repeat that dimerizes to form a PUR domain, is also capable of binding to DNA (152).
Filter binding assays suggest that Bb Pur binding to purine-rich DNA is comparable to
human Purα repeats I-II in (AGG GTT)2 sequences (152). Finally, while the differences
between repeat III in Pur and Pur were not predicted, they may in part provide a
rationale to the many functional differences observed in both proteins.
Prior to the studies reported here, the specific amino acid residues that mediate the
binding of each subdomain of Pur to ssDNA were not known. However, several studies
investigating Pur identified amino acid residues in repeat I and repeat II that interact
with nucleic acid. A double mutation of R80A, R158A eliminated Pur binding to
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ssDNA and RNA (173). Additionally, a double mutant of R65A, R142A impaired RNA
binding activity, but not ssDNA binding activity (173). Recently, a crystal structure of
Pur repeats I-II bound to ssDNA was solved and indicated that there are two DNA
binding sites, both localized to the beta sheets (169). Although it is not known whether
both binding sites are utilized simultaneously. The first DNA binding site includes
residues Q52, S53, K54 in repeat I and R142, N140, F145, K138 in repeat II. DNA
binding site 2 consists of K61, R80, D59, Y57, K70 on repeat I (169). The amino acid
residues at each binding site interact with the ssDNA through hydrogen bonds and base
stacking interactions mainly with guanosine, although one cytosine is implicated (169).
To a lesser extent Pur residues also bind to the sugar phosphate backbone (169). An
alignment of Pur crystal structures with and without DNA suggested that DNA binding
to the Pur domain does not induce major conformational changes in the protein. This
may also be true in the case of RNA binding as NMR studies have suggested that Pur III has similar binding modes to ssDNA and ssRNA (169).

DNA Helix Unwinding by Pur and Pur
As previously mentioned, both Pur and Pur have been implicated in DNA helix
destabilization. Pur is capable of destabilizing various forms of dsDNA though
different mechanisms are thought to be involved in the unwinding of linear dsDNA and
supercoiled DNA (168). The destabilization of short oligonucleotides (~18 bp) have
revealed that the N and C terminal regions are not involved, rather the core protein
containing repeats I-II-III is required for DNA unwinding ability (167, 168). Specifically
repeats I-II have been noted for their role in unwinding short oligonucleotides (167, 169).
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While one group has reported that a mutation in repeat II, F145, abolishes the ability of
Pur to unwind DNA, this should be taken with caution as other groups maintain that the
first and third repeat are independently capable of DNA unwinding (167, 168). Although,
the role of repeat III is also somewhat controversial with groups reporting it has no effect
(169) or is capable/essential (167, 168) in the unwinding linear double-stranded
oligonucleotides. Ultimately, these discrepancies may be due to specific reaction
conditions or species specific activity.
To identify structural features in Pur enabling destabilization of supercoiled
DNA, mutant Pur proteins were generated. The deletion of an alpha helix and most of
the fourth beta strand in the third repeat had minimal impact on Pur function (168).
This may suggest that the third repeat is not involved in the unwinding of supercoiled
DNA or that the involvement of the third repeat is restricted to specific loops and beta
strands in the DNA binding domain. Mutation of residue 77 or 155 impaired
destabilization and a double mutant resulted in complete loss of destabilization,
supporting the roles of repeats I-II in destabilizing the double helix (168). Lastly deletion
of the N terminal domain 1-54 in human Pur resulted in a protein with impaired
function perhaps suggesting that the N-terminal region contributes to the unwinding of
supercoiled DNA as well (168).
Further analysis revealed that Pur is not as effective as Pur in unwinding
dsDNA. This was most notable following incubation of Pur with linear dsDNA as Pur
demonstrated no destabilization ability (168). However, Pur is capable of destabilizing
supercoiled DNA and use of chimeric Pur/Pur proteins suggested that the protein core
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is responsible for this function (168). Further study is needed to identify specific features
of Pur that are required for the destabilization of supercoiled DNA.

5.4.2 Protein-Protein Interactions
The binding of the mouse Purβ WT, core, inter- and intramolecular PUR domains
to other nuclear proteins has been evaluated using a cell-lysate assay (165). Briefly,
purified recombinant Pur proteins were immobilized on high affinity binding plates,
AKR-2B nuclear lysate was added, and Pur-protein complexes were immunodetected
using antibodies against a variety of transcription factors (165). Compared to full length
Pur, the core had notably higher affinity for MSY1, TEF1, Sp3 and slightly higher
affinity for SRF, and Sp1, suggesting that the N and C termini impede Pur binding to
these transcription factors perhaps through either physical or chemical mechanisms (165).
Analysis of repeats I-II and III revealed that both were greatly impaired in binding to
MSY1, suggesting that all three repeats must be present for high affinity binding (165).
Interestingly, Pur repeat I-II had much higher affinity for Sp3 than full length Pur and
Pur repeat III was greatly impaired in binding to Sp3, perhaps indicating that inclusion of
Pur repeat III in the full length protein reduces the binding of Pur repeats I-II to Sp3
(165) . While other proteins were tested, binding activity was low making it difficult to
distinguish differences, if any. Even so, the results appear to indicate that Pur repeats
retain some ability to bind to proteins Pur, TEF1, SRF, and Sp1.
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6. Summary
To summarize, careful regulation of the Acta2 gene is essential in maintaining
homeostasis in a number of different cell-types. Expression of Acta2 enables medial
derived VSMCs to regulate blood flow and pressure and is required for the differentiated
myofibroblast phenotype, a primary contributor to granulation tissue in wound healing
(28, 34, 50). Conversely, dysregulation of Acta2 in these cell-types has been implicated
in disease with the downregulation of Acta2 in VSMCs associated with heart disease and
the persistent activation of myofibroblasts linked to wound healing disorders (29, 34, 48,
50). Therefore an understanding of the mechanisms that regulate Acta2 may be
beneficial in the development of novel therapeutic strategies for these disease states.
Studies have indicated that Acta2 is regulated by combinatorial interactions of
activators and repressors at cis elements in the Acta2 promoter. Among the repressor
proteins are two members of the purine-rich element binding protein family, namely Purα
and Purβ. Both of these proteins bind to single-stranded purine-rich DNA with high
affinity and specificity. Yet despite having similar structure and function, both loss-offunction and gain-of-function studies have suggested that Purβ is the dominant repressor
(158). As the specific molecular mechanisms by which Purβ represses of Acta2 are
unknown, studies have focused on identifying structural features of Purβ that mediate
repression.
This approach has revealed that Purβ repressor activity is dependent on the
presence of both an intramolecular and intermolecular PUR domain formed by repeats III and 2 repeats III respectively (165). Purification and biochemical analysis of each of
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the subdomains revealed that both domains affect Purβ -protein interactions and that the
intermolecular domain has higher affinity for ssDNA than the intramolecular domain
(165). However, further experiments were needed to confirm whether the intermolecular
domain contributes to DNA binding in the context of the full-length protein.
Additionally, the identification of specific amino acids that mediate Purβ repression of
Acta2 were needed.
Consequently, studies in this dissertation have identified amino acids in each of
the subdomains that contribute to full-length Purβ repressor activity. In the first study
amino acids were selected on the basis of positive charge and positional conservation.
Previous study in Purα reported that specific amino acids mediated Purα interaction with
nucleic acid. Similarly, this study reports that homologous amino acids in Purβ effect
Purβ repression of Acta2 and the ability to bind to purine-rich DNA, with an amino acid
in the intermolecular domain having a notable effect. The second study evaluated single
nucleotide polymorphisms variants of Purβ that result in missense mutation and are
primarily localized to the intermolecular domain. These variants also effected Purβ
repression, appearing to effect Purβ-protein interactions. Collectively, these studies
suggest that the intermolecular domain contributes to both DNA binding and proteinprotein interactions in the context of the full length protein.
The third study in this dissertation showed that Purβ represses the potent cofactor
activity of Myocd, a protein known as the master regulator of the smooth muscle
contractile phenotype (111, 112). Myocd induces potent transcriptional activation of
contractile proteins by binding to SRF and studies here suggest that Purβ represses
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Myocd cofactor activity by binding to both SRF and Myocd in the presence and absence
of DNA. Further analysis showed that variants and mutants were impaired in their ability
to repress Myocd cofactor activity suggesting that the intermolecular domain is also
important for full-length Purβ repression of Myocd cofactor activity.
Collectively these studies demonstrate that the third repeat is essential for fulllength Purβ repression of Acta2, contributing to dimerization, DNA binding, and proteinprotein interactions. Furthermore, these studies identify specific residues within the third
repeat that contribute to both DNA and protein binding. Additionally, Purβ repression of
Myocd is reported and a Purβ-protein mechanism is suggested. This finding was
supported through analysis of Purβ mutants and variants which also suggest that the
intermolecular domain is essential in Purβ repression of Myocd cofactor activity.
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Abstract
Myofibroblast differentiation is characterized by increased expression of cytoskeletal
smooth muscle -actin. In human and murine fibroblasts, the gene encoding smooth
muscle -actin (Acta2) is tightly regulated by a network of transcription factors that either
activate or repress the 5 promoter-enhancer in response to environmental cues signaling
tissue repair and remodeling. Purine-rich element binding protein B (Pur) suppresses the
expression of Acta2 by cooperatively interacting with the sense strand of a 5 polypurine
sequence containing an inverted MCAT cis-element required for gene activation. In this
study, we evaluated the chemical basis of nucleoprotein complex formation between the
Pur repressor and the purine-rich strand of the MCAT element in the mouse Acta2
promoter. Quantitative single-stranded DNA (ssDNA)-binding assays conducted in the
presence of increasing concentrations of monovalent salt or anionic detergent suggested
that high affinity nucleoprotein assembly is driven by a combination of electrostatic and
hydrophobic interactions. Consistent with the results of pH titration analysis, site-directed
mutagenesis revealed several basic amino acid residues in the intermolecular (R267) and
intramolecular (K82, R159) subdomains that are essential for Purtranscriptional
repressor function in Acta2 promoter-reporter assays. In keeping with their diminished
Acta2 repressor activity in fibroblasts, purified Purvariants containing an R267A
mutation exhibited reduced binding affinity for purine-rich ssDNA. Moreover, certain
double and triple point mutants were also defective in binding to the Acta2 corepressor
protein, Y-box binding protein 1. Collectively, these findings establish the repertoire of
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non-covalent interactions that account for the unique structural and functional properties
of Pur.

Introduction
Myofibroblasts arise from the differentiation of connective tissue fibroblasts and play
a key role in granulation tissue formation and wound healing by mediating extracellular
matrix deposition and wound closure (1-4). Although the smooth muscle cell-like
contractile properties of myofibroblasts are beneficial for wound repair, chronic activation
and survival of extracellular matrix-producing myofibroblasts provokes aberrant tissue
remodeling including hypertrophic scar formation, vascular stiffening, and chronic organ
fibrosis particularly of the heart, liver, and lung (5-7). To develop better and more effective
therapeutic strategies for treating fibrotic diseases, it is necessary to identify and
characterize the molecular pathways that govern myofibroblast proliferation and
differentiation.
Smooth muscle -actin (SMA) is the most widely accepted protein biomarker of
fibroblast to myofibroblast conversion and acquisition of a contractile phenotype (2, 8-10).
Consistent with its phenotype-defining properties, expression of the murine SMA gene
(Acta2) in fibroblasts is tightly regulated by a network of transcriptional activators and
repressors (11, 12). The 5-flanking region of Acta2 contains a variety of positive cisregulatory elements including an inverted muscle-CAT (MCAT) motif, CArG boxes,
CAGA elements, and GC-rich sequences that serve as cognate binding sites for certain
basal or growth factor-responsive trans-activators, namely transcription enhancer factor 1
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(TEF-1), serum response factor (SRF), small mothers against decapentaplegic (Smad)
proteins, and specificity proteins 1 and 3 (Sp1/3), respectively (13-17). Conversely,
repression of Acta2 transcription in fibroblasts is apparently mediated by the coordinate
interaction of purine-rich element binding proteins A and B (Pur and Pur) and Y-box
binding protein (YB-1) with the opposing strands of an asymmetric polypurinepolypyrimidine (Pur/Pyr) tract containing the MCAT motif (14, 18-20). Although Pur
and Pur both interact with purine-rich single-stranded nucleic acids and possess the
capacity to destabilize duplex DNA (21-23), Pur appears to function as a more potent
repressor of Acta2 transcription in both fibroblasts and smooth muscle cells (24-26).
Pur is a member of a small but highly conserved family of purine-rich
ssDNA/RNA-binding proteins (27). Each member of the Pur family (Pur, Pur, Pur
variant A, Pur variant B) contains three central sequence elements designated PUR repeats
I, II, and III (27-29). These elements account for the roughly 70% sequence homology
between mammalian Pur and Pur. The recently solved x-ray crystal structures of
Drosophila melanogaster (Dm) Pur (amino acids 40 to 185) and Borrelia burgdorferi
(Bb) Pur (amino acids 8 to 105) revealed that PUR repeat sequences fold to form a 4stranded anti-parallel -sheet followed by an -helix. In the case of Dm Pur,
intramolecular association of PUR repeats I and II produces a Whirly-like globular domain
(dubbed the PUR domain) capable of ssDNA interaction (28). In the case of Bb Pur,
intermolecular dimerization of the single encoded PUR repeat forms a ssDNA-binding
PUR domain, which is nearly identical to the domain generated by intramolecular
association of PUR repeats I and II of Dm Pur (29). Because full-length Pur proteins in
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metazoans contain three PUR repeats, PUR repeat III likely serves to mediate
intermolecular interaction of Pur protein monomers to form dimers as first reported in Dm
Pur (28).
Our efforts to establish the molecular basis for ssDNA-binding and Acta2 repression
by Mus musculus (Mm) Pur have provided additional insight into the similarities and
differences in the structural and functional properties of members of the Pur protein family.
For example, hydrodynamic analyses revealed that recombinant mouse Purreversibly
self-associates to form a homodimer in the absence of ssDNA (30). Rigorous quantitative
analyses of nucleoprotein complex formation between Pur and the 32 nt sense strand of
the MCAT-containing Pur/Pyr element from Acta2 were consistent with a cooperative,
multisite binding mechanism leading to formation of a high-affinity 2:1 Pur:ssDNA
complex (31). Results of limited tryptic digestion suggested that the presence of all three
PUR repeats is required for high affinity binding of Pur to the purine-rich strand of the
Acta2-derived MCAT enhancer element (32). To further define the structural elements in
Pur responsible for multisite binding to ssDNA and consequent Acta2 repression in
fibroblasts, we recently reported that dimeric Pur is comprised of three distinct PUR
subdomains each capable of interacting with a separate ssDNA binding site (33).
Consistent with the cooperative nature of Pur-ssDNA interaction, all three PUR
subdomains are required for high affinity interaction of the Pur homodimer with the Acta2
promoter. Interestingly, when studied in isolation, the central dimerization subdomain of
Pur formed by intermolecular association of two PUR repeat III sequences exhibited
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markedly higher ssDNA-binding affinity than the comparable subdomain formed by
intramolecular association of PUR repeats I and II (33).
In this report, the detergent- and salt-sensitivity of the nucleoprotein complex formed
between Pur and its Acta2-derived purine-rich target sequence was initially evaluated to
estimate the contribution of hydrophobic and ionic interactions in facilitating the high
affinity binding of Pur to ssDNA. Based on homology modeling of the tertiary and
quaternary structure of Pur in comparison to Pur, several basic amino acid residues in
PUR repeats I, II, and III were identified and empirically validated as essential for the
Acta2 repressor activity of Purin fibroblasts. Biochemical analyses implicated these
residues in mediating the high affinity binding of Purto purine-rich ssDNA and to the
corepressor protein mouse YB-1 (MSY1). Our findings suggest that a combination of
hydrophobic and electrostatic interactions are responsible for the unique ssDNA-binding
and transcriptional regulatory properties of Pur.

Experimental Procedures
Computational modeling of Pur. Hydrophobic side chains were identified in a Mus
musculus Pur homology model using PyMOL to depict regions of Pur with high
hydrophobic amino acid content (33, 34). Additionally, electrostatic surface maps were
generated to identify solvent-exposed, charged amino acids. To select positively charged
amino acid residues of Pur that might confer Acta2 repression, a ClustalW multiple
pairwise sequence alignment of Mm Pur and Dm Pur was performed to identify Pur
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residues corresponding to the Pur residues (R80, R158, and R229) that had been
previously implicated in single-stranded nucleic acid interaction (35-37). The lack of
conservation of Pur R158 led us to align the crystal structure of Dm Pur (amino acids
40-185) and the homology model of Mm Pur I-II to identify a positionally conserved
arginine in spatial proximity to Dm Pur R158.

Construction of Expression Vectors. The original mammalian expression plasmid
encoding recombinant N-terminally hexahistidine-tagged mouse Pur (pCI-NHis-Pur)
was described in a previous study (14, 20). The QuikChange Primer Design Program
(Stratagene) was used to design complementary oligonucleotide primers (Table S2-1) for
site-directed mutagenesis of the pCI-NHis-Pur template. Multiple plasmids encoding
different combinations of single, double, and triple point mutations of selected lysine or
arginine residues in the Purb open reading frame were sequentially produced using the
QuikChange® XL site-directed mutagenesis kit as directed by the manufacturer (Agilent).
Plasmids encoding Pur mutants K82A, R159A, R267A, K82A/R159A, K82A/R267A,
R159A/R267A, and K82A/R159A/R267A were sequence validated (Vermont Cancer
Center DNA Analysis Facility) and purified by double cesium chloride gradient
centrifugation. Quantification of isolated plasmids was achieved by measuring the optical
density at 260 nm. Plasmid purity was assessed via analytical agarose gel electrophoresis
following double restriction enzyme digestion with BamHI and KpnI to validate the size of
the cDNA inserts. The cDNAs encoding selected single, double, and triple Pur mutants
(R267A, R159A/R267A, and K82A/R159A/R267A) were excised from pCI with EcoRI
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and SalI and then subcloned into the bacterial expression plasmid pQE30, which had been
treated with the same restriction enzymes. The resulting bacterial expression plasmids were
propagated in E. coli JM109 cells and screened for cDNA insertion and sequence fidelity
as described above.

Protein Purification. Wild-type NHis-Pur and selected deletion and point mutants
were expressed in E. coli JM109 cells by induction with isopropyl β-D-1thiogalactopyranoside (IPTG) as previously described (30). The recombinant NHis-tagged
proteins expressed included full-length Pur (Pur FL), the core ssDNA-binding region
(Pur I-II-III, residues 41-303), the intermolecular subdomain (Pur III, residues 209-303),
the R267A single point mutant, the R159A/R267A double point mutant, and the
K82A/R159A/R267A triple point mutant. NHis-Pur proteins were purified from E. coli
cell lysates by a combination of metal chelate affinity chromatography, heparin-agarose
ion exchange chromatography, and size exclusion chromatography (SEC) (33). Additional
details about the purification steps used for each point mutant are provided in Supporting
Information. Column fractions were monitored for protein content either by optical density
measurement at 280 nm (A280) or by Bradford assay (Thermo Scientific) using bovine
serum albumin (BSA) as a standard. The relative size and purity of isolated Pur proteins
were assessed by denaturing sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) on 10% or 12% mini-gels. Resolved proteins were visualized by staining
with Coomassie Brilliant Blue R-250 on gels standardized with the PageRuler Broad
Range Protein Ladder (Thermo Scientific). The protein concentration of purified Pur
87

preparations was determined by A280 measurement using theoretical molar extinction
coefficients for full-length or truncated Pur (33). Purified protein preparations were
assayed to ensure the absence of nuclease contamination (30, 33).

Protein Thermostability Assay. The relative thermostability of wild-type and mutated
Pur proteins was evaluated by thermal shift assay using SYPRO Orange (Life
Technologies) to monitor protein unfolding as a function of temperature (38, 39). Assays
were conducted at protein concentrations ranging from 0.3-8.5 M in SEC/storage buffer
consisting of 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole pH 8.0 with 10 mM mercaptoethanol (BME). In some cases, assays were conducted in buffer composed of 20
mM HEPES, 150 mM NaCl, 10 mM BME adjusted to selected pH values. A 4 L solution
of a 100 stock of SYPRO Orange pre-diluted in protein storage buffer was combined
with solutions of wild-type or mutated Pur proteins to achieve a final volume of 80 L.
The mixture was then dispensed in 40 L aliquots into the wells of a 96 well PCR
microplate (Axygen Scientific), which was covered with optical quality sealing tape
(Applied Biosystems). Fluorescence data points were collected at 1C increments at
temperatures ranging from 25 to 94C on an AB 7500 Fast Sequence Detection System
real-time PCR instrument (Applied Biosystems) with excitation and emission wavelengths
set at 480 nm and 568 nm, respectively (Vermont Cancer Center DNA Analysis Facility).
The average background fluorescence detected in the buffer only control was subtracted
from each incremental fluorescence value obtained in wells containing protein. The data
points were then normalized by dividing the background-corrected fluorescence measured
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at each temperature by the maximum fluorescence (Fmax) obtained in that well. To calculate
the temperature midpoint of the protein unfolding transition curve (Tm), data points
obtained in the range of 40ºC-70ºC were fit to the Boltzmann equation using Prism 6
(GraphPad Software, Inc.). Data points acquired below 40ºC and after the fluorescence
maximum were excluded from the curve fitting analysis due to the well-to-well variability
in baseline protein fluorescence seen at low temperature and excessive protein aggregation
occurring at high temperature.

Single-Stranded DNA-Binding Assay. The interaction of purified, recombinant Pur
proteins with a synthetic 3 biotinylated ssDNA probe corresponding to the purine-rich
sense

strand

of

the

Acta2

MCAT

element

(5-

GGGAGCAGAACAGAGGAATGCAGTGGAAGAGA-3, nt −195 to −164, dubbed
PE32-bF) was monitored by enzyme-linked immunorsorbent assay (ELISA) as described
previously (32, 40). To assess the effects of either detergent or salt on nucleoprotein
complex formation, the DNA binding step was carried out by incubating 1.0 nM fulllength, wild-type Pur, 1.0 nM Pur I-II-III, or 5.0 nM Pur III with 0.5 nM PE32-bF
immobilized on StreptaWells (Roche) in binding buffer containing varying
concentrations of sodium deoxycholate or NaCl (Sigma). In these experiments, the DNA
binding buffer consisted of 20 mM HEPES, 150 mM NaCl, 1.5 mM MgCl 2-6H2O pH 7.5
plus 0.2% (w/v) BSA, 0.05% (v/v) Tween 20, 0.5 mM dithiothreitol (DTT), and 100 nM
dT32 oligonucleotide. To assess the effects of point mutations on nucleoprotein complex
formation, varying concentrations of wild-type Pur or mutants R267A, R159A/R267A,
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or K82A/R159A/R267A were incubated with 0.5 nM PE32-bF pre-bound to
StreptaWells (Roche). After overnight incubation (typically 16 h) at room temperature,
wells were washed and solid-phase Pur:PE32-bF complexes were immunodetected by
sequential 1 h incubations with 1.0 g/ml of an affinity-purified primary rabbit polyclonal
antibody directed against mouse Pur amino acids 210-229(20) followed by a 1:8000
dilution of a secondary goat anti-rabbit IgG conjugated to horseradish peroxidase (Santa
Cruz Biotechnology). Antibody bound nucleoprotein complexes were detected by the
addition of colorimetric substrate solution 2, 2-AZINO-bis [3-ethylbenziazoline-6sulfonic acid] (ABTS) (Millipore). After quenching color development with 1% (w/v)
sodium dodecyl sulfate, endpoint absorbance measurements were obtained at 405 nm (A405)
using a Vmax plate reader (Molecular Devices).
For detergent and salt inhibition assays, data points were fit by nonlinear least squares
regression analysis to a four-parameter variable-slope equation to obtain an IC50 value
using Prism 6 (Graphpad Software, Inc.). For assessment of the relative ssDNA-binding
affinity of wild-type vs. mutant Pur proteins, A405 readings were corrected for background
by subtracting the A405 signal generated in wells without DNA at each concentration of
protein tested. Background corrected A405 values were fit by nonlinear least squares
regression analysis to the equation for a rectangular hyperbola to estimate the Bmax (i.e.
Amax ) for each protein using Prism 6 (GraphPad Software, Inc.). The calculated Amax was
used to normalize absorbance values at each concentration of protein tested (A/Amax) for
the purpose of evaluating the reproducibility of the apparent Kd or EC50 determined in
separate trials. In some experiments, the coating concentration of biotinylated ssDNA
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probe was varied and the amount of fluid-phase Pur was fixed. To assess ssDNA-binding
specificity, titration assays were performed with the mutant probe in which the PUR
elements were substituted with thymidylate (PE32-bF-3I5T7) (31).

Protein-Protein Interaction Assay. The binding of purified Pur proteins to purified
MSY1 was evaluated by ELISA as previously described (40). Briefly, NHis-tagged
MSY1(20) was diluted to 100 nM in coating buffer consisting of 20 mM HEPES, 150 mM
NaCl, 1.5 mM MgCl2-6H2O pH 7.5 with 5.0 g/ml BSA and then applied to microtiter
wells (Costar® EIA/RIA plate, 96 Well Easy Wash, Certified High Binding, Corning,
Inc.). After a 3 h incubation at room temperature, the wells were washed, blocked, and
solutions of either wild-type or mutant Pur protein were applied in binding buffer
consisting of 20 mM HEPES, 150 mM NaCl, 1.5 mM MgCl2-6H2O pH 7.5 plus 0.2% (w/v)
BSA, 0.05% (v/v) Tween 20, and 0.5 mM DTT. After overnight incubation ( 16 h) at 4C,
wells were washed and solid-phase Pur:MSY1 complexes were detected in the same
manner as described for the ssDNA-binding ELISA using a primary rabbit antibody
recognizing amino acids 210-229 or 302-324 of mouse Pur(20). To estimate the relative
affinity of wild-type vs. mutant Pur proteins for MSY1, A405 readings were corrected for
background by subtracting the A405 signal generated in wells coated with BSA only from
the MSY1-coated wells at each concentration of Pur protein tested. Background corrected
A405 values were fit by nonlinear least squares regression analysis to the equation for a
rectangular hyperbola to estimate the apparent Kd using Prism 6 (GraphPad Software, Inc.).
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Transient Transfection Assay. AKR-2B mouse embryo fibroblasts (MEFs) were
seeded at 4.0 × 104 in McCoy’s 5A medium supplemented with 5% heat-inactivated FBS
in 6-well plates. Cells were incubated at 37°C in an incubator with 5% CO 2 for 24 h to
facilitate adherence to the plate. MEFs were transiently transfected with a total of 2 g of
DNA consisting of 0.1 g of pSV40-Gal, 1 g of expression plasmid encoding single,
double, or triple point mutations, and 0.9 g of Acta2 promoter-reporter construct,
pVSMP8-luciferase (33). After 48 h incubation at 37°C, transfected cells were washed
with PBS and harvested by lysis in 1× Passive Lysis Buffer (Promega) supplemented with
protease inhibitors leupeptin, pepstatin A, and aprotinin at 1.0 g. Cleared lysates were
assayed for total protein content by either Bradford or BCA assay (Thermo Scientific)
and reporter gene expression by luciferase activity assay (Promega). Datasets were
analyzed by performing a one-way analysis of variance and Tukey’s multiple comparison
test with significance of p <0.05 using Prism 6 (Graphpad Software, Inc.).

Immunoblotting. Total soluble protein from cell lysates was precipitated by addition
of 5 volumes of cold ethanol and incubation at –20°C for 1 h. Precipitated protein was
collected by centrifugation and dissolved in 1 SDS-PAGE loading buffer (20 mM TrisCl, pH 6.8, 0.5% w/v SDS, 5% v/v glycerol, 0.005% w/v bromophenol blue, 5% v/v BME),
heated for 3-5 minutes at 100°C, and run on a 12% w/v acrylamide/bisacrylamide (29:1)
mini-gel with molecular weight standards (BenchMark Prestained Protein Ladder,
Invitrogen). Protein (10 g or 20 g) was transferred to an Immobilon-P polyvinylidene
difluoride membrane (Millipore) at 125 V for 90 min at 4°C in 25 mM Trizma base, 192
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mM glycine, 20% v/v methanol. His-tagged Pur proteins were detected with a mouse antiRGS-His monoclonal antibody (Qiagen) at 1.0 g/ml followed by a goat anti-mouse IgGHRP antibody. Bands were visualized via chemiluminescent detection (Pierce® ECL
Western Blotting Substrate, Thermo Scientific).

Results
Mapping of polar and nonpolar regions in Mm Pur. The chemical properties of
amino acid residues in the homology model of the homodimeric form of Mm Pur(33) were
displayed using hydrophobic and electrostatic maps generated in PyMOL(34). As
expected, hydrophobic amino acid residues are predominantly located at the interior of
both the intramolecular (PUR repeat I-II) and intermolecular subdomains (PUR repeat III)
(Figure 2-1C, D). Hydrophobic side chains in the  structure formed by each PUR
repeat protrude away from the surface and in toward the interface of two PUR repeats. This
arrangement suggests that a hydrophobic core is located at the center of each PUR
subdomain presumably to facilitate protein folding and dimerization.
An electrostatic map of presumably solvent-exposed residues in the Mm Pur
homodimer model shows regions of localized negative charge around the -helices of each
PUR subdomain and pockets of positively charged residues on the -sheet surface (Figure
2-1E, F). Interestingly, the PUR I-II intramolecular domain exhibits one positively charged
pocket on the surface of the -sheets while evidence of two positively charged channels
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Figure 2- 1. Hydrophobic and electrostatic surface maps of the Mm Pur
homodimer generated by computational homology modeling.
(A, B) Ribbon model of the Mm Pur dimer highlighting sequences corresponding to PUR
repeats I (violet), II (blue), and III (green). Two intramolecular subdomains are formed by
association of PUR repeats I and II. The central dimerization subdomain is formed by
intermolecular interaction of PUR repeat III sequences from each monomer. (C, D)
Hydrophobic maps of the Mm Pur dimer show the non-polar core of each subdomain.
Yellow spheres represent hydrophobic amino acids while purple spheres represent nonhydrophobic residues. (E, F) Electrostatic surface maps of the Mm Pur dimer show
regions of charged amino acids. Blue areas indicate positively charged residues and red
represents negatively charged residues. Images in B, D, and F are rotated 180° around the
horizontal axis with respect to the corresponding images in A, C, and E.
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exist at the surface of the -sheets in the PUR III intermolecular dimerization domain
(Figure 2-1E). These results are consistent with surface charge maps of the Dm Pur I-II
crystal structure which exhibited moderately negative charges on the -helix surface side
and positive charges around the -sheets (28, 29). The positively charged channels
localized around the -sheets of the PUR subdomains point to potential binding surfaces
for negatively charged nucleic acid.

Effect of detergent or salt on Purbinding to the Acta2 MCAT element. To investigate
whether hydrophobic interactions play a role in Pur nucleoprotein complex formation,
ssDNA-binding ELISAs were conducted in binding buffer supplemented with increasing
concentrations of selected detergents. In this assay system, a 3’ biotinylated single-stranded
oligonucleotide (PE32-bF) corresponding to the purine-rich sense strand of the MCAT
enhancer of Acta2 was used as the ssDNA probe. This oligonucleotide has previously been
shown to form high-affinity 2:1 Pur:PE32-F nucleoprotein complex with a macroscopic
Kd of approximately 0.3 nM (31). Thus, the protein-ssDNA binding step of the assay was
conducted with a limiting concentration of PE32-bF (0.5 nM) and a 2-5 fold molar excess
of purified recombinant Pur proteins. Predictably, the non-ionic and non-denaturing
detergent, Triton X-100, had no effect on the binding of full-length Pur to ssDNA, while
the anionic and denaturing detergent, sodium dodecyl sulfate, was a much more potent
inhibitor than the anionic bile salt detergent sodium deoxycholate (Figure S2-1). The
amphiphilic properties of deoxycholate allow this detergent to interact with hydrophobic
surfaces of proteins in a non-cooperative and non-denaturing manner (41). Consequently,
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deoxycholate is useful in disruption of protein-protein interaction (42, 43). As shown in
Figure 2-2A, very low concentrations of deoxycholate (< 0.0156% or 0.38 mM) had little
to no effect on Pur binding to purine-rich ssDNA. However, at deoxycholate
concentrations exceeding 1 mM, protein binding to PE32-bF was markedly inhibited in the
case of full-length Pur (IC50 = 0.098%, 2.36 mM), the core Pur I-II-III construct (IC50 =
0.084%, 2.03 mM), and the isolated Pur III intermolecular subdomain (IC50 = 0.060%,
1.45 mM). The concentration-dependent inhibitory effect of deoxycholate on Pur-ssDNA
interaction is presumably due to detergent-mediated disruption of hydrophobic contacts
that dictate the structural stability and/or ssDNA-binding activity of the intermolecular
subdomain of the protein. Consistent with this interpretation, thermal shift assay revealed
that the isolated Pur III dimerization domain becomes progressively less thermostable at
sodium deoxycholate concentrations between 0.38 and 2.0 mM (Figure S2-2).
To evaluate the involvement of electrostatic charges in Pur-ssDNA interaction, the
effects of increasing NaCl concentration on the binding of full-length Pur, the core I-IIIII construct, and the isolated Pur III subdomain to PE32-bF was monitored by ELISA
(Figure 2-2B). Results indicated that salt concentrations greater than ~0.5 M abolished
the binding of each Pur construct to PE32-bF. Given the similarity of the competition
curves, these data suggest that each Pur subdomain possesses charged amino acid
residues that enable stable nucleoprotein complex formation between Purand ssDNA.
In support of this contention, assessment of the effect of pH on the interaction of Pur
with PE32-bF indicated that nucleoprotein complex formation was markedly reduced at
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Figure 2- 2. Effect of anionic detergent and salt on the interaction of Pur with
Acta2 ssDNA.
(A) The binding of full-length Pur (Pur FL), its core region (Pur I-II-III), and its
intermolecular subdomain (Pur III) to 0.5 nM PE32-bF ssDNA was assessed in assay
buffer containing varying concentrations of sodium deoxycholate. Solid-phase Pur-PE32bF complexes were detected by ELISA using rabbit anti-mouse Pur 210-229 as the
primary antibody. (B) The same ELISA format was used to evaluate the effect of varying
concentrations of salt on the binding of Pur FL, Pur I-II-III, and Pur III to ssDNA. Data
points show absorbance values at 405 nm normalized to the maximum absorbance
observed at the lowest concentration of deoxycholate tested (A) or normalized to the
absorbance obtained in buffer with 0.15 mM NaCl (B) (mean  SD, n = 4).
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solution pH  10.5 (Fig. 2-3A). This outcome was not attributable to protein unfolding as
thermal shift assay revealed that Pur retains it native structure at pH 10.5 and 11.5 (Fig.
2-3B). The thermal shift profiles of full-length Pur at pH 7.5, 10.5, and 11.5 were
virtually identical (Tm = 53.2  0.92 C) while some degree of structural instability was
apparent at pH 12.5. Interestingly, lowering the pH had no substantive effect on the
binding of full-length Pur to PE32-bF, while raising the pH had an analogous inhibitory
effect on ssDNA-binding by the core I-II-III construct and the isolated Pur III
subdomain (Fig. S2-3). Collectively, these results are consistent with the deprotonation of
the side chains of solvent-exposed lysine, arginine, and possibly tyrosine residues leading
to reduced electrostatic interaction of Pur with ssDNA.

Identification of K/R residues in PUR repeats I, II, and III that are essential for
Pur repressor activity. Based on the reported ability of certain basic amino acid residues
to mediate RNA-binding by Dm Pur (37), three basic residues located in -strands of each
PUR repeat of Mm Pur were selected for site-directed mutagenesis. Alignment of human
and mouse Pur and Pur sequences revealed that Dm Pur residues R80 and R229 are
positionally conserved in Pur and Pur orthologs and correspond to residues K82 and
R267 located in the fourth -strand of the PUR I and PUR III repeats in mouse Pur (Figure
S2-4). The absence of a conserved basic residue in the PUR II repeat led us to align the
PUR repeat I-II subdomain of the Mm Pur homology model with the Dm Pur I-II
structure (28, 33). This maneuver uncovered a unique R159 residue located in the 3rd -
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Figure 2- 3. Effect of solution pH on the interaction of Pur with Acta2 ssDNA.
(A) The binding of full-length Pur (1.0 nM) to PE32-bF ssDNA (0.5 nM) was assessed in
assay buffer without MgCl2 at pH ranging from 7.5 to 12.5. Solid-phase Pur-PE32-bF
complexes were detected by ELISA using rabbit anti-mouse Pur 210-229 as the primary
antibody. Nonspecific background absorbance at 405 nm in control wells without any DNA
was subtracted from the signal generated in PE32-bF-coated wells. Background corrected
A405 values measured at each pH were normalized by dividing by the mean A405 value
determined at pH 7.5 (mean  SD, n = 4). (B) Effect of solution pH on the thermostability
of Pur. The unfolding of full-length Pur was evaulated by thermal shift assay at a protein
concentration of 2.8 M in 20 mM HEPES, 150 mM NaCl, 10 mM -mercaptoethanol
adjusted to pH 7.5, 10.5, 11.5, or 12.5.
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sheet of Pur repeat II in spatial proximity to Pur R158. Mapping the three residues onto
the homology model of the Pur homodimer shows that each residue is predicted to be
surface exposed in the intramolecular (K82, R159) or intramolecular (R267) subdomains
(Figure S2-5).
To evaluate the consequence of K82A, R159A, and R267A point mutations on the
Acta2 repressor activity of Pur, AKR-2B MEFs were co-transfected with Pur expression
vectors and a full-length Acta2 promoter-reporter construct (VSMP8-luciferase) (33). All
single point mutants tested demonstrated reduced repressor activity toward the VSMP8
promoter-reporter in MEFs with R267A being the most influential mutation (Figure 2-4A).
The effects of double and triple point mutations were more pronounced than the single
point mutations. Immunoblotting of the cell lysates confirmed that all the Pur point
mutants were stably expressed in MEFs (Figure 2-4B). Interestingly, all Pur constructs
containing the PUR repeat III R267A mutation exhibited greatly diminished Acta2
repressor activity suggesting that the R267 residue plays a critical role in the physical and
functional interaction of Pur with the Acta2 gene. The K82A/R159A/R267A triple mutant
and R159A/R267A double mutant were much weaker repressors than the single R267A
mutant alone. The results of transient co-transfection assays comparing the Acta2 repressor
activity of Pur K82A/R159A/R267A and R159A/R267A expressed at increasing
concentrations in MEFs confirmed the functional impairment of these mutants relative to
wild-type Pur (Figure 2-4C, D).
Purification and structural characterization of Pur K/R mutants. Results of cellbased promoter-reporter assays suggested that certain basic residues in each Pur
101

Figure 2- 4. Evaluation of the Acta2 repressor activity of Pur point mutants
expressed in fibroblasts.
(A) Subconfluent AKR-2B MEFs were transiently co-transfected with mammalian
expression plasmids encoding either wild-type (WT) Pur or the indicated point mutants
and an Acta2 promoter-luciferase reporter plasmid, VSMP8. After 48 h, transfected MEFs
were harvested and whole cell extracts were assayed for both luciferase enzyme activity
and total protein concentration. Relative luciferase reporter expression measured in MEFs
co-transfected with an empty pCI vector control was defined as 1. Bars show the fold
repression of the VSMP8 reporter by each Pur construct (mean ± SEM, n = 6-15). ****,
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p  0.0001 compared to Pur WT. (B) Immunoblot analysis was performed with a His tag
antibody to confirm the expression of single, double, and triple NHis-Pur point mutants
in transfected cells. The anti-His tag blot was reprobed with a GAPDH antibody as a
loading control. (C) A titration assay was performed with plasmids encoding the indicated
double and triple Pur point mutants in comparison to the wild-type protein. Symbols show
the relative VSMP8 repressor activity of each Pur construct (mean± SEM, n = 3). (D)
Immunoblot analysis was performed to confirm the dose-dependent expression of NHisPur in transfected cells. The anti-His tag blot was reprobed with a GAPDH antibody as a
loading control. (B, D) Numbers on the left indicate molecular mass in kilodaltons.
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subdomain are likely involved in mediating the functional properties of Pur. To assess the
effect of these mutations on protein structure, mouse Pur mutants R267A, R159A/R267A,
and K82A/R159A/R267A were expressed in and purified from E. coli. Protein preparations
obtained after metal chelate and heparin affinity chromatography were analyzed by
calibrated SEC. As evidenced by the SEC elution profiles of each protein, the single,
double, and triple mutants were each capable of forming homodimers when resolved at
protein loading concentrations in the micromolar range (Figure S2-6). Peaks corresponding
to homodimer were collected and the purity and structural integrity of each of the point
mutants was evaluated by a combination of SDS-PAGE and thermal shift assay. As shown
in Figure 2-5A, the thermal shift profiles of the Pur mutants are comparable to the wildtype protein when evaluated under relatively high ionic strength conditions. The calculated
midpoint temperatures for the protein unfolding transition were nearly identical when
assayed across a range of protein concentrations suggesting that the mutant Pur proteins
are properly folded (Figure 2-5B). Results of SDS-PAGE revealed that the isolated mutants
were of sufficient purity to merit further functional analysis (Figure S2-7).

Effect of K/R mutations on Pur binding to ssDNA. To determine the effect of
R267A, R159A/R267A, and K82A/R159A/R267A mutations on Pur function, the single,
double, and triple mutants were quantitatively evaluated for Acta2 ssDNA-binding affinity
and specificity. All purified Pur preparations were checked to ensure that any proteins
tested in the ssDNA-binding assay were free of nuclease contamination (Figure S2-8).
Nucleoprotein complex formation between Pur and the Acta2 probe, PE32-bF,
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Figure 2- 5. Assessment of the relative thermostability of purified Pur point
mutants.
(A) The unfolding of wild-type (WT) Pur in comparison to point mutants R267A
(single), R159A/R267A (double), and K82A/R159A/R267A (triple) was evaulated by
thermal shift assay at a protein concentration of 2.8 M in 50 mM sodium phosphate pH
8.0, 300 mM NaCl, 10 mM imidazole, 10 mM -mercaptoethanol. (B) Bars show the
calculated Tm of each protein determined at multiple protein concentrations ranging from
1.0 to 8.5 M (mean  SD, n = 6-10).
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immobilized on streptavidin-coated microtiter wells was measured by ELISA. The primary
Pur antibody used to detect complex formation was initially screened to ensure that the
residue 210-229 epitope located between the PUR II and PUR III repeats was recognized
equivalently in the wild-type and mutated Pur proteins (Figure S2-9). To evaluate the
effects of the K/R mutations on ssDNA-binding affinity and specificity, each mutant
protein was tested for interaction with PE32-bF and a mutated probe in which each PUR
element (3 end, internal, 5 end) was substituted with thymidylate (PE32-3I5T7). As
shown in Figure 2-6A and B, the single R267A mutation in PUR repeat III reduced the
apparent ssDNA-binding affinity of the protein by ~3-fold (Kd = 0.57  0.04 nM) relative
to wild-type Pur (Kd = 0.17  0.01). The addition of the R159A mutation in PUR repeat
II did not result in any further diminishment in ssDNA-binding affinity in the
R159A/R267A double mutant (Kd = 0.60  0.04). Importantly, addition of the K82A
mutation in PUR repeat I reduced the ssDNA-binding affinity of the triple mutant by ~8fold (Kd = 1.39  0.12 nM) (Figure 2-6A and B). Interestingly, the K/R mutations did not
affect ssDNA-binding specificity per se as each Pur mutant tested demonstrated
preferential interaction with the wild-type, purine-rich Acta2 probe but only weak binding
to the T7 mutated probe (Figure 2-6). Collectively, these data indicate that specific basic
residues in both the intra- and intermolecular subdomains account for the high affinity
binding of Pur to purine-rich ssDNA.

Effect of K/R mutations on Pur binding to MSY1. To evaluate the potential effect
of these mutations on heterotypic interaction between Pur and its Acta2 corepressor
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Figure 2- 6. Effect of R/K point mutations on the interaction of Pur with Acta2
ssDNA.
(A and B) The binding of wild-type (WT) Pur and the indicated single (R267A), double
(R159A/R267A), or triple (K82A/R159A/R267A) point mutants to 0.5 nM PE32-bF
ssDNA (filled symbols) or 0.5 nM mutated PE32-3I5T7 ssDNA (open symbols) was
evaluated by ELISA. Solid-phase Pur-ssDNA complexes were detected using rabbit antimouse Pur 210-229 as the primary antibody. (A) Protein concentration ranges were
chosen to achieve saturable binding to the PE32-bF probe. Binding isotherms were
generated by fitting data points obtained from multiple, independent titration experiments
(n = 3-5) to the equation for a rectangular hyperbola. (B) Replot of the same datasets fit to
a log(agonist) vs. response (four parameters) equation. The apparent Kd (A) or EC50 (B)
of each Pur protein tested for the PE32-bF probe was extrapolated accordingly.
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partner MSY1, the single, double, and triple mutants were tested for their ability to bind to
purified MSY1 by ELISA. As shown in Figure 2-7, the R267A mutant actually exhibited
a somewhat higher binding affinity for MSY1 compared to wild-type Pur, while the
double and triple point mutants demonstrated reduced MSY1 binding affinity consistent
with their diminished Acta2 repressor activity. The use of a different Pur antibody
recognizing a C-terminal epitope to detect Pur-MSY1 complex formation gave
essentially identical results (Figure S2-10) and further validated the distinction in MSY1
binding affinity among the Pur mutants tested.

Discussion
During normal wound repair, inflammatory cytokine-stimulated trans-differentiation
of resident stromal fibroblasts leads to the transient formation of contractile myofibroblasts
expressing SMA(3). However, persistent myofibroblast activation resulting from
sustained inflammatory signaling can promote excess connective tissue deposition
resulting in aberrant tissue remodeling associated with many fibrotic diseases(44, 45). A
better understanding of the intracellular factors that regulate Acta2 transcription in
myofibroblasts is necessary to identify relevant molecular targets for the purpose of
developing novel therapies to reverse myofibroblast differentiation and to limit
pathological tissue fibrosis. Pur may represent one such target as this protein functions as
a transcriptional repressor of Acta2 by virtue of its ability to interact with the purine-rich
strand of a MCAT-containing element in the 5 flanking region of the gene. Pur likely
operates in conjunction with other ssDNA-binding corepressors, namely MSY1, to disrupt
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Figure 2- 7. Effect of R/K point mutations on the interaction of Pur with MSY1.
(A) The binding of purified Pur wild-type (WT) protein or the indicated single (R267A),
double (R159A/R267A), or triple (K82A/R159A/R267A) point mutants to immobilized
MSY1 (filled symbols, solid lines) or BSA (open symbols, dashed lines) was evaluated by
ELISA. Pur-MSY1 complexes were detected using rabbit anti-Pur 210-229 as the
primary antibody. Binding isotherms were generated by fitting data points obtained from
several independent titration experiments (n = 3) to the equation for a rectangular
hyperbola. (B) Binding curves generated after subtracting out the nonspecific absorbance
measured in BSA only-coated wells from the absorbance obtained in MSY1-coated wells.
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the combinatorial assembly of canonical double-stranded DNA-binding trans-activators on
their respective MCAT, CArG, or G/C-rich elements in Acta2 promoter in fibroblasts(14,
20, 26, 33).
Previous homology modeling of the tertiary and quaternary structure of Pur in
conjunction with empirical analysis of the physical and functional properties of the
intermolecular and intramolecular subdomains indicated the presence of three discrete
ssDNA-binding modules in the Pur homodimer (33). In this report, in silico analysis of
the distribution of non-polar and polar amino acid residues in each subdomain revealed an
asymmetric arrangement with hydrophobic residues predominating in the interior and
charged residues on the solvent-exposed surface of each subdomain. While this is not
necessarily surprising based on principles of protein folding, there is a clear distinction in
the extent of clustering of positively charged residues in the intramolecular subdomain
composed of PUR repeats I and II in comparison to the intermolecular dimerization
subdomain composed of two PUR III repeats. Notably, the two basic channels evident in
the intermolecular dimerization domain may explain why this subdomain demonstrates a
higher ssDNA-binding affinity than the isolated intramolecular subdomain (33).
Because these computational modeling studies implied the importance of both
hydrophobic and electrostatic forces in mediating protein self-association and DNAbinding, we tested this concept by evaluating the effects of anionic detergent, monovalent
salt, and pH on the binding of purified Pur to ssDNA. To ensure conceptual relevance to
Acta2 gene regulation, the assembly of nucleoprotein complexes composed of Pur and
the purine-rich strand of the Acta2 promoter element (PE32-bF) containing a functional
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MCAT motif was monitored by quantitative ELISA. Our results indicated that at
concentrations in excess of 1.0 mM, sodium deoxycholate inhibited the binding of fulllength Pur and truncated Pur proteins containing the PUR repeat III dimerization domain
to the PE32-bF probe. The anionic detergent-sensitivity of each of the recombinant Pur
constructs analyzed is consistent with previous findings in which the inhibitory effect of
deoxycholate on the interaction of native fibroblast-derived Pur and Pur with ssDNA
was documented by band shift assay in comparison to Triton X-100 (20). It should be noted
that all protein-DNA binding assays presented in this report were conducted in the presence
of 0.05% (v/v) Tween 20, another non-ionic detergent which has no apparent effect on
Pur-ssDNA interaction. Consequently, the ability of deoxycholate to hinder Pur-ssDNA
interaction is potentially due to interference with PUR repeat III dimerization and/or
obstruction of hydrophobic contacts between Pur and nucleobases in the ssDNA.
Although physical destabilization of the PUR repeat I-II subdomain by deoxycholate
cannot be formally excluded, our results do corroborate existing structural data implicating
hydrophobic interactions as the principal driver of both intramolecular and intermolecular
association of the homologous PUR repeats in Pur (29).
With respect to the salt and pH sensitivity of Pur interaction with ssDNA, protein
binding to ssDNA was blocked at concentrations of NaCl exceeding 0.6 M in the case of
full-length Pur, Pur I-II-III, and the Pur III intermolecular domain. Pur-ssDNA
complexes were relatively stable across a wide range of solution pH conditions. However,
in accordance with a specific role for basic, positively charged residues in mediating
nucleoprotein complex formation, assembly of Pur-ssDNA complexes was abolished at
111

pH  10.5 where deprotonation of the  amino and guanidino groups of lysine and arginine
would be predicted to occur(46). Collectively, our findings suggest that a combination of
hydrophobic and electrostatic interactions contribute to the formation and stability of the
Pur-PE32-bF complex. In particular, the hydrophobic core of each subdomain
presumably accounts for the structural stability of each ssDNA-binding module while basic
residues located on the solvent-exposed surface serve to mediate subdomain contact with
nucleic acid. This interpretation is entirely consistent with the subdomain architecture of
the Pur dimer and the cooperative mechanism of nucleoprotein complex assembly (31,
33). Furthermore, the recently solved x-ray crystal structure of the Dm Pur I-II subdomain
in complex with CGG trinucleotide-repeats substantiates the importance of direct
electrostatic and hydrophobic contacts between specific amino acid residues and
nucleobases in mediating Pur binding to ssDNA (47).
Inspired by the results of the pH and salt sensitivity assays, we investigated the role of
several basic residues that are positionally conserved in PUR repeats I (K82), II (R159)
and III (R267) of mouse and human Pur proteins and for which data exists indicating their
involvement in mediating nucleic acid interaction by Dm Pur(28, 37). To evaluate the
effect of PUR repeat-specific K82A, R159A, and R267A point mutations on Pur function,
either single, double, or triple mutants were expressed in undifferentiated MEFs and
assayed for their ability to repress an Acta2 promoter-luciferase reporter gene. The results
showed that Pur constructs containing the R267A mutation were the most demonstrably
defective in Acta2 repressor activity. Of the mutants tested, Pur R159A/R267A,
K82/R159/R267, and K82A/R267A demonstrated the most profound deficiency in Acta2
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repressor activity. These findings suggest that residue R267 in PUR repeat III plays a
critical role in mediating Pur repressor activity but that residues K82A and/or R159A in
PUR repeats I and II contribute to Acta2 repression as well. This interpretation was further
validated by the finding that the deficiency in Acta2 repressor activity of the R159A/R267A
and K82A/R159A/R267A mutants was evident over a broad range of expressed protein
concentrations.
Consistent with the stable expression of the Pur point mutants in fibroblasts, structural
analyses performed on the purified R267A, R159A/R267A, and K82/R159A/R267A point
mutants indicated that each mutant protein was properly folded and capable of selfassociation. However, further biochemical analyses of the single, double, and triple point
mutants in comparison to wild-type Pur revealed a 3.5-8.5 fold reduction in binding
affinity of the point mutants for the purine-rich strand of the Acta2 MCAT element. Loss
of electrostatic contacts between basic, solvent-exposed residues in the protein and
potential hydrogen bond acceptors or negatively-charged phosphate groups in the DNA
presumably account for this finding. Although we cannot formally exclude the possibility
of altered subcellular trafficking of the expressed Pur point mutants, such a defect in
ssDNA-binding function would translate into a deficiency in Acta2 repressor activity.
Interestingly, these particular mutations did not impact ssDNA-binding specificity per se
as all the mutants demonstrated preferential interaction with purine-rich ssDNA in
comparison to a ssDNA probe containing thymidylate substitutions in each of three
putative binding sites(31). It is important to note that the analogous mutations in the 4 th strand of PUR repeats I, II, and III of Dm Pur have been reported to abolish RNA-binding
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without having any effect on Pur protein dimerization(37). Moreover, the R80 residue in
PUR repeat I of Dm Pur, which is positionally-conserved with the K82 residue in Pur,
has been reported to participate in direct hydrogen bond interaction with guanine in
GCGGCGG ssDNA(47).
Although the results of ssDNA-binding assays were consistent with changes in ssDNAbinding affinity as the biophysical basis for the impaired Acta2 repressor function of each
Pur mutant, the results of protein-protein interaction assays suggested another possible
reason for the diminished repressor activity particularly of the Pur double and triple point
mutants. As previously reported, MSY1 binds to the pyrimidine-rich strand of the Acta2
MCAT element (14, 20). Consequently, a deficiency in the ability of Pur to interact with
MSY1 may impair the ability of these corepressor proteins to assemble an inhibitory
nucleoprotein complex capable of altering DNA structure and preventing cis-element
recognition by transcriptional activators. The fact that the Pur K82A/R159A/R267A
mutant exhibited the most dramatic reduction in MSY1 binding affinity is consistent with
the original study suggesting that the entire core ssDNA-binding region of Pur is required
to mediate robust interaction of human Pur with human YB-1(48). In the case of Pur,
we have found that the isolated intermolecular and intramolecular subdomains of the
protein interact much more weakly with fibroblast-derived MSY1 than does full-length
Pur or a truncation protein containing all three PUR repeats (33). The observation that the
single R267A point mutant has apparently enhanced affinity while the R159A/R267A
double and K82/R159A/R267A triple mutants have reduced affinity for MSY1 points to a
differential role for each subdomain in modulating the interaction of the assembled Pur
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homodimer with MSY1. Consequently, the preponderance of the evidence presented in this
report suggests that the loss of Acta2 repressor function, particularly in the triple point
mutant, is likely due to decreased interaction of Pur with both ssDNA and corepressor
binding partners.
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Supplemental Material and Methods
Epitope Screening ELISA. Purified recombinant NHis-Pur proteins were diluted to
a concentration of 100 nM in coating buffer consisting of 20 mM HEPES, 150 mM NaCl,
1.5 mM MgCl2-6H2O pH 7.5 (HBSM pH 7.5) supplemented with 0.5 mM DTT and 5.0
g/ml BSA. Coating solutions were applied at 100 L per well to an EIA/RIA plate
(Costar 96 Well Easy Wash, Certified High Binding, Corning, Inc.) and the plate was
incubated overnight at 4C. All subsequent steps were carried out at room temperature.
Protein-coated wells were rinsed twice with 300 µL of wash buffer consisting of HBSM
pH 7.5 with 0.05% (v/v) Tween 20 and then blocked for 2 h with 300 µL of 2% (w/v) BSA
in HBSM pH 7.5. Blocking buffer was removed and 100 µL of primary rabbit anti-Purβ
210-229 antibody diluted in antibody buffer consisting of 0.2% (w/v) BSA, 0.05% (v/v)
Tween 20 in HBSM pH 7.5 was applied to the wells. Following a 1 h incubation with
primary antibody, wells were washed three times and 100 µL of a 1:4000 dilution of goat
anti-rabbit IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology, Inc.) was
applied to each well. Following a 1 h incubation with secondary antibody, wells were
washed four times before addition of 100 µL ABTS peroxidase substrate solution
(Millipore). The reaction was quenched by the addition of 100 µL of 1% (w/v) SDS.
Following a short 5 min stabilization period, the absorbance value of each well at 405 nm
was obtained using a Vmax plate reader operated by SoftMax Pro Version 6.4.1 software
(Molecular Devices). Absorbance values were corrected for nonspecific binding by
subtracting background absorbance generated in BSA only-coated wells. Data points were
plotted and fit to a hyperbola using Prism 6 (GraphPad Software, Inc.).
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Expression and purification of NHis-Pur point mutants. A total of 4 L of Miller’s
LB broth (Fisher Scientific) containing 100 g/mL ampicillin was inoculated with a 1:16
dilution of starter culture (pQE30-NHis-Pur WT or mutated plasmid transformed into E.
coli strain JM109) and incubated in a shaker-incubator at 250 rpm and 37C. Once the
culture reached a density of 0.6 absorbance units at 600 nm, isopropyl-Dthiogalactopyranoside (IPTG) was added to a final concentration of 0.1 mM in the case of
Pur R267A and the culture was incubated for an additional 5 h at ambient temperature.
The expression of all other NHis-Pur point mutants was achieved using 1.0 mM IPTG for
4 h at 37C. The cells were collected by centrifugation at 6,540  g for 16 min at 4C and
then frozen at −80C.
Cell pellets were treated with lysozyme and then sonicated in lysis buffer consisting of
50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole pH 8.0, 10 mM β-mercaptoethanol
(BME), 0.5 mM phenylmethylsulfonyl fluoride (PMSF), and 1.0 g/mL each of pepstatin
A, leupeptin, and aprotinin as previously described 1, 2. Cleared cell lysate was combined
with 3-4 mL of HIS-Select Nickel Affinity Gel (Sigma-Aldrich) and incubated on a
rocker overnight at 4C. The resin was transferred into a small chromatography column
and washed with lysis buffer until the absorbance at 280 nm (A280) of the eluate was less
than 0.1 units. In the case of NHis-Pur R267A mutant, the resin was then washed with
imidazole-free lysis buffer containing 2 M NaCl until A280 of the eluate was less than 0.02
units. In the case of the double (R159A/R267A) and triple (K82/R159A/R267A) point
mutants, 10 mM imidazole was retained in the 2 M NaCl wash buffer. After reequilibrating the column with complete lysis buffer, His-tagged protein was eluted from
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the resin using a gradient of 10 to 500 mM imidazole in lysis buffer. Fractions were
monitored for the presence of protein by A280 measurement in conjunction with SDSPAGE. In the case of the double and triple point mutants, fractions enriched in NHis-Pur
protein were pooled, concentrated, and then subjected to calibrated size exclusion
chromatography (SEC) in buffer consisting of 50 mM NaH2PO4, 300 mM NaCl, 10 mM
imidazole pH 8.0, 10 mM BME. In the case of NHis-Pur R267A, an additional
purification step was required prior to SEC due to the presence of degradation products
and other contaminants. Specifically, R267A-enriched fractions from the Ni-affinity
column were pooled, diluted 2-fold, and dialyzed into low salt heparin affinity buffer
consisting of 20 mM Tris-Cl pH 7.4, 100 mM NaCl, 0.5 mM EDTA, pH 7.4, 10 mM BME,
and 0.5 mM PMSF. The dialyzed protein was applied to a heparin agarose column and
washed with low salt buffer until the A280 reached a constant baseline value. Bound protein
was eluted with a 0.1-2 M NaCl gradient in heparin affinity buffer. Fractions enriched in
NHis-Pur R267A were pooled, dialyzed against SEC buffer, and concentrated to ~2 mL
using a 10,000 MWCO Amicon Ultra Centrifugal filter device (Millipore). The
concentrated protein was then applied to a 1.5  120 cm Sephacryl S200-HR and resolved
at a flow rate of ~1.5 mL/min. Fractions enriched in NHis-Pur were pooled and the final
protein concentration was determined from A280 and A320 measurements using the Rayleigh
correction factor for light scattering and a theoretical molar extinction coefficient of 20,400
M−1 cm−1.
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Supplemental Tables and Figures

Table S2- 1. Primers used to generate expression plasmids encoding mouse Pur
point mutants
Primer Name
Primer Sequence (5 to 3)
R267A sense
GTGAAGCCGTCCTACGCCAATGCCATCACCGT
R267A antisense ACGGTGATGGCATTGGCGTAGGACGGCTTCAC
K82A sense
GTGGGCGCGGGCGGCTCCGCGAGCCGCCTCACGCTGTCGATG
K82A antisense CATCGACAGCGTGAGGCGGCTCGCGGAGCCGCCCGCGCCCAC
R159A sense
GCTTCCTGCGCATCGCCCAGACGGTGAACC
R159A antisense GGTTCACCGTCTGGGCGATGCGCAGGAAGC
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Figure S2- 1. Effect of various detergents on the interaction of Pur with Acta2
ssDNA.
The binding of 1.0 nM full-length Pur to 0.5 nM PE32-bF ssDNA was assessed in assay
buffer containing varying concentrations of sodium deoxycholate (DOC), sodium dodecyl
sulfate (SDS), or Triton X-100 (TX100). Solid-phase Pur-PE32-bF complexes were
detected by ELISA using rabbit anti-mouse Pur 210-229 as the primary antibody.
Nonspecific background absorbance at 405 nm in control wells without any DNA was
subtracted from the signal generated in PE32-bF-coated wells. Data points show
absorbance values at 405 nm normalized to the mean absorbance value determined in wells
without added detergent (mean  SD, n = 3).
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Figure S2- 2. Relative thermostability of the isolated Pur III intermolecular
subdomain in the presence of deoxycholate.
The unfolding of the Pur III dimerization domain was evaulated by thermal shift assay at
a protein concentration of 100 g/mL in buffer composed of 20 mM HEPES, 150 mM
NaCl, 10 mM -mercaptoethanol pH 7.5 supplemented with increasing concentrations of
sodium deoxycholate (DOC). The leftward shift of the curves as a function of increasing
DOC concentration from 0.05 to 2.0 mM is indicative of some loss in the structural
integrity of this subdomain.
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Figure S2- 3. Effect of solution pH on the interaction of Pur truncation proteins
with Acta2 ssDNA.
(A) The binding of 1.0 nM full-length Pur (Pur FL) to 0.5 nM biotinylated PE32-bF
ssDNA was assessed in complete binding buffer at pH ranging from 3.5 to 12.5. Solidphase Pur-PE32-bF complexes were detected by ELISA using rabbit anti-mouse Pur
210-229 as the primary antibody. Nonspecific background absorbance at 405 nm in control
wells without any DNA was subtracted from the signal generated in PE32-bF-coated wells.
Background corrected A405 values measured at each pH were normalized by dividing by
the mean A405 value determined at pH 7.5. (B) The interaction of Pur I-II-III (1.0 nM)
and Pur III (5.0 nM) with 0.5 nM PE32-bF ssDNA was assessed by ELISA as in (A) in
binding buffer without MgCl2 at pH ranging from 7.5 to 12.5.
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Figure S2- 4. CLUSTAL 2.1 multiple sequence alignment of mouse and human
Pur, Pur, and Pur proteins in comparison to Dm Pur.
Residues selected for mutagenesis in Pur are highlighted in yellow or light blue. The
peptide epitopes of the rabbit anti-mouse Pur antibodies (B210-229 and B302-324) used
in this study are underlined.
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Figure S2- 5. Homology model of Mm Pur highlighting basic residues implicated in
ssDNA-binding.
(A) Space-filling model of the Mm Pur dimer depicting surface exposure of K82 (red),
R159 (blue), and R267 (purple). (B) Model in (A) rotated 90° around the vertical axis
clearly shows the location of K82 and R159. (C) A 3D ribbon model of the Mm Pur dimer
highlighting the location of the selected basic residues. (D) Model in (C) rotated 90° around
the vertical axis. (E) Electrostatic surface maps of the Mm Pur dimer showing distinct
regions of charged amino acids. All selected basic amino acids are located within positively
charged clusters (blue areas). (F) Model in (E) rotated 90° around the vertical axis to depict
a distinct positively charged channel.
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Figure S2- 6. Quaternary structure of Pur point mutants. Calibrated SEC was
conducted on preparations of Pur WT
(A), Pur K82A/R159A/R267A (B), Pur R159A/R267A (C), and Pur R267A (D) at
loading concentrations in excess of 10 M (open circles). The elution profile of a mixture
of molecular weight standards is shown for comparison (dash lines). Numbers in (A)
indicate the apparent molecular weights of the four globular protein standards used to
calibrate the 1.5  120 cm column packed with Sephacryl S200. Arrows in (A) indicate the
elution positions of Blue Dextran and DNP-asparate, respectively. The minor protein peaks
eluting after the homodimer in (D) correspond to contaminants and/or degradation
products. WT, wild-type, BSA, bovine serum albumin, OVA, ovalbumin, CAH, carbonic
anhydrase, CYC, cytochrome C.
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Figure S2- 7. SDS-PAGE analysis of Pur point mutants.
The indicated proteins (1.5 g) were resolved on a 12% mini-gel and stained with
Coomassie Brilliant Blue. Numbers on the left indicate molecular mass in kilodaltons of
each standard protein in the ladder in lane 1.
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Figure S2- 8. Absence of detectable nuclease activity in purified preparations of
recombinant Pur.
(A, B) Solutions containing 1.0 M of the indicated NHis-Pur proteins plus 2.0 g of
either double-stranded pBLCAT3 plasmid (A) or single-stranded M13mp18 DNA (B) were
incubated for 1 h at 37C. Solvent conditions were identical to those used in nucleoprotein
binding assays with the exception that DTT and the dT32 oligonucleotide were left out of
the buffer. As a positive control for the presence of nuclease activity, DNA substrates were
incubated in parallel with 100 to 0.01 mUnits of DNase I. The DNA in each reaction
mixture was extracted, precipitated, and resolved (~1 g per lane) on a 1% w/v agarose gel
in the presence of ethidium bromide. Fluorescent DNA bands were visualized by UV
illumination. Numbers on the left indicate the size of bands (in bp) present in the 1 kb DNA
ladder (lane 1). WT, wild-type.
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Figure S2- 9. Screening of a rabbit anti-mouse Pur antibody raised against
residues 210-229 for reactivity with wild-type Pur (Pur WT) and single (R267A),
double (R159A/R267A), or triple (K82A/R159A/R267A) Pur point mutants.
Microtiter wells coated with 100 nM of the indicated Pur proteins were incubated with
varying concentrations of peptide affinity-purified rabbit anti-mouse Pur 210-229
antibody. Complex formation was detected by ELISA. Binding curves were generated by
fitting absorbance values at 405 nm to the equation for a hyperbola. As shown, the resultant
lines are virtually superimposable.
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Figure S2- 10. Effect of R/K point mutations on the interaction of Pur with MSY1.
(A) The binding of purified Pur wild-type (WT) protein or the indicated single (R267A),
double (R159A/R267A), or triple (K82A/R159A/R267A) point mutants to immobilized
MSY1 (filled symbols, solid lines) or BSA (open symbols, dashed lines) was evaluated by
ELISA. Pur-MSY1 complexes were detected using rabbit anti-Pur 302-324 as the
primary antibody. Binding isotherms were generated by fitting data points to the equation
for a rectangular hyperbola. (B) Binding curves generated after subtracting out the
nonspecific absorbance measured in BSA only-coated wells from the absorbance obtained
in MSY1-coated wells.
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Abstract
Purine-rich element-binding protein B (Purβ) inhibits myofibroblast differentiation by
repressing the expression of the smooth muscle -actin gene (Acta2). Several reports
have identified the structural domains in Purβ that enable its characteristic interaction
with purine-rich single-stranded DNA (ssDNA) sequences in the Acta2 promoter.
However, little is known about the physical and functional effects of single nucleotide
polymorphisms that alter individual amino acid residues in Pur. This study evaluated
seven rare single amino acid variants of human PURB engineered into the homologous
mouse Pur protein. Mapping the location of variant residues on a homology model of
the Purβ homodimer suggested that most of the altered residues are remote from the
predicted ssDNA-binding regions of the protein. The repressor activity of each Pur
variant was assessed in transfected fibroblasts and smooth muscle cells via Acta2
promoter-reporter assays. A Q64* nonsense variant was completely inactive while
missense variants exhibited repressor activity that ranged from ~1.5-fold greater to ~2fold less than wild-type Pur. Lower activity variants P223L and R297Q were expressed
in bacteria and purified to homogeneity. Each variant was physically indistinguishable
from wild-type Pur in terms of quaternary structure and thermostability. Results of
DNA and protein binding assays indicated that the P223L and R297Q variants retained
high affinity and specificity for purine-rich ssDNA sequences but differed in their
interaction with other Acta2 regulatory proteins. These findings suggest that the presence
of certain variant residues affects the Acta2 repressor activity of Pur by altering its
interaction with other transcription factors but not with ssDNA.
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Introduction
Wound healing is a complex process involving a network of injury-activated cell
types and regulatory factors that participate in the systematic repair of tissue damage. A
key feature of this process is the formation and contraction of granulation tissue that
effectively brings wound edges together (1-3). Once the wound is closed, certain cell
types in the granulation tissue typically undergo apoptosis (4). However, in
fibrocontractive diseases, granulation tissue remains active resulting in excessive
accumulation of extracellular matrix (ECM) and additional tissue contraction, which
collectively disfigure and impair the affected organ (2, 5-7). Myofibroblasts are a
distinctive cell type in granulation tissue and directly contribute to wound contraction and
stability by transducing force from internal contractile proteins to the local ECM and by
producing ECM components such as collagen (2, 5, 8, 9). The primary driver in the
pathogenesis of fibrosis is the persistent activation of resident connective fibroblasts to
form differentiated myofibroblasts (10, 11). Therefore, a better understanding of the
molecular mechanisms that control myofibroblast differentiation may provide insight into
potential regulatory targets to limit fibrosis and tissue damage.
One of the early cytological characteristics of fibroblast to myofibroblast
differentiation is the appearance of cytoskeletal stress fibers, which form the forcegenerating contractile apparatus (5, 12, 13). While a number of components have been
implicated in stress fiber formation, the expression of the smooth muscle -actin isoform
has been shown to be a distinctive biochemical marker of the myofibroblast phenotype
(14). The presence of smooth muscle -actin in stress fibers also enhances myofibroblast
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contractile activity making the regulation of smooth muscle -actin expression relevant
to both the healthy and pathological states of wound repair (15). A number of studies
have revealed that the mouse smooth muscle -actin gene (Acta2) is subject to both
positive and negative transcriptional regulation in fibroblasts by virtue of the interaction
of certain trans-activators and trans-repressors with cognate cis-acting elements in the 5’flanking region of the gene (16-19). The repertoire of transcription factors involved in
Acta2 gene activation include a combination of ubiquitous, growth factor-responsive, and
muscle-associated factors. For example, the Smad activator proteins have been reported
to induce Acta2 expression by binding to CAGA elements following the exposure of
fibroblasts to transforming growth factor 1 (TGF-1) (18, 19). Specificity proteins 1 and
3 (Sp1, Sp3), serum response factor (SRF), and transcription enhancer factor 1 (TEF1)
are also components of a multi-protein Acta2 activation complex formed by their
interaction with G/C-rich, CArG, and muscle-CAT (MCAT) recognition motifs,
respectively (16-18). Conversely, repression of Acta2 in fibroblasts appears to be
governed by the purine-rich element-binding proteins A and B (Pur and Purβ) and Ybox binding protein 1 (YB1), which bind in a strand-specific manner to DNA sequences
that overlap the G/C-rich and MCAT elements (17, 20, 21). Pur and Purβ proteins may
also mediate gene repression by binding directly to other transcription factors associated
with positive and negative regulation of Acta2 including TEF1, Smad3, and YB1 (17,
20).
Insights into the specific molecular mechanism by which Purα and Purβ repress Acta2
have been provided by studies that have uncovered the unique structural features of each
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protein. The primary sequences of Pur and Purβ each contain three regions of internal
homology known as Pur repeats I, II, and III (22, 23). The solved x-ray crystal structures
of the truncated repeat I-II region of Drosophila melanogaster (Dm) Pur and full-length
Borrelia burgdorferi (Bb) Pur showed that certain -strand and -helix forming
sequences located in each repeat associate to form a so-called PUR domain. Importantly,
this domain adopts a whirly-like fold and is capable of binding to ssDNA (23, 24). The
more recently reported crystal structure of repeat III from Dm Pur confirmed that
another PUR domain is formed by the intermolecular association of two repeat III
sequences in a manner which mediates Pur dimerization (25). This result is consistent
with other biochemical data indicating that repeat III also corresponds to the dimerization
domain in Purβ (22). Yet despite sharing similar structural features, the isolated repeat III
domain from Purβ binds with high affinity and specificity to ssDNA, while the isolated
repeat III domain from Pur is apparently deficient in binding to ssDNA (22, 25). This
distinction along with other structural differences may explain why Purβ functions as a
dominant repressor of Acta2 in comparison to Pur when evaluated using both gain-offunction and loss-of-function approaches (26, 27).
The National Heart Lung and Blood Institute (NHLBI) Grand Opportunity Exome
Sequencing Project has analyzed the exomes of over 200,000 individuals enrolled in a
number of well-known epidemiological studies to identify variants within the population.
To date, a total of 13 rare, single nucleotide polymorphisms (SNPs) have been identified
in the open reading frame of human PURB of which six encode missense substitutions
and one a pre-mature stop codon [Exome Variant Server, NHLBI GO Exome Sequencing
142

Project] (28). Curiously, five of the six missense substitutions are located within or close
to the repeat III dimerization domain. Because of the conspicuous positional and
chemical features of these substitutions, we chose to evaluate whether the presence of
variant residues would affect the structure and/or function of Purβ in relation to
repression of Acta2 in fibroblasts. Our findings reveal that some amino acid substitutions
produce relatively modest but significant changes in the repressor activity of Pur toward
the Acta2 promoter. Results of biochemical assays indicate that these changes are likely
dictated by how the Pur variants physically interact with other transcriptional regulatory
proteins rather than with ssDNA.

Material and Methods
Materials
Coomassie Plus™ Protein Assay Reagent, PageRuler Prestained Protein Ladder,
Pierce™ Enhanced Chemiluminescence Reagent, SYPRO Orange, and 6His tag
antibody HIS.H8 were obtained from Thermo Fisher Scientiﬁc, Grand Isle, NY. Cell
culture media were procured from Mediatech, Inc., Manassas, VA. Fetal bovine serum
(FBS) was purchased from Sigma-Aldrich, St. Louis, MO. Costar EIA/RIA plates were
acquired from Corning Inc., Corning, NY. Polyplus-transfection SA jetPEI and
jetPRIME transfection reagents were purchased from VWR International, Radnor, PA.
Luciferase Assay System and Reporter Lysis Buffer were obtained from Promega Corp.,
Madison, WI. Immobilon-P polyvinylidene difluoride membrane (PVDF) transfer
membrane, 2, 2’-AZINO-bis [3-ethylbenziazoline-6-sulfonic acid] (ABTS) peroxidase
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substrate solution, and mouse anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
monoclonal antibody clone 6C5 were obtained from EMD Millipore, Billerica, MA.
StreptaWell strips were purchased from Roche Diagnostics, Indianapolis, IN. The
QuikChange II XL Site-Directed Mutagenesis Kit was acquired from Agilent
Technologies, Santa Clara, CA. Horseradish peroxidase (HRP)-conjugates of goat anti-rat
IgG, goat anti-rabbit IgG, goat anti-mouse IgG, and mouse IgG kappa binding protein
were procured from Santa Cruz Biotechnology, Inc. Dallas, TX.

Computational Modeling of Purβ Protein Structure
Updated computational homology models of the Mus musculus (Mm) Purβ monomer
and homodimer were generated based on Dm Pur crystal structures: 3K44 (Pur repeats
I-II, no DNA) and 5FGO (two Pur repeats III, no DNA) (24, 25). A combination of
web-based modeling servers, bioinformatics, and simulated annealing (CNS version
1.3)(29) were used to create models using approaches similar to those previously
described (22, 23, 30). Briefly, amino acid sequences corresponding to Mm Pur residues
1-236 and 180-324 were separately submitted to the web-based modeling server ITASSER (31, 32) using 3K44 and 5FGO, respectively, as templates. The structural
predictions generated by I-TASSER were checked for consistency using several other
web-based modeling programs including PSIpred, LOMETS and Phyre2 (33-35). Both
resulting homology models were examined in PyMOL and selected glycine residues in
the linking region between repeats II and III were aligned (36). Using PyMOL editing
features, glycine 218 or 225 was used as an axis to rotate the repeat III subdomain away
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from repeats I-II and then any regions of overlap were resolved to create a composite
model of the 324 residue monomer. Several different models of the Pur monomer were
generated by systematically adjusting the angle of rotation around glycine 218 or 225. To
form a homodimer, the repeat III sequences from two Purβ monomers were aligned to the
crystal structure of the intermolecular domain of Pur, 5FGO, using Lsqman (37).
Models of the homodimer were optimized by simulated annealing, which effectively
relaxed close contacts and regularized local bond angle geometries. A final model was
selected as it best fit with the dimensions of the Pur homodimer based on hydrodynamic
analyses of the protein (38).

Construction of Expression Vectors Encoding Pur Variants
The mammalian expression plasmid encoding N-terminal hexahistidine-tagged
murine Purβ (pCI-NHis-Purβ) has been previously described (21). Plasmids encoding six
different full-length Pur variants (L46V, G215S, P223L, F274L, G282S, R297Q) and
one nonsense variant (Q64*) were generated in pCI-NHis-Purβ backbone via sitedirected mutagenesis. Primers were selected using the QuikChange Primer Design
Program (Table S1) and mutated plasmids were amplified using procedures specified by
the manufacturer of the QuikChange II XL kit. Correctly mutated plasmids were
validated by automated DNA sequencing performed by the Vermont Cancer Center DNA
Analysis Facility. Mutated plasmids were isolated from bacterial host cells via double
cesium chloride gradient centrifugation. The purity of isolated plasmids was assessed by
electrophoresis of intact and restriction enzyme-digested plasmid on 1% w/v agarose
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gels. The cDNA sequences encoding Purβ variants P223L and R297Q were released from
their respective pCI-NHis-Purβ plasmids by treatment with EcoRI and SalI. Isolated
cDNAs were then subcloned into the bacterial expression vector pQE30 linearized with
the same restriction enzymes. The resultant pQE30-NHis-Pur P223L or R297Q
plasmids were transformed into Escherichia coli JM109 cells. Plasmids were purified and
sequenced as described above.

Acta2 Promoter-Luciferase Reporter Assays
AKR-2B mouse embryo-derived fibroblasts (MEFs) and A7r5 rat aortic smooth
muscle cells (SMCs) were cultured as previously described (39). For transfections, AKR2B MEFs were seeded into 6 well plates at a density of 4 104 cells/well in McCoy’s 5A
medium with 5% v/v heat-inactivated FBS. A7r5 SMCs were seeded at a density of 6 
104 cells/well in Dulbecco’s modification of Eagle’s medium with 10% v/v FBS. The
cells were cultured for 24 h at 37°C in a humidified 5% CO2 incubator. Adherent cells
were then transiently transfected with a mixture of expression and reporter plasmids at a
ratio of 2 L jetPEI or jetPrime reagent per 1 g of DNA as instructed by the
manufacturer. Mixtures contained 1 g of empty pCI plasmid or pCI-NHis-Purβ plasmid
plus 0.9 g of Acta2 promoter-luciferase reporter plasmid (pVSMP8-Luc) (22) and 0.1
g of pSV40-Gal control reporter plasmid. Transfected AKR-2B cells or A7r5 cells
were cultured for 48 h or 72 h, respectively. Cells were washed twice with phosphatebuffered saline and then extracted with 1 Reporter Lysis Buffer supplemented with 0.5
mM phenylmethylsulfonyl fluoride (PMSF) and 1 g/mL each of pepstatin A, leupeptin,
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and aprotinin. Cell lysates were frozen at −20°C. Prior to use in endpoint assays, lysates
were thawed and subjected to centrifugation at 15,800  g for 30 min at 4°C. Total
protein concentration in the cleared supernatants was determined by Bradford assay using
bovine serum albumin (BSA) as a standard. Reporter enzyme activity was assessed in a
Turner Designs TD-20/20 luminometer as directed by the manufacturer of the Luciferase
Assay System reagents. Luciferase activity measured in each cell lysate was normalized
for total protein content. Numerical datasets were analyzed via one-way analysis of
variance in conjunction with Dunnett’s multiple comparison test with significance set at p
< 0.05. Statistical analyses were conducted with the use of Prism 7.01 software
(Graphpad Software, Inc., La Jolla, CA).

Immunoblotting of Cell Extracts
Total protein at amounts ranging from 15-30 g from AKR-2B cells and 30-50 g
from A7r5 cells was precipitated using five volumes of ice cold ethanol to one volume of
cleared cell lysate. Mixtures were incubated at −20°C for at least 1 h before
centrifugation at 15,800  g for 30 min at 4°C. Protein-containing pellets were air dried
briefly and then dissolved in 2 sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) sample preparation buffer composed of 40 mM Tris-Cl pH
6.8, 1% w/v SDS, 10% v/v glycerol, 0.01% w/v bromophenol blue, 5% v/v mercaptoethanol. After heating protein samples for 5 min at 96°C, the samples were
subjected to electrophoresis on 8% acrylamide/bisacrylamide (29:1) mini-gels. Separated
proteins were then transferred to PVDF membrane in transfer buffer consisting of 25 mM
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Tris base, 192 mM glycine, 20% v/v methanol for 90 min at 125 volts. Blots were
incubated overnight in blocking buffer composed of 5% w/v nonfat dry milk powder
dissolved in wash buffer composed of 20 mM Tris-Cl pH 7.5, 150 mM NaCl, 0.1 % v/v
Tween 20. Blots were probed sequentially for 1-2 h with primary mouse anti-6His tag
antibody followed by HRP-conjugated goat anti-mouse IgG or HRP-conjugated mouse
IgG kappa binding protein. Primary antibody and secondary HRP-conjugated reagents
were used at a working dilution of 1:2000 in blocking buffer. Blots were rinsed 3-4 times
with wash buffer after the primary and secondary incubations. Immunoreactive bands
were revealed with the use of chemiluminescent detection reagents and visualized on a
Fujifilm LAS-4000 imaging system or blue autoradiography film. Blots were routinely
reprobed with mouse anti-GAPDH monoclonal antibody as a loading control.

Recombinant Protein Purification
NHis-Purβ wild type (WT) or variant (R297Q, P223L) proteins were expressed in and
purified from E. coli JM109 cells as previously described (40). Some modifications to the
process were necessary to optimize the production and purity of the Pur variants as
outlined in Supporting Information. All recombinant protein preparations were subjected
to calibrated size exclusion chromatography as a final purification step (38). Final protein
concentrations were determined by dye-binding assay using Coomassie Plus™ Protein
Assay Reagent and NHis-Purβ WT as a calibration standard. The concentration of NHisPur WT stock solutions was ascertained by absorbance measurement at 280 nm and
calculated using a theoretical molar extinction coefficient for Pur (22). The purification
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of NHis-tagged mouse YB1 (MSY1) from E. coli was performed as previously described
(41).

Thermal Shift Assay
The thermostability of purified NHis-Pur variants was assessed by differential
scanning fluorimetry as previously described (40). Briefly, each protein was diluted to
concentrations ranging from 75 to 300 g/mL in buffer containing 50 mM NaH2PO4, 300
mM NaCl, 10 mM imidazole, pH 8.0 with 10 mM -mercaptoethanol and 5 SYPRO
Orange. Solutions were aliquoted into the wells of a 96-well polymerase chain reaction
(PCR) plate at 40 L/well. Plates were covered with optical sealing film and centrifuged
briefly. Plates were heated in increments of 1°C per min starting at 25°C and ending at
94°C with the use of an Applied Biosystems 7500 Fast Sequence Detection System realtime PCR instrument. Fluorescence signal emitted at 568 nm was detected and recorded
over time. The minimum baseline fluorescence (Fmin) measured in each sample well was
subtracted from all data points collected and the difference was divided by the maximum
fluorescence (Fmax) measured in each sample well. Data points collected between 40°C
and 71°C were analyzed via non-linear fitting to the Boltzmann equation with the use of
Prism 7.01 software to determine the melting temperature (Tm) of each Pur variant.

Quantitative Pur-DNA Interaction Assay
An enzyme linked immunosorbent assay (ELISA) system was used to evaluate
nucleoprotein complex formation between purified recombinant Pur and immobilized
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DNA as previously described (22). Oligonucleotides tagged with 3’ biotin were diluted to
a concentration of 0.5 nM in coating buffer composed of 20 mM HEPES pH 7.5, 150
mM NaCl, 1.5 mM MgCl2-6H2O. Aliquots of 100 L were applied to streptavidin-coated
microtiter wells, which were incubated for 2 h at room temperature. In all subsequent
steps, solutions were applied to wells in volumes of 100 L except for the wash and
blocking buffers, which were used at 300 L. Wells were rinsed with wash buffer
consisting of 20 mM HEPES pH 7.5, 150 mM NaCl, 1.5 mM MgCl2-6H2O, 0.05% v/v
Tween 20 and then incubated for 1 h with blocking buffer containing 20 mM HEPES pH
7.5, 150 mM NaCl, 1.5 mM MgCl2-6H2O, and 2% w/v BSA. Wells were emptied and
NHis-Pur WT or variant proteins were then applied at concentrations ranging from 9.0
nM to 0.074 nM in binding buffer supplemented with 0.5 mM dithiothreitol (DTT) and 1
g/mL polydeoxythymidylate (dT32). The binding buffer was composed of 20 mM
HEPES pH 7.5, 150 mM NaCl, 1.5 mM MgCl2-6H2O, 0.2% w/v BSA and 0.05% v/v
Tween 20. Wells were incubated for ~17 h at room temperature and then rinsed three
times with wash buffer. Primary rabbit anti-mouse Purβ 302-324 antibody (21) diluted to
a concentration of 1 g/mL in binding buffer was next applied to the wells. After a 1 h
incubation with primary antibody, wells were washed three times and then incubated for
1 h with goat anti-rabbit IgG-HRP diluted 1:4000 in binding buffer. Wells were washed
three times followed by the addition of ABTS peroxidase substrate solution. Colorimetric
reactions were quenched by adding an equal volume of 1% w/v SDS. After a 5 min
stabilization period, endpoint absorbance readings at 405 nm were acquired using a 96
well microplate reader. To correct for background signal, absorbance values produced in
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wells with NHis-Pur but no DNA were subtracted from A405 values obtained in wells
with NHis-Pur plus DNA. Apparent Kd or EC50 values were determined by non-linear
least squares fits of data points to equations for either a hyperbola or a four parameter
dose response with the use of Prism 7.01 software.

Quantitative Purβ-MSY1 Interaction Assay
The relative affinity of Purβ for MSY1 was assessed using an ELISA strategy as
previously described (40). The compositions of the coating, blocking, binding, and wash
buffers were the same as those used in the solid-phase protein-DNA interaction assay
except where noted. Purified MSY1 diluted to 100 nM was initially adsorbed to the wells
of an EIA/RIA plate in coating buffer composed of 20 mM HEPES, 150 mM NaCl, 1.5
mM MgCl2-6H2O, pH 7.5 with 5.0 g/mL BSA for 3 h at room temperature. MSY1coated wells were washed and blocked prior to the application of varying concentrations
of purified NHis-Purβ WT or variant protein. Wells were then incubated overnight at 4°C
for 17 h. Wells were washed and then incubated with primary rabbit anti-Pur 302-324
antibody at 1 g/mL for 1 h followed by secondary goat anti-rabbit IgG-HRP at a 1:4000
dilution for 1 h. Wells were washed and ABTS substrate was added. Color development
was quenched by the addition of an equal volume of 1% w/v SDS. Following a
stabilization period of 5 min, endpoint absorbance values at 405 nm were obtained using
a 96 well microplate reader. Background absorbance values generated in MSY1- or BSAcoated wells incubated with binding buffer alone were subtracted from absorbance values
obtained in wells incubated with fluid-phase Pur. The contribution of non-specific
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binding was accounted for by subtracting absorbance values obtained in BSA only-coated
wells from MSY1-coated wells at identical Pur protein concentrations. Data points were
analyzed using an equation for a hyperbola to determine apparent Kd with the use of
Prism 7.01 software.

Qualitative Protein-Protein Interaction Assay
The ability of native mouse or human cell extract-derived proteins to interact with
recombinant Purβ WT and variant proteins was screened using an ELISA approach.
Nuclear extracts were prepared from AKR-2B fibroblasts or HEK 293FT cells as
described in Supporting Information. NHis-Purβ WT, P223L, or R297Q were
immobilized on EIA/RIA wells at 300 nM in coating buffer composed of 20 mM HEPES
pH 7.5, 150 mM NaCl, 5 g/mL BSA, and 0.5 mM DTT for 2 h at room temperature.
Pur-coated wells were rinsed twice with wash buffer consisting of 20 mM HEPES pH
7.5, 150 mM NaCl, 1 mM EDTA, and 0.05% v/v Tween-20 and then blocked in buffer
supplemented 2% w/v BSA for 2 h. Nuclear extract was then applied at 300 g
protein/mL in binding buffer composed of 20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM
EDTA, 0.05% v/v Tween 20, and 0.2% w/v BSA. Wells were incubated at 4°C for 17 h
and then washed three times. Wells were then incubated with selected primary antibodies
diluted to 1 g/mL in binding buffer for 1 h followed by HRP-conjugated secondary
antibodies at 1:2000 dilutions for 1 h. The specific primary and secondary antibodies
used are listed in Supporting Information. Color development was achieved by addition
of ABTS substrate solution and quenched with an equal volume of 1% w/v SDS. After 5
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min stabilization period, absorbance values at 405 nm were obtained using a 96 well
microplate reader. Values were corrected for background absorbance measured in wells
that contained buffer instead of nuclear extract. Numerical datasets were analyzed via
one-way analysis of variance and Dunnett’s multiple comparison test with significance
set at p < 0.05 with the use of Prism 7.01 software.

Pur Antibody Screening Assay
The effect of variant amino acid residues on epitope recognition by Pur antibodies
was tested by ELISA as previously described (40). Briefly, purified Purβ WT or variant
proteins at 100 nM were immobilized on the wells of EIA/RIA plates in coating buffer
composed of 20 mM HEPES pH 7.5, 150 mM NaCl, 1.5 mM MgCl2-6H2O, 0.5 mM DTT
and 5.0 g/mL BSA for 17 h at 4°C. Wells were then washed and blocked. This was
followed by application of varying concentrations of primary rabbit antibodies
recognizing Pur residues 210-229 or 302-324 (21). After a 1 h incubation, wells were
washed and HRP-conjugated goat anti-rabbit IgG diluted 1:4000 was next applied for 1 h.
Generation of a colorimetric signal and acquisition of absorbance values were carried out
as described above.

Results
Identification of Rare SNP-Encoded Purβ Variants
The NHLBI Grand Opportunity Exome Sequencing Project has identified allelic
variants in the exomes of over 200,000 individuals and compiled them in a searchable
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web-based server [Exome Variant Server, NHLBI GO Exome Sequencing Project] (28).
A query of this database for PURB revealed 13 SNPs in the open reading frame of which
six produce synonymous codons, six encode missense variants (L34V, G203S, P211L,
F262L, G270S, and R285Q) , and one (Q52*) generates a premature stop codon (Table
S2). Interestingly, five of the six residues changed in the rare missense variants are
located in or near the third repeat of Purβ, a region known to enable protein dimerization
and high affinity binding to purine-rich ssDNA (22). Sequence alignment of Purβ
proteins from several species revealed that the wild-type amino acid residues found at the
positions of the SNP-generated missense and premature stop codons are highly conserved
among mammalian Pur sequences (Figure 3-1).
The web-based Polymorphism Phenotyping v2 (PolyPhen2) predictor was used to
estimate whether the presence of the variant amino acid residues might affect the
structure and function of Purβ. The projected effects ranged from benign to probably
damaging, with four of the six variant amino acid substitutions achieving at least a
possibly damaging classification (Table S3-2). However, considering the chemical
properties of the amino acids involved in the “benign” substitutions, the PolyPhen2
predictions must be taken cum grano salis. Consequently, we chose to empirically
determine how these particular amino acid substitutions affect the structure and function
of Pur.
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Figure 3- 1. Sequence homology of Purβ proteins from different species.
The primary amino acid sequences of Pur from human (Uniprot ID: Q96QR8), mouse
(O35295), rat (Q68A21), zebra fish (Q6PHK6), and the African clawed frog (Q8AVS4)
were aligned using Clustal Omega. The hashtags above the text designate amino acid
residues located at positions associated with rare, SNP-encoded missense or stop gained
variants in human Pur (L34V, Q52*, G203S, P211L, F262L, G270S, R285Q). The
residues conserved at each position in wild-type human/mouse Pur are as follows:
L34/L46, Q52/Q64, G203/G215, P211/G223, F262/F274, G270/G282, and R285/R297.
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Mapping of Variant Residues on a Homology Model of Mm Purβ
An updated model of the higher order structure of full-length Pur was
computationally derived to gain a greater appreciation for the position of the common
and variant amino acid residues in relation to the specific subdomains formed by Pur
repeats I, II, and III (Figure 3-2A). Homology models of the Mm Purβ monomer and
homodimer were generated using a combination of web-based modeling servers, energy
minimization, and the known three-dimensional structures of specific subdomains of Dm
Pur. The crystal structure of the Dm Pur repeat I-II domain served as a template for
Mm Purβ repeat I-II and the crystal structure of the Dm Pur repeat III dimerization
domain served as a template for Mm Purβ repeat III in the modeling program I-TASSER.
Composite models of the intact Pur monomer and homodimer were then derived using
PyMOL alignment and editing features in conjunction with other energy minimization
and alignment optimization programs. Consistent with the earlier model of the Pur
homodimer (22), the updated model includes three distinct subdomains putatively formed
by the intramolecular association of sequences in repeats I and II and the intermolecular
association of two repeat III sequences (Figure 3-2B). However, the new model also
features a more compact linker region between repeats II and III and slightly altered
positions of  helices and  strands in the intermolecular dimerization domain (Figure
S3-1).
Mouse and human Pur are ~94% identical in primary amino acid sequence with the
core region comprising repeats I, II, and III being 99% identical. With the exception of a
longer glycine-rich N-terminus, mouse Pur contains the same common amino acid
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Figure 3- 2. Structural features of Mm Purβ highlighting the location of variant
residues.
(A) A linear schematic of the Mm Purβ protomer highlights three regions of internal
homology known as PUR repeats I, II, and III in blue, red, and green respectively.
Numbers displayed above the diagram represent the amino acids encompassing each
repeat. (B) An updated homology model of the Mm Pur homodimer depicts two
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intramolecular PUR domains composed of repeats I and II (red and blue) and an
intermolecular PUR domain composed of a repeat III dimer (green). (C) Amino acid
positions associated with missense substitutions in human Pur are highlighted in a
cartoon depiction of the Mm Purβ homodimer as follows: L46V (blue), G215S (green),
P223L (purple), F274L (orange), G282S (yellow), and R297Q (red). (D) A representation
of the surface area of the Mm Pur homodimer is shown with the position of variant
residues in the same colors as noted above. In the case of the Q64* nonsense variant, the
predicted truncated product is shown in the insets of panels (C) and (D).
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residues at variant positions identified in the human protein (Figure 3-1). The location of
these amino acids were mapped on the new computational model of Mm Purβ to gain a
better understanding of how substitutions at these positions may impact protein structure
and function (Figure 3-2C and D). The L46V (L34V in human) substitution is in an
unstructured N-terminal region of repeat I just prior to the first  strand. The Q64*
(Q52*) nonsense mutation also resides in repeat I between the second and third  strands
and would produce a small truncated N-terminal peptide (Figure 3-2C and D, inset). All
other missense substitutions are associated with the repeat III segment of the protein.
P223L (P211L) and G215S (G203S) reside in a linker region connecting the subdomains
formed by repeats I-II and repeat III. G282S (G270S) and R297Q (R285Q) are located
within the  helices of the repeat III dimerization domain, while F274L (F262L) is
present in a loop preceding each  helix. Depiction of surface area of the Pur
homodimer implies that all but one of the amino acids involved in missense substitutions,
namely G282S, would likely be solvent exposed (Figure 3-2D). Superimposing the new
homology model of Pur on the x-ray diffraction-derived model of Dm Pur repeats I-II
in complex with ssDNA suggests that most of these variant residues are relatively far
away from residues predicted to mediate interaction with ssDNA (Figure S3-2).

Acta2 Repressor Activity of Purβ Variants
The effect of variant residues on the transcriptional repressor function of Pur was
assessed by evaluating the relative activity of each engineered Pur variant toward an
Acta2 promoter-reporter construct in rodent fibroblast or SMC lines. Mammalian
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expression plasmids encoding NHis-Purβ WT or variant proteins were transiently cotransfected with an Acta2 promoter-luciferase reporter construct into mouse AKR-2B
fibroblasts. The particular promoter-reporter construct used contains a large ~3.6 kb
fragment of the murine Acta2 gene, which includes DNA sequence beginning in the 5’
flanking region and extending through the first intron (−1070 to +2582). Five of the six
Pur missense variants were modestly impaired in their ability to repress the Acta2
promoter in AKR-2B cells, with the exception of the L46V variant, which appeared to be
a slightly more effective repressor than wild-type Pur (Figure 3-3A). Missense variants
G215S, P223L, and R297Q were the most significantly different compared to wild-type
Purβ averaging ~2-fold less activity. These functional differences could not be explained
by a reduction in protein synthesis or stability as Western blotting of whole cell lysates
was consistent with equivalent expression of NHis-Pur WT and each missense variant
(Figure 3-3B). Furthermore, biochemical analysis of the nuclear and cytosolic
distribution of each Pur missense variant expressed in fibroblasts indicated that the
amino acid substitutions had no effect on the ability of the protein to traffic to the nucleus
(Figure S3-3).
The repressor activity of the Pur variants was also evaluated in rat A7r5 SMCs to
determine if the functional effects conferred by the amino acid substitutions was
dependent or independent of cell type. Interestingly, all the missense variants were at
least partially deficient in repressor activity toward the transfected Acta2 promoterreporter construct in A7r5 SMCs (Figure 3-3C). The magnitude of the inhibitory effect
seen with the G215S, P223L, and R297Q substitutions was similar in both cell types.
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Figure 3- 3. The effect of amino acid substitutions on the transcriptional repressor
activity of Purβ.
AKR-2B MEFs (A, B) or A7r5 SMCs (C, D) were transiently co-transfected with
expression vectors encoding NHis-Purβ WT or variants with the indicated single amino
acid substitutions together with an Acta2 promoter-luciferase reporter construct. Cells
were harvested 48 or 72 h later and cell extracts were assayed for luciferase activity, total
protein concentration, and NHis-Pur expression. (A, C) Total protein adjusted luciferase
values from cells transfected with pCI-NHis-Pur plasmids were normalized to baseline
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values from cells transfected with empty pCI vector (defined as 1) and the reciprocal was
taken to obtain fold repression. Data are presented as a bar graph specifying the group
mean and standard error. Asterisks denote statistical differences from Pur WT based on
Dunnett’s multiple comparison test as follows: *, p  0.05; **, p  0.01; ***, p  0.001,
****, p < 0.0001. (A) Bars show the relative activity of Purβ variants expressed in AKR2B MEFs (mean and SEM, n = 12-18). (B) Immunoblot detection of NHis-Purβ WT and
missense variants in AKR-2B cell lysates (top) and GAPDH as a loading control
(bottom). (C) Bars show the relative activity of Purβ variants expressed in A7r5 SMCs
(mean and SEM, n = 9 except for Q64* where n = 6). (D) Immunoblot detection of NHisPurβ WT and missense variants in A7r5 cell lysates (top) and GAPDH as a loading
control (bottom).
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However, the activity of variants G282S, F274L, and L46V was more significantly
impaired in transfected SMCs than in fibroblasts. Once again, these functional
differences could not be accounted for by altered expression of the Pur variants
compared to the wild-type protein based on Western blot analysis (Figure 3-3D). Unlike
the missense variants, the stop-gained variant, Q64*, was completely devoid of Acta2
repressor activity in both cell types (Figure 3-3A and C). This result was expected since
this nonsense mutation would theoretically produce a highly truncated and presumably
nonfunctional polypeptide.

Structural Integrity of Purified Purβ Missense Variants
Pur missense variants P223L and R297Q were selected for further biochemical
analysis because of the distinctive location of the amino acid substitutions and the fact
that each variant showed significantly reduced Acta2 repressor activity in both fibroblasts
and SMCs. His-tagged Pur variants were expressed in E. coli and purified to
homogeneity. Calibrated size exclusion chromatography was employed as the final step
in the purification process for the purpose of removing residual contaminants and to
determine the quaternary structure of the variants. Column fractions were monitored by a
combination of SDS-PAGE to assess protein purity and dye-binding assay to determine
protein concentration. NHis-Purβ WT, P223L and R297Q each eluted from the S200
column at a volume consistent with the homodimeric form of the native protein (Figure
S3-4B-D). SDS-PAGE analysis revealed that protein preparations were virtually free of
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contamination with each purified Pur variant exhibiting an apparent molecular weight
corresponding to the monomeric form of the denatured protein (Figure S3-4E).
The structural stability of each Pur variant was next evaluated by thermal shift assay
in aqueous buffer to assess the degree to which amino acid substitutions impact protein
folding and thermostability. The thermal shift curves generated with the P223L and
R297Q variants were very similar to the wild type protein (Figure 3-4A). The calculated
melting temperatures of R297Q, P223L, and Purβ WT were 57.61 ± 0.89°C, 58.64 ±
0.51°C, and 59.04 ± 1.11°C, respectively (Figure 3-4B). The near identity of the thermal
shift profiles and temperatures of unfolding suggest that the P223L and R297Q variants
are equally thermostable to the wild-type protein and thus share comparable folded states.

Antibody Recognition of Purβ Variants
Affinity-purified rabbit antibodies directed against amino acid sequences 201-229 or
302-324 of mouse Pur were initially screened for their ability to detect each epitope in
the purified Pur variants. NHis-Purβ WT, R297Q, and P223L were each passively
immobilized on the wells of high-binding ELISA plates and primary antibodies
recognizing Purβ epitopes 210-229 or 302-324 were applied at concentrations ranging
from 0.0156 to 1.0 g/mL. Since the Purβ 210-229 epitope contains the 223 residue, the
rabbit anti-Pur 210-229 antibody interacted more weakly with the P223L variant
compared to Purβ WT and R297Q (Figure S3-5). Conversely, the rabbit anti-Purβ 302324 antibody bound to Purβ WT and each variant equivalently on account of the epitope
being independent of site of the mutated P223L and R297Q residues. Based on these
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Figure 3- 4. Evaluation of the thermostability of Purβ variants.
(A) The thermal unfolding of purified NHis-Purβ WT, R297Q, and P223L was monitored
by differential scanning fluorimetry. Solutions of 300 g/mL protein in aqueous buffer
containing SYPRO Orange were heated in 1°C increments per min and changes in
fluorescence were monitored over time. The Boltzmann equation was used to fit the
fluorescence data points and the resulting thermal shift curves for Purβ WT, R297Q, and
P223L are displayed. (B) Additional assays were performed at protein concentrations
ranging from 75 to 300 g/mL. Multiple Tm values for Purβ WT, R297Q, and P223L
were determined from the midpoint of thermal shift curves generated at each protein
concentration. Bars show the average Tm determined for each protein (mean and SD, n =
6-8).
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results, the rabbit-anti-Pur 302-324 antibody was selected for use in all subsequent
solid-phase binding assays used to detect Pur interaction with DNA or with other
proteins.

DNA Binding Properties of Pur Variants
The interaction of Pur R297Q and P223L with DNA was assessed using an ELISA
system in which multiple single-stranded and double-stranded biotinylated
oligonucleotides (Table S3-3) were immobilized on streptavidin-coated microtiter wells
at a fixed concentration of 0.5 nM. The specific DNA sequences initially studied included
the individual purine-rich strands of known Pur recognition elements from the Acta2
promoter (PE32-bF, SPUR32-bF), as well as the complementary pyrimidine-rich strands
(PE32-bR, SPUR32-bR) as negative controls (Figure 3-5A). Each Acta2 cis-element was
also evaluated in dsDNA configuration. Additionally, a purine-rich element from the 5’flanking region of the human MYC gene (PUR24-bF) was utilized as an independent
positive control for Pur-ssDNA interaction (42). Fluid-phase Pur WT and variant
proteins were evaluated at a limiting protein concentration of 1.0 nM in the primary
binding step in the ELISA. Subsequent antibody-based detection of solid-phase
nucleoprotein complexes revealed that the interaction of Purβ P223L and R297Q with
purine-rich ssDNA sequences was indistinguishable from wild-type Pur (Figure 3-5B).
Furthermore, all Pur proteins tested showed little or no binding to dsDNA, pyrimidinerich ssDNA, or wells with no DNA consistent with the preferential interaction of Pur
with purine-rich ssDNA.
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Figure 3- 5. Qualitative assessment of the interaction of Purβ variants with different
DNA sequences.
(A) A schematic of the mouse Acta2 5’-flanking region and first intron is shown
highlighting various cis-elements implicated in gene activation (MCAT, THR, TCE,
CArG) and the location of Pur recognition sequences PE32 and SPUR32. Numbers
denote the 5’ and 3’ ends of each element. CArGi identifies a functional CArG element
located in the first intron between exons 1 and 2 (Ex 1 and Ex 2). (B) The binding of
NHis-Purβ WT, R297Q, and P223L to purine-rich ssDNA (PE32-bF, SPUR32-bF,
PUR24-bF), pyrimidine-rich ssDNA (PE32-bR, SPUR32-bR), or annealed dsDNA
(dsPE32-bR, dsSPUR32-bR) was assessed by ELISA. The concentration of fluid-phase
Pur and solid-phase DNA was fixed at 1.0 nM and 0.5 nM, respectively, in the primary
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binding step of the assay. Solid-phase Pur-DNA complexes were detected using a
primary antibody recognizing a carboxy terminal epitope in Pur. Bars show relative
A405 values normalized to the signal generated by Pur WT in complex with PE32-bF
defined as 1 (mean and SD, n = 4-12).
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The relative binding affinity of Pur P223L and R297Q for purine-rich ssDNA was next
quantitatively determined by generating protein-ssDNA binding curves using the same
ELISA system. To do so, solutions of NHis-Pur protein at concentrations ranging from
9.0 to 0.074 nM were incubated with wells coated with a fixed concentration (0.5 nM) of
PE32-bF. Solid-phase nucleoprotein complexes were then detected by sequential
incubation of wells with primary and secondary antibodies followed by color
development. The resultant binding profiles were essentially superimposable indicating
that the relative binding affinity and stoichiometry of the Purβ variants for PE32-bF
ssDNA were comparable to wild-type Purβ (Figure 3-6 A, B). The apparent Kd
determined for each variant protein based on hyperbolic fits was 0.160  0.012 nM for
P223L and 0.156  0.017 nM for R297Q compared to 0.160  0.012 nM for WT.

Heterotypic Protein Binding Properties of Pur Variants
Purβ has been implicated in modulating Acta2 promoter activity through interaction
with other transcription factors, including the co-repressor protein mouse YB1 (MSY1).
Direct protein-protein interaction assays were performed to determine if Purβ-MSY1
association is impacted by the amino acid substitutions in the Pur variants. Solutions of
fluid-phase NHis-Purβ WT, P223L, and R297Q at differing concentrations were
incubated with microplate wells coated with a fixed concentration of MSY1. Solid-phase
Pur-MSY1 complexes were then detected with the use of the same ELISA system
employed in the DNA binding assay. The raw binding curves generated indicated that
P223L has slightly higher affinity for MSY1 compared to Purβ WT, while R297Q has a
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Figure 3- 6. Quantitative analysis of the interaction of Purβ variants with ssDNA.
The binding of NHis-Purβ WT, R297Q, and P223L to a purine-rich, Acta2-derived,
ssDNA sequence (PE32-bF) and a corresponding mutant (3I5T7) was assessed by
ELISA. The concentration of fluid-phase Pur ranged from 9.0 to 0.074 nM while the
concentration of the solid-phase DNA was fixed at 0.5 nM in the primary binding step of
the assay. Solid-phase Pur-DNA complexes were detected using a primary antibody
recognizing a carboxy terminal epitope in Pur. Each variant was evaluated in
comparison to the wild-type protein in multiple titration trials conducted with PE32-bF
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(mean ± SD, n = 5-18) or 3I5T7 (mean ± SD, n = 3-5). Binding curves were generated by
fitting normalized absorbance values to an equation for a hyperbola (A) or a fourparameter logistic model (B) for the purpose of determining apparent binding constants,
which are noted in the text.
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slightly lower affinity (Figure 3-7A). Binding constants were calculated after correcting
for non-specific binding of Pur to wells coated with BSA alone (Figure 3-7B). The
apparent Kd determined for each variant protein was consistent with P223L having a
higher binding affinity for MSY1 (Kd = 24.84 ± 4.40 nM) than R297Q (Kd = 42.75 ±
5.70) with the wild-type protein showing an intermediate affinity (Kd = 31.4 ± 3.70).
A screening assay for the formation of multiprotein complexes with Pur was also
conducted to determine if other transcription factor interactions were altered by the amino
acid substitutions in the Pur P223L and R297Q variants. Microtiter wells coated with
purified NHis-Purβ WT, P223L, or R297Q were incubated overnight with nuclear extract
prepared from AKR-2B MEFs. Solid-phase nuclear protein-Purβ complexes were then
detected by ELISA using a number of different primary antibodies directed against
transcription factors implicated in Acta2 gene regulation (Table S3-4). The proteinprotein interaction profile generated using AKR-2B nuclear extract was consistent with
the P223L variant having a somewhat stronger affinity for MSY1 compared to R297Q
and wild-type Pur (Figure 3-8A). The interaction of Pur and Sp3 was comparable for
Pur WT, P223L, and R297Q. Interestingly, the formation of protein complexes
containing Smad 2/3 and Smad4 was apparently inhibited in wells coated with the P223L
variant in comparison to Purβ WT or R297Q. However, it is important to note that wells
coated with P223L had higher levels of background binding by the Smad2/3 and Smad4
antibodies than Purβ WT or R297Q coated wells. This screening assay was also
conducted with nuclear extract from HEK293 cells to assess the reproducibility of these
findings with human cell-derived factors. Consistent with the results obtained using
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Figure 3- 7. Quantitative analysis of the interaction of Purβ variants with MSY1.
(A) The binding of NHis-Purβ WT, R297Q, and P223L to MSY1 was assessed by
ELISA. The concentration of fluid-phase Pur ranged from 400 to 3.13 nM. MSY1 was
immobilized on microtiter wells at a fixed concentration of 100 nM. Solid-phase PurβMSY1 complexes were detected using a primary antibody directed against the carboxy
terminal tail of Pur. Each Pur variant was evaluated in comparison to the wild-type
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protein in multiple titration trials. Non-specific binding was measured concurrently by
assessing Purβ binding to wells coated with BSA alone. Binding curves were generated
by fitting data points to the equation for a hyperbola (mean ± SEM, n = 10-16). (B)
Absorbance values obtained in wells coated with BSA only were subtracted from
absorbance values generated in wells coated with MSY1. Binding curves represent
specific Pur-MSY1 interaction. Apparent binding constants are noted in the text.
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MEF-derived nuclear extract, Pur P223L once again showed a higher binding capacity
for human YB1 but was apparently deficient in interaction with Smad4 and Smad2/3
(Figure 3-8B). Purβ WT, R297Q, and P223L were essentially equivalent in binding
human Pur, Sp3, and the retinoblastoma tumor suppressor protein (RB), a factor
previously implicated in the cell-cycle dependent regulation of Acta2 promoter activity
(39). A small but significant decrease in human TEF1 binding by Pur P223L was also
detected in extracts from HEK293 cells.

Discussion
The smooth muscle cell-like myofibroblast plays a critical, albeit transient, functional
role in promoting wound healing following tissue injury. On the other hand, persistent
myofibroblast activation and survival contributes to dysfunctional wound healing and
fibrosis due to excessive ECM accumulation and aberrant tissue constriction (2, 5, 9).
Possible therapeutic strategies to limit destructive tissue fibrosis include the targeting of
molecular regulators that promote sustained connective tissue fibroblast to myofibroblast
differentiation. Some studies have evaluated components of inflammatory response
pathways, but have been met with limited success (19). An alternative approach is to
target the regulatory factors that control Acta2 expression since smooth muscle -actin
contributes to myofibroblast contractility and is the classic marker of the myofibroblast
phenotype (14, 15). The transcriptional repressor protein, Purβ, is of special interest
because of its unique ability to interact with specific ssDNA sequences in the Acta2
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Figure 3- 8. Qualitative analysis of the interaction of Purβ variants with selected
nuclear extract-derived proteins.
(A) The binding of fluid-phase nuclear proteins from AKR-2B MEFs to solid-phase
NHis-Purβ WT, R297Q, and P223L immobilized at 300 nM was assessed by ELISA.
Solid-phase transcription factor-Pur complexes formed after an overnight incubation
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were detected using primary antibodies against MSY1, Pur, Sp3, Smad 4, or Smad 2/3.
Absorbance values were normalized to the Pur WT-MSY1 complex defined as 1.0 and
the data are plotted in a bar graph (mean and SEM, n = 6-12). (B) The binding of fluidphase nuclear proteins from HEK293 cells to solid-phase NHis-Purβ WT, P223L, and
R297Q was assessed by ELISA in the same manner as described above (mean and SEM,
n = 6-12). Asterisks denote statistical differences from Pur WT based on one-way
ANOVA and Dunnett’s multiple comparison test as follows: *, p  0.05; ***, p  0.001,
****, p < 0.0001.
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promoter and with other transcription factors that dictate Acta2 expression in fibroblasts
(17, 20, 21).
A number of recent reports have shed light on the structural features of Purβ that
account for its functional activity as an ssDNA-binding protein and repressor of Acta2
gene expression. Limited tryptic digestion of recombinant Mm Purβ revealed that the
residues 29-302 are necessary for high affinity binding of the protein to a purine-rich
ssDNA sequence from the Acta2 promoter (43). This core region of Pur contains
sequence elements termed Pur repeats I, II, and III that are highly conserved in Pur.
Homology modeling suggested that Mm Pur repeats I and II together fold to form an
intramolecular PUR domain while two repeat IIIs associate to form an intermolecular
PUR domain (22). This original computational analysis was based, in part, on
information gleaned from the x-ray crystal structure of the homologous repeat I-II
domain of Dm Pur (24). Empirical cell-based assays in conjunction with biochemical
analyses demonstrated the necessity of the intermolecular and intramolecular PUR
domains in mediating both the Acta2 repressor and ssDNA binding activities of Pur
(22).
Recently, the x-ray crystal structure of the repeat III intermolecular domain of Dm
Pur was solved revealing a similar, but not identical, structure to the repeat I-II
intramolecular domain (25). With this new structural information in hand, we generated
revised homology models of the Mm Pur intermolecular domain and the intact Pur
homodimer. Like the earlier model, the updated model of the Mm Purβ homodimer
reported herein depicts the protein in an extended conformation with each PUR domain
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as a distinct folded entity. This concept is consistent with hydrodynamic studies
suggesting that the Purβ homodimer adopts an elongated conformation in solution (38).
In addition, the glycine-rich linker region between repeats II and repeat III is slightly
more condensed (by ~5 Å) than in the previous model (22). This linker region, which is
unique to Pur, may allow for some degree of flexibility in the orientation of repeat I-II
intramolecular domains relative to repeat III intermolecular domain particularly in the
DNA-bound state.
The repeat III intermolecular domain plays several essential functional roles in the
Purβ homodimer (22). In addition to mediating protein self-association, the repeat III
intermolecular domain has a higher affinity for purine-rich ssDNA than the repeat I-II
intramolecular domain and accounts for heterotypic binding of Pur to other transcription
factors. A recent report identified several positively charged residues associated with one
of the  strands in each Pur repeat of Pur that contribute to Acta2 repressor function of
the protein (40). Interestingly, mutation of the R267 in the third repeat had the single
most dramatic effect on the interaction of Pur with ssDNA. In light of this finding, the
functional role of other structural elements in repeat III including the  helices and
flexible linker region between repeats II and III seemed to merit further investigation.
A perusal of the NHLBI Exome Sequencing Project Exome Variant Server revealed
13 rare, SNP-associated variants in the human PURB open reading frame of which six
encode missense substitutions and one a premature stop codon (28). Interestingly, five of
the six missense variants are associated with the repeat III domain. Mapping the positions
of the missense residues on our updated homology model revealed that most of the
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variant residues are predicted to reside in either the  helix of repeat III or in the linker
region separating repeats II and III. All but one variant residue is likely to be solvent
accessible. Additionally, the premature stop variant in repeat I would necessarily produce
a highly truncated, and presumably, non-functional peptide. Therefore, we hypothesized
that the missense substitutions and premature stop at these highly conserved positions
may alter the activity of Purβ, and as such, may provide insight into the functional role(s)
of the flexible regions and repeat III  helices. This idea was tested by engineering the
specific amino acid substitutions into the backbone of Mm Pur, which is 99% identical
to human Pur in the core region containing repeats I, II, and III. The effects of these
amino acid substitutions on the structure and function of Pur was then systematically
evaluated using a combination of cellular and biochemical approaches.
The functional activity of each of the engineered variants was initially assessed in
transiently transfected MEFs and SMCs by way of Acta2 promoter-reporter assays in
conjunction with Western blotting. With the exception of the Q64* stop codon variant, all
other missense variants were stably expressed in both cell types, and in the case of MEFs,
were capable of trafficking to the nucleus of the cell. Results of luciferase reporter assays
showed that the premature stop variant construct, Q64*, was completely deficient of
Acta2 repressor activity while four of the six missense variants (G215S, P223L, F274L,
R297Q) were modestly but significantly less active than wild-type Pur in both cell
types. Two other variants, L46V and G282S, exhibited either greater or lesser Acta2
repressor activity depending on the cell type studied. This result suggests that these
particular amino acid substitutions may affect the interaction of Pur with other
180

regulatory factors, which are unique to each cell type. The R297Q and P223L variants
were selected for further biochemical characterization as both missense variants had
significantly reduced Acta2 repressor activity in both MEFs and SMCs. Furthermore,
each substitution results in a substantive change in the physicochemical properties of the
amino acid residue at that particular position.
NHis-Purβ WT, R297Q, and P223L were each expressed in E. coli and purified to
homogeneity under non-denaturing conditions. Calibrated SEC analysis of each variant
indicated that the single amino acid substitutions had no effect on the ability of the
protein to self-associate into a homodimer. Thermal shift assays showed that each variant
was equally thermostable to wild-type Pur suggesting that there were no ill effects of the
R297Q and P223L substitutions on protein folding. Qualitative ELISA-based assessment
of the interaction of purified Pur with DNA targets of differing sequence and secondary
structure indicated that each variant bound preferentially to purine-rich ssDNA sequences
from the Acta2 promoter. Like the wild-type protein, Pur R297Q and P223L
demonstrated little to no interaction with pyrimidine-rich ssDNA or dsDNA. Moreover,
quantitative analysis of Pur-ssDNA complex formation showed that the relative affinity
and specificity of the P223L and R297Q variants for purine-rich ssDNA was the same as
Pur WT. Taken together, these results clearly demonstrate that the R297Q and P223L
substitutions have no effect on the DNA binding properties of Pur. These empirical
findings are consistent with computational modeling indicating that P223 and R297 are
located in regions of the protein that probably do not make direct contact with ssDNA.
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The degree to which the amino acid substitutions affects interaction of Pur with
other Acta2 regulatory proteins was next investigated. In contrast to results of
comparative DNA binding assays, quantitative analysis of the binding of Pur to corepressor partner MSY1 indicated that the P223L and R297Q substitutions altered
protein-protein interaction. While P223L displayed a slightly higher affinity for MSY1,
R297Q exhibited a slightly lower affinity for MSY1 compared to Purβ WT. Interestingly,
previous studies have suggested that structural elements residing in both the repeat I-II
intramolecular domain and the repeat III dimerization domain mediate the interaction of
Pur with MSY1 (22, 40). Hence, a P223L substitution in the linker region may alter the
spatial orientation of inter- and intramolecular domains in a manner which enhances
MSY1 binding affinity. An R297Q substitution in the  helix of repeat III may impact
ionic interactions in a manner that reduces MSY1 binding affinity.
Pur P223L and R297Q were also screened for their ability to interact with several
other transcription factors implicated in Acta2 gene regulation to determine if these
amino acid substitutions impact Pur binding to nuclear extract-derived proteins. AKR2B MEFs and HEK 293 cells were used as a source of mouse and human nuclear
proteins. Consistent with the results obtained with purified MSY1, Pur P223L was more
efficient in binding MSY1/YB1 from nuclear extract of both cell types than Purβ WT and
R297Q. Increased interaction of the P223L variant with MSY1/YB1 may facilitate more
efficient removal of the variant from the nucleus owing to the coordinated transport of
Pur-MSY1/YB1 complexes by Acta2 mRNA (19, 44). In contrast, P223L was defective
in binding to transcription factors regulated by TGF-1 signaling, namely Smad2/3 and
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Smad4. It has been established that Smad4 associates with Smad2 or Smad3 to induce
smooth muscle -actin gene expression in response to TGF-1 signaling (45).
Furthermore, Purβ has been shown to physically associate with protein complexes
containing phosphorylated Smad3 (pSmad3) during the process of myofibroblast
differentiation and to inhibit the interaction of pSmad3 activator with the Acta2 promoter
(20). Although the ELISA format using nuclear extract as a source of protein binding
partners does not allow the ready discrimination of direct vs. indirect interactions, the
apparent inability of Pur P223L to efficiently bind Smad proteins may explain why this
variant is partially deficient in Acta2 repressor activity. While this interpretation is
mechanistically plausible, it will require further experimental validation because of some
technical concerns about the specificity of the commercial Smad antibodies, which had a
higher background signal in P223L-coated wells in the ELISA.
In summary, this study has characterized the functional consequence of rare amino
acid substitutions at conserved positions in Pur based on SNPs identified in human
PURB by the NHLBI Exome Sequencing Project. The location of the modified residues
mapped to regions of the Pur homodimer that are not predicted to be directly involved
in mediating protein-ssDNA interaction. Curiously, while the nonsense variant
predictably resulted in a complete loss-of-function, many of the missense variants
differed modestly but significantly from wild-type Pur in Acta2 repressor activity (~1.5
to 2-fold) and, in some cases, in a cell type-dependent manner. The mechanistic basis for
these functional differences was not attributable to altered expression, subcellular
localization, polypeptide folding/stability, or ssDNA binding properties but appeared to
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be due to subtle changes in Pur variant interaction with other gene regulatory factors. At
the present time, we can only speculate as to whether any of the human PURB SNP
variants are phenotypically significant from the standpoint of fibrosis or any other disease
process. Interestingly, a variety of missense, in-frame deletion, and truncation mutations
in PURA have been linked to profound neurodevelopmental phenotypes (46-48). As for
the potential disease consequence of being a carrier of a PURB nonsense allele, at least
one study has found that hemizygous deletion of PURA or PURB is linked to
myelodysplastic syndrome that progresses to acute myelogenous leukemia (49).
Moreover, our findings with the engineered missense variants do fit with the general
concept that rare variants may contribute to disease susceptibility through small changes
in protein-protein association (50). Finally, our results also suggest that the -helices in
the repeat III dimerization domain and less structured linker regions, participate in
protein-protein interactions that affect the Acta2 repressor activity of Purβ.

184

References
1.

Martin, P. (1997) Wound healing--aiming for perfect skin regeneration. Science
(New York, N.Y.) 276, 75-81

2.

Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., and Brown, R. A. (2002)
Myofibroblasts and mechano-regulation of connective tissue remodelling. Nature
reviews. Molecular cell biology 3, 349-363

3.

Gurtner, G. C., Werner, S., Barrandon, Y., and Longaker, M. T. (2008) Wound
repair and regeneration. Nature 453, 314-321

4.

Desmouliere, A., Redard, M., Darby, I., and Gabbiani, G. (1995) Apoptosis
mediates the decrease in cellularity during the transition between granulation
tissue and scar. The American journal of pathology 146, 56-66

5.

Gabbiani, G. (2003) The myofibroblast in wound healing and fibrocontractive
diseases. The Journal of pathology 200, 500-503

6.

Schurch, W., Seemayer, T. A. & Gabbiani, G. . (1997) Histology for Pathologists
Raven Press, Ltd, New York

7.

Rockey, D. C., Bell, P. D., and Hill, J. A. (2015) Fibrosis--A Common Pathway to
Organ Injury and Failure. The New England journal of medicine 373, 96

8.

Dugina, V., Fontao, L., Chaponnier, C., Vasiliev, J., and Gabbiani, G. (2001)
Focal adhesion features during myofibroblastic differentiation are controlled by
intracellular and extracellular factors. Journal of cell science 114, 3285-3296

9.

Gabbiani, G., Le Lous, M., Bailey, A. J., Bazin, S., and Delaunay, A. (1976)
Collagen and myofibroblasts of granulation tissue. A chemical, ultrastructural and
immunologic study. Virchows Archiv. B, Cell pathology 21, 133-145

10.

Darby, I. A., and Hewitson, T. D. (2007) Fibroblast differentiation in wound
healing and fibrosis. International review of cytology 257, 143-179

11.

Hinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M. L., and
Gabbiani, G. (2007) The myofibroblast: one function, multiple origins. The
American journal of pathology 170, 1807-1816

12.

Hinz, B., Mastrangelo, D., Iselin, C. E., Chaponnier, C., and Gabbiani, G. (2001)
Mechanical tension controls granulation tissue contractile activity and
myofibroblast differentiation. The American journal of pathology 159, 1009-1020
185

13.

Hinz, B. (2007) Formation and function of the myofibroblast during tissue repair.
The Journal of investigative dermatology 127, 526-537

14.

Darby, I., Skalli, O., and Gabbiani, G. (1990) Alpha-smooth muscle actin is
transiently expressed by myofibroblasts during experimental wound healing.
Laboratory investigation; a journal of technical methods and pathology 63, 21-29

15.

Hinz, B., Celetta, G., Tomasek, J. J., Gabbiani, G., and Chaponnier, C. (2001)
Alpha-smooth muscle actin expression upregulates fibroblast contractile activity.
Molecular biology of the cell 12, 2730-2741

16.

Cogan, J. G., Subramanian, S. V., Polikandriotis, J. A., Kelm, R. J., Jr., and
Strauch, A. R. (2002) Vascular smooth muscle alpha-actin gene transcription
during myofibroblast differentiation requires Sp1/3 protein binding proximal to
the MCAT enhancer. The Journal of biological chemistry 277, 36433-36442

17.

Carlini, L. E., Getz, M. J., Strauch, A. R., and Kelm, R. J., Jr. (2002) Cryptic
MCAT enhancer regulation in fibroblasts and smooth muscle cells. Suppression
of TEF-1 mediated activation by the single-stranded DNA-binding proteins, Pur
alpha, Pur beta, and MSY1. The Journal of biological chemistry 277, 8682-8692

18.

Subramanian, S. V., Polikandriotis, J. A., Kelm, R. J., Jr., David, J. J., Orosz, C.
G., and Strauch, A. R. (2004) Induction of vascular smooth muscle alpha-actin
gene transcription in transforming growth factor beta1-activated myofibroblasts
mediated by dynamic interplay between the Pur repressor proteins and Sp1/Smad
coactivators. Molecular biology of the cell 15, 4532-4543

19.

Strauch, A. R., and Hariharan, S. (2013) Dynamic Interplay of Smooth Muscle
alpha-Actin Gene-Regulatory Proteins Reflects the Biological Complexity of
Myofibroblast Differentiation. Biology 2, 555-586

20.

Hariharan, S., Kelm, R. J., Jr., and Strauch, A. R. (2014) The Puralpha/Purbeta
single-strand DNA-binding proteins attenuate smooth-muscle actin gene
transactivation in myofibroblasts. Journal of cellular physiology 229, 1256-1271

21.

Kelm, R. J., Jr., Cogan, J. G., Elder, P. K., Strauch, A. R., and Getz, M. J. (1999)
Molecular interactions between single-stranded DNA-binding proteins associated
with an essential MCAT element in the mouse smooth muscle alpha-actin
promoter. The Journal of biological chemistry 274, 14238-14245

22.

Rumora, A. E., Wang, S. X., Ferris, L. A., Everse, S. J., and Kelm, R. J., Jr.
(2013) Structural basis of multisite single-stranded DNA recognition and ACTA2
repression by purine-rich element binding protein B (Purbeta). Biochemistry 52,
4439-4450
186

23.

Graebsch, A., Roche, S., Kostrewa, D., Soding, J., and Niessing, D. (2010) Of bits
and bugs--on the use of bioinformatics and a bacterial crystal structure to solve a
eukaryotic repeat-protein structure. PloS one 5, e13402

24.

Graebsch, A., Roche, S., and Niessing, D. (2009) X-ray structure of Pur-alpha
reveals a Whirly-like fold and an unusual nucleic-acid binding surface.
Proceedings of the National Academy of Sciences of the United States of America
106, 18521-18526

25.

Weber, J., Bao, H., Hartlmuller, C., Wang, Z., Windhager, A., Janowski, R.,
Madl, T., Jin, P., and Niessing, D. (2016) Structural basis of nucleic-acid
recognition and double-strand unwinding by the essential neuronal protein Puralpha. eLife 5

26.

Knapp, A. M., Ramsey, J. E., Wang, S. X., Godburn, K. E., Strauch, A. R., and
Kelm, R. J., Jr. (2006) Nucleoprotein interactions governing cell type-dependent
repression of the mouse smooth muscle alpha-actin promoter by single-stranded
DNA-binding proteins Pur alpha and Pur beta. The Journal of biological
chemistry 281, 7907-7918

27.

Kelm, R. J., Jr., Wang, S. X., Polikandriotis, J. A., and Strauch, A. R. (2003)
Structure/function analysis of mouse Purbeta, a single-stranded DNA-binding
repressor of vascular smooth muscle alpha-actin gene transcription. The Journal
of biological chemistry 278, 38749-38757

28.

Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP). Seattle,
WA (URL: http://evs.gs.washington.edu/EVS/ ) [date (February, 2018) accessed].

29.

Rice, L. M., and Brunger, A. T. (1994) Torsion angle dynamics: reduced variable
conformational sampling enhances crystallographic structure refinement. Proteins
19, 277-290

30.

Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., GrosseKunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R.
J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Crystallography & NMR
system: A new software suite for macromolecular structure determination. Acta
crystallographica. Section D, Biological crystallography 54, 905-921

31.

Zhang, Y. (2008) I-TASSER server for protein 3D structure prediction. BMC
bioinformatics 9, 40

32.

Roy, A., Kucukural, A., and Zhang, Y. (2010) I-TASSER: a unified platform for
automated protein structure and function prediction. Nature protocols 5, 725-738
187

33.

McGuffin, L. J., Bryson, K., and Jones, D. T. (2000) The PSIPRED protein
structure prediction server. Bioinformatics (Oxford, England) 16, 404-405

34.

Wu, S., and Zhang, Y. (2007) LOMETS: a local meta-threading-server for protein
structure prediction. Nucleic acids research 35, 3375-3382

35.

Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N., and Sternberg, M. J. (2015)
The Phyre2 web portal for protein modeling, prediction and analysis. Nature
protocols 10, 845-858

36.

Schrodinger, L. (2010) The PyMOL Molecular Graphics System, Version 1.3r1.

37.

Kleywegt, G. J. (1996) Use of non-crystallographic symmetry in protein structure
refinement. Acta crystallographica. Section D, Biological crystallography 52,
842-857

38.

Ramsey, J. E., Daugherty, M. A., and Kelm, R. J., Jr. (2007) Hydrodynamic
studies on the quaternary structure of recombinant mouse Purbeta. The Journal of
biological chemistry 282, 1552-1560

39.

Wang, S. X., Elder, P. K., Zheng, Y., Strauch, A. R., and Kelm, R. J., Jr. (2005)
Cell cycle-mediated regulation of smooth muscle alpha-actin gene transcription in
fibroblasts and vascular smooth muscle cells involves multiple adenovirus E1Ainteracting cofactors. The Journal of biological chemistry 280, 6204-6214

40.

Rumora, A. E., Ferris, L. A., Wheeler, T. R., and Kelm, R. J., Jr. (2016)
Electrostatic and Hydrophobic Interactions Mediate Single-Stranded DNA
Recognition and Acta2 Repression by Purine-Rich Element-Binding Protein B.
Biochemistry 55, 2794-2805

41.

Knapp, A. M., Ramsey, J. E., Wang, S. X., Strauch, A. R., and Kelm, R. J., Jr.
(2007) Structure-function analysis of mouse Pur beta II. Conformation altering
mutations disrupt single-stranded DNA and protein interactions crucial to smooth
muscle alpha-actin gene repression. The Journal of biological chemistry 282,
35899-35909

42.

Kelm, R. J., Jr., Lamba, G. S., Levis, J. E., and Holmes, C. E. (2018)
Characterization of purine-rich element binding protein B as a novel biomarker in
acute myelogenous leukemia prognostication. Journal of cellular biochemistry
119, 2073-2083

188

43.

Rumora, A. E., Steere, A. N., Ramsey, J. E., Knapp, A. M., Ballif, B. A., and
Kelm, R. J., Jr. (2010) Isolation and characterization of the core single-stranded
DNA-binding domain of purine-rich element binding protein B (Purbeta).
Biochemical and biophysical research communications 400, 340-345

44.

Kelm, R. J., Jr., Elder, P. K., and Getz, M. J. (1999) The single-stranded DNAbinding proteins, Puralpha, Purbeta, and MSY1 specifically interact with an exon
3-derived mouse vascular smooth muscle alpha-actin messenger RNA sequence.
The Journal of biological chemistry 274, 38268-38275

45.

Derynck, R., and Zhang, Y. E. (2003) Smad-dependent and Smad-independent
pathways in TGF-beta family signalling. Nature 425, 577-584

46.

Hunt, D., Leventer, R. J., Simons, C., Taft, R., Swoboda, K. J., Gawne-Cain, M.,
Magee, A. C., Turnpenny, P. D., and Baralle, D. (2014) Whole exome sequencing
in family trios reveals de novo mutations in PURA as a cause of severe
neurodevelopmental delay and learning disability. Journal of medical genetics 51,
806-813

47.

Lalani, S. R., Zhang, J., Schaaf, C. P., Brown, C. W., Magoulas, P., Tsai, A. C.,
El-Gharbawy, A., Wierenga, K. J., Bartholomew, D., Fong, C. T., BarbaroDieber, T., Kukolich, M. K., Burrage, L. C., Austin, E., Keller, K., Pastore, M.,
Fernandez, F., Lotze, T., Wilfong, A., Purcarin, G., Zhu, W., Craigen, W. J.,
McGuire, M., Jain, M., Cooney, E., Azamian, M., Bainbridge, M. N., Muzny, D.
M., Boerwinkle, E., Person, R. E., Niu, Z., Eng, C. M., Lupski, J. R., Gibbs, R.
A., Beaudet, A. L., Yang, Y., Wang, M. C., and Xia, F. (2014) Mutations in
PURA cause profound neonatal hypotonia, seizures, and encephalopathy in
5q31.3 microdeletion syndrome. American journal of human genetics 95, 579-583

48.

Tanaka, A. J., Bai, R., Cho, M. T., Anyane-Yeboa, K., Ahimaz, P., Wilson, A. L.,
Kendall, F., Hay, B., Moss, T., Nardini, M., Bauer, M., Retterer, K., Juusola, J.,
and Chung, W. K. (2015) De novo mutations in PURA are associated with
hypotonia and developmental delay. Cold Spring Harbor molecular case studies
1, a000356

49.

Lezon-Geyda, K., Najfeld, V., and Johnson, E. M. (2001) Deletions of PURA, at
5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute
myelogenous leukemia. Leukemia 15, 954-962

50.

Bodmer, W., and Bonilla, C. (2008) Common and rare variants in multifactorial
susceptibility to common diseases. Nature genetics 40, 695-701

189

Supporting Information

Structural and Functional Analysis of Single Nucleotide Polymorphic Variants of
Purine-Rich Element Binding Protein B

Lauren A. Ferris1 and Robert J. Kelm, Jr.1, 2*

1

Department of Biochemistry, 2Department of Medicine, Division of Cardiovascular

Medicine University of Vermont, Robert Larner, M. D. College of Medicine, Burlington,
VT 05405

190

Supplemental Methods
Purification of NHis-Pur variants
E. coli JM109 cells transformed with pQE30-NHis-Pur P223L or R297Q plasmids
were grown in 4 liters of lysogeny broth containing 100 g/mL ampicillin or carbenicillin
at 37°C. Expression of the NHis-Purβ variants was induced during log phase growth by the
addition of isopropyl β-D-1-thiogalactopyranoside to a final concentration of 0.1 mM.
Cells were switched to room temperature and cultured for an additional 17 h. Cells were
collected by centrifugation at 6540  g for 16 min at 4°C and cell pellets were stored at 80°C. Cell pellets were thawed on ice and cells were resuspended in lysis buffer composed
of 50 mM NaH2PO4 pH 8.0, 300 mM NaCl, 10 mM imidazole, 10 mM -mercaptoethanol
supplemented with a protease inhibitor cocktail of 0.5 mM PMSF and 1 g/mL each of
aprotinin, pepstatin A, and leupeptin. Lysozyme was added to a final concentration of 1
mg/mL and the mixture was rocked at 4°C for 20 min. Complete lysis of cells was
accomplished by sonication at the maximum setting (Branson Sonifier 150) for three 10
sec bursts with 1 min rest intervals on ice between each sonication. Cellular debris was
removed by centrifugation at 60,000  g for 30 min at 4°C. The cleared lysate was then
brought to 0.7 M NaCl, supplemented with 2.8 units/mL DNase I and 2.0 units/mL RNase
A, and incubated for a 1 h at room temperature. HIS-Select® Nickel Affinity Gel (SigmaAldrich, St. Louis, MO) was added to the lysate and the mixture was gently rocked
overnight at 4°C.
The Nickel Affinity Gel was collected in a small column and washed with lysis buffer
containing 2 M NaCl until an A280 of 0.02 was reached. A 50/50 gradient of lysis buffer
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and elution buffer (lysis buffer plus 500 mM imidazole) was applied to elute the His-tagged
Purβ. Fractions enriched in NHis-Pur were pooled and dialyzed against 20 mM Tris-HCl
pH 7.4, 100 mM NaCl, and 0.5 mM EDTA. Protein was then applied to a 1.5  10 cm
heparin-agarose column, which was subsequently washed and eluted using a 50/50 gradient
of wash buffer (20 mM Tris-HCl pH 7.4, 100 mM NaCl, 0.5 mM EDTA) and elution buffer
(20 mM Tris-HCl pH 7.4, 2 M NaCl, 0.5 mM EDTA). Fractions enriched in NHis-Pur
were pooled and concentrated in preparation for final size exclusion chromatography on a
1.5  120 cm column packed with Sephacryl S200 resin. The column was pre-calibrated
with blue dextran (2000 kDa), bovine serum albumin (66 kDa), ovalbumin (43 kDa),
carbonic anhydrase (29 kDa), cytochrome C (12.4 kDa), and DNP-aspartate to assess the
quaternary structure of the major NHis-Pur peak eluting from the column. Protein elution
from each column was tracked using a combination of A280 readings and Bradford assays
on the fractions collected. Protein purity in individual and pooled fractions was assessed
by denaturing SDS-PAGE in the presence of reducing agent. Gels were calibrated with
molecular weight standards and stained with Coomassie Blue R-250.

Preparation of Nuclear Extracts
Subcellular fractionation was performed using two different buffer systems depending
on the cell type. Confluent monolayers of AKR-2B fibroblasts were initially washed with
phosphate-buffered-saline (PBS) and then trypsinized to detach the adherent cells. Trypsin
was neutralized with McCoy 5A medium contain 5% w/v FBS and the cells were collected
by centrifugation at 453  g for 10 min at 4°C. Cells were washed three times with 10 mL
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of cold PBS. Cells were collected by centrifugation after each wash. The volume of the
final washed cell pellet was approximated and the cells were suspended in a 10 volume
of cytoplasmic extraction buffer composed of 10 mM HEPES pH 8.0, 50 mM NaCl, 0.5 M
sucrose, 1 mM EDTA, 0.5 mM spermidine, 0.15 mM spermine, 0.2% v/v Triton X-100, 7
mM -mercaptoethanol supplemented with protease inhibitors 1 mM PMSF, 0.5 g/mL
each of leupeptin, pepstatin A, and aprotinin. The cell lysate was gently rocked for 15 min
at 4°C and then subjected to centrifugation at 3,220  g for 15 min at 4°C. Nuclei in the
pellet were resuspended with 3.33 volume of nuclear extraction buffer consisting of 10
mM HEPES pH 8.0, 350 mM NaCl, 0.1 mM EDTA, 0.5 mM spermidine, 0.15 mM
spermine, 25% v/v glycerol plus a cocktail of protease inhibitors as described above. The
mixture was vortexed briefly and then subjected to centrifugation at 15,800  g for 20 min
at 4°C. The cleared nuclear extract was removed and a second extraction was performed
as above using nuclear extraction buffer containing 530 mM NaCl. The nuclear extracts
were pooled and stored at −20°C.
Subcellular fractionation of HEK 293FT cells was performed similarly to the process
described above with some minor modifications. Confluent cell monolayers were detached
with trypsin, which was neutralized with DMEM containing 10% w/v FBS. Cells were
collected by centrifugation and washed three times with PBS. Cells were then lysed with a
10 volume of cytoplasmic extraction buffer composed of 10 mM HEPES pH 8.0, 0.25 M
sucrose, 25 mM KCl, 5 mM MgCl2-6H2O, 0.5 mM dithiothreitol, 0.2% v/v Triton X-100,
0.5 mM PMSF and 1 g/mL each of leupeptin, pepstatin A, and aprotinin. Nuclei were
collected by centrifugation and then extracted with 5 volume of nuclear extraction buffer
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containing 10 mM HEPES pH 8.0, 25% v/v glycerol, 25 mM KCl, 5 mM MgCl2-6H2O,
0.5 M NaCl, and 0.5 mM dithiothreitol plus protease inhibitors. Protein concentration in
nuclear extracts prepared from AKR-2B or HEK 293FT cells was determined by Bradford
assay using BSA as a standard.
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Supplemental Tables and Figures
Table S3-1. Primers used for site-directed mutagenesis to generate cDNA constructs
encoding single amino acid variants in mouse Pur.
Red text highlights the mutated codon in the open reading frame.
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Table S3-2. Human PURB SNP variants identified by the NHLBI Grand Opportunity
Exome Sequencing Project.
Selected data columns from the Exome Variant Server are shown including the
distribution of PURB genotypes across sequenced exomes (1). For rare SNPs encoding
missense and premature stop codons, the amino acid change is reported as well as the
PolyPhen2 score, which predicts how amino acid changes may affect protein function.
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Table S3-3. Synthetic oligonucleotides containing 3’ biotin tags were used to
evaluate the DNA binding affinity and specificity of Purβ by solid-phase ELISA.
Oligonucleotides correspond to sequences elements present in the mouse Acta2 promoter
(PE32, SPUR32)(2) or the human c-MYC 5’ flanking region (PUR24 also known as
MF0677)(3). The sequences of each oligonucleotide are written in the 5’ to 3’ direction.
Double-stranded PE32 and SPUR32 probes were created by annealing the complementary
oligonucleotides in which only the reverse or antisense strand was labeled with a 3’ biotin
tag. bR, biotinylated reverse or antisense strand; bF, biotinylated forward or sense strand.
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Table S3-4. Primary antibodies used to detect Purβ-protein complexes by ELISA.
A variety of antibodies were used to screen for proteins that may interact with Purβ directly
or indirectly. The source of each antibody is noted along with the clone designation or
peptide epitope.
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Figure S3- 1. Comparison of the Mm Purβ repeat III dimerization domain in the
past and present model.
(A) Depictions of homology models of the Mm Pur homodimer reported in 2013 (top,
green)(4) and updated in this study (bottom, blue). The earlier 2013 model derived the
structure of the dimerization domain composed of two repeat III sequences based on the
crystal structure of repeats I-II of Dm Pur. The updated model reported herein used the
crystal structure of Dm Pur repeat III as a template. (B, C) A structural alignment of the
past and present models of the Mm Pur repeat III dimerization domain (residues 209-303)
highlights the positional differences of  helices and  strands in the two computational
models (RMSD = 2.84 Å).
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Figure S3- 2. Position of missense variant residues mapped in the Mm Purβ model in
comparison to amino acid residues in Dm Pur that interact with DNA.
(A) A recent crystal structure of Dm Pur repeats I-II (5FGP) revealed the specific amino
acid residues that mediate protein interaction with two individual strands of DNA
(cyan).(5) Residues shown in red interact with strand 1 (cyan). Residues shown in orange
interact with strand 2 (not shown). (B) A structural alignment of 5FGP (pink) to Mm Purβ
repeats I-II residues 125-210 (RMSD = 0.54 Å) highlights the position of residues L46V
(blue), G215S (green), and P223L (purple) in relation to the DNA binding residues in Dm
Pur. (C) A structural alignment of 5FGP to Mm Purβ repeat III residues 209-303 (RMSD
= 1.56 Å) reveals the spatial relationship of variant residues G215S (green), P223L
(purple), F274L (light orange), G282S (yellow), and R297Q (red) to the DNA binding
residues in Dm Pur.
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Figure S3- 3. Subcellular localization of Pur variants expressed in MEFs.
Transiently-transfected AKR-2B cells overexpressing NHis-Pur WT, G215S, P223L,
F274L, or R297Q were harvested and processed for subcellular fractionation to generated
cytosolic and nuclear extracts. Cytosolic or nuclear proteins (100 g loaded per lane) were
resolved by SDS-PAGE on an 8% mini gel and then transferred to a PVDF membrane.
NHis-Purβ was detected via immunoblotting using a primary antibody directed against the
6 His tag present on Pur. The blot was reprobed for GAPDH as a cytoplasmic marker
and a loading control. WT, wild-type. The number on the left indicates the size of the
nearest prestained molecular mass standard in kDa.
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Figure S3- 4. Analysis of NHis-Purβ variants by size exclusion chromatography and
SDS-PAGE.
(A) A 1.5  120 cm column packed with Sephacryl S200 resin was calibrated with a
mixture of molecular weight standards including blue dextran (BLU), bovine serum
albumin (ALB), ovalbumin (OVA), carbonic anhydrase (CARB), cytochrome C (CYT),
and DNP aspartate (DNP). (B-D) Metal chelate affinity-purified preparations of NHis-Pur
WT (B, black circles and line) P223L (C, purple circles and line), and R297Q (D, red circles
and line) were size fractionated on the S200 column. The profile of the calibration
standards is shown in background as gray circles and line. The protein concentration in
each fraction collected off the S200 column was determined by Bradford assay. (E) Peak
fractions containing NHis-Pur were pooled and protein purity was assessed by SDSPAGE on an 8% gel stained with Coomassie Blue. Two different preparations NHis-Pur
WT are shown. The numbers on the left designate the size of the different bands in the
ladder in kDa.
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Figure S3- 5. Screening of antibody reactivity with Purβ variants R297Q and
P223L.
(A, B) Schematics show the location of epitopes of each primary Pur antibody relative
to residues P223 and R297 (abbreviated P and R). Purified NHis-Pur WT, R297Q, and
P223L were immobilized on microtiter wells at 100 nM. Wells were incubated with a
dilution series of rabbit anti-mouse Pur 302-324 antibody (A) or rabbit anti-mouse Pur
210-229 antibody (B). Solid-phase antibody-Pur complexes were detected by ELISA.
Nonspecific binding was accounted for by evaluating primary and secondary antibody
binding to wells coated with BSA alone. Binding isotherms were generated by fitting data
points to a rectangular hyperbola (mean ± SD, n = 6-12).
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Abstract
Myocardin (Myocd) is a potent coactivator of smooth muscle gene expression in
cardiac and smooth muscle cells. For this and other reasons, it has been described as a
master regulator of the differentiated vascular smooth muscle cell state. This activity is
mediated by the binding of Myocd to serum response factor (SRF), a trans-activator
which binds to CArG boxes in the promoter of contractile protein genes. By itself SRF
has limited activation ability, but association with Myocd induces a strong activation
response. Therefore, studies have focused on identifying transcriptional mechanisms that
regulate Myocd-SRF transactivation. In this paper, the effect of purine rich element
binding proteins A and B, Purα and Purβ respectively, on Myocd-SRF activation is
evaluated. Both Purα and Purβ proteins are recognized for their repression of contractile
protein gene expression, which is thought to be primarily driven by high affinity binding
to single-stranded purine-rich DNA. Promoter-reporter assays showed that high
concentrations of Purβ repress Myocd co-activation, an ability that was not shared by
Purα. DNA binding assays demonstrate that Purβ binds to CArG elements with low
affinity suggesting that Purβ repression of the Myocd coactivation is not mediated by
direct binding to DNA encoding CArG elements. Additional evaluation suggests that
Purβ associates with the Myocd-SRF complex in both the presence and absence of DNA.
Furthermore Purβ association does not appear to limit Myocd-SRF association to DNA.
Together, these studies identify Purβ as a repressor of the Myocd-SRF activation and
suggest that repression is mediated through protein-protein interactions.
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Introduction
Cardiovascular disease is the leading cause of death in the United States (1, 2). In
2015, 633,842 deaths were attributed to cardiovascular disease correlating to
approximately 1 in 4 deaths (2). Given both past and present trends, over 130 million
people are projected to have some form of the disease by 2035 (1). While the term
cardiovascular disease encompasses a range of conditions, the primary contributors to
death are associated with atherosclerosis and include coronary heart disease (43.8%) and
stroke (16.8%) (1). In short, atherosclerotic diseases are characterized by an
accumulation of lipid, cells, and cellular debris below the intimal layer of the arterial
wall, which results in the narrowing of the vessel (3). As the plaque grows it can become
unstable and rupture releasing coagulation factors into the lumen. Death occurs when the
resulting clot occludes the vessel and limits blood from supplying neighboring tissue with
oxygen and nutrients (3).
While coagulation in the vasculature precedes death, the primary etiology of the
disease is in the formation and development of the vulnerable plaque. Plaque formation
is marked by dysfunction in the intimal layer of the vessel, in which the endothelium and
extracellular matrix becomes permeable to low density lipoproteins enabling entry and
retention (3, 4). In addition macrophages migrate to the subinitimal space and
phagocytose oxidized low density lipoproteins to form foam cells (3, 4). The lesion
continues to develop as foam cells and other cell-types, lipids, and cell debris accumulate
eventually forming a necrotic core that is covered by a fibrous cap (3, 4). The cap is
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composed of vascular smooth muscle cells (VSMCs) along with extracellular matrix
proteins and thin caps are attributed to instability, rupture, and thrombosis. (3-6).
While the causative factors in plaque development are highly debated several
hypotheses consider the role of phenotypic switching with particular interest in VSMCs
(7). In the physiologic state VSMCs reside in the medial layer of the vessel where they
contract to regulate blood flow and blood pressure (7, 8). In the classical depiction of
phenotypic switching, VSMC lose their quiescent contractile phenotype and become
highly migratory and proliferative. This is accompanied with the downregulation of
contractile proteins including smooth muscle alpha actin, smooth muscle myosin heavy
chain, calponin, and transgelin (5, 8). However, phenotypic switching of VSMCs is not
bimodal and enables VSMCs to obtain a range of phenotypes (9). Indeed, one study
reported that VSMCs contribute to 30% of macrophage-like, 7% of mesenchymal stem
cell-like, and 12% of myofibroblast-like cells in atherosclerotic plaques from mouse
models (10).
Historically, many have believed that the maladaptive contribution of VSMCs is
their role in the formation of the fibrous cap. This was based on findings in animals that
reported that VSMCs migrate from the medial layer of the vessel to the intima where they
contribute to the formation of the cap (5). Another hypothesis also suggests that VSMCs
contribute to the apoptotic cells and cell debris of the necrotic core (5, 11, 12).
Additional reports have expanded the maladaptive role of VSMCs to include cell function
obtained following phenotypic switching of VSMCs. This includes the macrophage-like
phenotype and contribution to foam cells as VSMCs have been shown to take up lipid (5,
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13). As VSMC derived macrophages exhibit reduced phagocytic activity, some have
suggested that these cells are responsible for limited clearance of cell debris in the
growing necrotic core (14). Collectively these studies suggest that the maladaptive role is
likely more complex and extensive than originally believed.
Independent of the VSMC “end point” during phenotypic switching, contractile
proteins of the differentiated state are down-regulated suggesting that phenotypic
switching is induced by changes in transcriptional regulation. The differentiated VSMC
state is directly linked to the activity of a potent co-activator, myocardin (Myocd) (15,
16). In fact, Myocd has been described as the master regulator of the differentiated
VSMC phenotype and is responsible for the upregulation of smooth muscle contractile
genes including the smooth muscle alpha actin gene (Acta2) (15). Myocd interacts with
the transcriptional activator serum response factor (SRF) to induce a transcriptional
response at least 3x that of baseline activity (16). Although Myocd does not directly bind
to DNA, rather Myocd binds to SRF and indirectly associates with degenerate CArG
boxes in the promoter of smooth muscle contractile genes (17).
Given the regulatory activity of Myocd, it is likely that transcriptional repressors
modulate phenotypic switching of VSMCs. In this study, we evaluated the effect of two
repressor proteins, purine rich element binding proteins A and B, Purα and Purβ
respectively, on Myocd cofactor activity. These proteins mediate repression of
contractile proteins through high affinity and specificity binding to single-stranded
purine-rich sequences and through protein-protein interactions (18, 19). Promoterreporter assays were performed using expression vectors encoding Myocd and either
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Purβ or Purα. Suprisingly, Purβ was capable of repressing Myocd coactivation at high
concentrations, while Purα had no effect on repression. Further analysis revealed that
Purβ repression was observed with the promoters of other contractile proteins residing in
smooth muscle and activity was independent of Myocd isoform. Purβ also associates
with Myocd and SRF in nuclear extract both in the presence and absence of CArG boxes
from the Acta2 promoter. Taken together this paper suggests a novel mechanism of Purβ
repression, that appears to be based on protein-protein interactions between Purβ, Myocd,
and SRF.

Experimental Procedures
Subcellular Fractionation
HEK 293FT human embryonic kidney cells were seeded at a density of 2.0 x10 6
cells in a T75 flask in DMEM supplemented with 10% Fetal Bovine Serum, 4 mM Lglutamine, 1% Penicillin/Streptomycin, and 500 μg/mL Geneticin. After incubation at
37°C, 5% CO2 for 72 h, cells were transiently co-transfected with multiple expression
vectors encoding 1 μg of HA-Myocd, 1 μg Myc-SRF, and 10 μg of pCI or NHis-Purβ for
a total of 12 μg of DNA. The transfection reagent jetPRIME® was used at a ratio of 2 μL
reagent: 1 μg DNA as directed by the manufacturer. After approximately 48 h, cells were
washed with phosphate-buffered saline, trypsinized, and quenched with culture media.
Cells were collected by centrifugation at 453 x g for 10 minutes at 4°C and pellets were
gently washed in 10 mLs of PBS three times with centrifugations separating each wash.
The volume of the cell pellet was estimated and cytoplasmic buffer (10 mM Hepes, pH
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8.0, 50 mM NaCl, 0.5 M sucrose, 1 mM EDTA, 0.5 mM spermidine, 0.15 mM spermine,
0.2% (v/v) Triton X-100, 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.5 μg/mL
leupeptin, pepstatin A, aprotinin, 7 mM β-mercaptoethanol) was added at 10x the volume
of the pellet. After rocking for 15 min at 4°C, lysates were collected by centrifugation at
3,220 x g for 10 min at 4°C. The nuclear pellet volume was estimated and Nuclear
Buffer 1 (10 mM Hepes, pH 8.0, 350 mM NaCl, 0.1 mM EDTA, 0.5 mM spermidine,
0.15 mM spermine, 25% (v/v) glycerol, 1 mM PMSF, 0.5 μg/mL leupeptin, pepstatin A,
aprotinin, 7 mM β-mercaptoethanol) was added at 3.33 times the volume of the pellet.
Mixtures were vortexed 3 times for 10 seconds and then nuclei were collected by
centrifugation at 15,800 x g for 20 min at 4°C. A second nuclear extraction was
performed using Nuclear Buffer 2 (10 mM Hepes, pH 8.0, 530 mM NaCl, 0.1 mM
EDTA, 0.5 mM spermidine, 0.15 mM spermine, 25% (v/v) glycerol, 1 mM PMSF, 0.5
μg/mL leupeptin, pepstatin A, aprotinin, 7 mM β-mercaptoethanol) in the same manner.
Total protein in cytoplasmic and nuclear fractions was quantified by Bradford assay using
BSA as a standard and lysates were stored at -20°C.

Promoter- Reporter Assays
AKR-2B mouse embryonic fibroblast cells were seeded at 4 x 104 cells in
McCoys 5A medium supplemented with 5% Fetal Bovine Serum in six well plates. After
a 24 h incubation at 37°C, 5% CO2, cells were transiently transfected with 2 μg of DNA
using JetPEI at a ratio of 2 μL reagent: 1 μg DNA. Transfected DNA included 1μg of
reporter DNA consisting of 0.9 μg VSMP8 promoter-luciferase reporter, 0.1 μg pSV40-
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βgal and 1 μg of expression DNA containing 0.1 μg Myocd, 0.5 μg Purβ, and pCI.
Following a 48 h incubation, cells were harvested with 1x Reporter Lysis Buffer
supplemented with protease inhibitors. Total protein in cleared lysates was quantified
using Bradford assays and reporter activity was measured using luciferase assays. Data
was analyzed using a one-way analysis of variance and Dunnett’s multiple comparison
test with Prism 7.01. Gel samples were made using total soluble protein at a
concentration of 30 μg, which was precipitated using 5x the volume of ice cold ethanol.
Following a 1 h incubation at -20°C, protein was collected by centrifugation and
resuspended as described below.

DNA Pulldown Assays
To evaluate the binding of transcription factors to CArG boxes, pulldown assays
were performed using either short or long DNA probes listed in the Supplemental
Information. Initial binding reactions were composed of 100 pmoles DNA probe and
200-300 μg nuclear extract from HEK 293FT cells transfected with combinations of
Myocd, SRF, pCI or Purβ, in 10 mM Hepes, pH 8.0, 50 mM NaCl, 0.5 mM EDTA, 0.5
mM DTT, 0.5 μg/mL poly dI/dC. Streptavidin Magnesphere® paramagnetic particles
(Promega) sufficient for binding 100 pmoles of DNA were washed twice with 600 μL of
7.5 mM Sodium Citrate, pH 7.0, 75 mM NaCl, once with 600 μL of 20 mM Hepes, pH
8.0, 150 mM NaCl and once with 200 μL of 10 mM Hepes, pH 8.0, 75 mM NaCl. After
protein-DNA mixtures were incubated for 1 h rocking at room temperature, washed
streptavidin paramagnetic particles were added to the mixture for 30 min, rocking at
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room temperature. Beads were collected using a magnetic bead stand and were washed
three times with 20 mM Hepes, pH 8.0, 300 mM NaCl. To elute bound protein, 2x SDSPAGE loading buffer (40 mM Tris-HCl (pH 6.8), 1% (w/v) SDS, 10% (v/v) glycerol,
0.01% (w/v) bromophenol blue) was added to the beads, followed by a 10 min incubation
at 65°C. Beads were collected and 5% (v/v) β-mercaptoethanol was added to the
supernatant prior to boiling at 95°C for 5 min.

Immmunoprecipitation Assays
To assess protein-protein interactions, immunoprecipitations were performed.
Primary antibody listed in the Supplemental Information was added to 200-400 μg of
nuclear extract from HEK cells transfected with combinations of Myocd, SRF, pCI, and
Purβ and brought to 20 mM Tris, pH 7.5, 50 mM NaCl for a final volume of 500 μL.
Protein A/G magnetic beads (Pierce) were washed 3x with 20 mM Trizma base, pH 7.5,
150 mM NaCl. After initial binding reaction incubated overnight rocking at 4°C, 25 μL
of washed A/G magnetic beads were added to each reaction for 1 hour at room
temperature. Beads were collected using a magnetic stand and washed three times with
20 mM Tris, pH 7.5, 150 mM NaCl. To elute protein from the beads 15 μL of 2x SDSPAGE loading buffer (40 mM Tris-HCl (pH 6.8), 1% (w/v) SDS, 10% (v/v) glycerol,
0.01% (w/v) bromophenol blue) and 5% (v/v) β-mercaptoethanol was added and gel
samples were heated at 95°C for 5 min. Samples were analyzed using immunoblotting
techniques as described below. CleanBlot IP Detection HRP (Thermoscientific) was

213

added to the blots after primary antibody application to minimize background signal from
denatured IgG bands.

DNA binding ELISA
The binding of purified Purβ to CArG boxes was evaluated using a DNA binding
ELISA as previously described (20). Purified Purβ at a concentration of 1 nM was
applied to Streptawells coated with biotinylated DNA described in the Supplemental
Information at varying concentrations from 0.082 nM to 60 nM in binding buffer (20 mM
Hepes, 150 mM NaCl, 1.5 mM MgCl2, pH 7.5, 0.05% (v/v) Tween-20, 0.2% (w/v) BSA,
0.5 mM dithiothreitol (DTT), 1 μg/mL dT-32 oligonucleotide) for about 16 h at room
temperature. A primary rabbit polyclonal antibody against mouse amino acids 302-324
was applied to wells at 1 μg/mL in 20 mM Hepes, 150 mM NaCl, 1.5 mM MgCl2, pH
7.5, 0.05% (v/v) Tween-20, 0.2% (w/v) BSA, and was followed by an incubation with
secondary goat anti-rabbit antibody at a 1:4000 dilution. Protein-DNA complexes were
detected after the addition of 2,2’-azino-bis(3-ethylbenziazoline-6-sulfonic acid) (ABTS)
and reactions were quenched with 1% (w/v) sodium dodecyl sulfate. After a 5 minute
stabilization period, absorbances were measured at 405 nm using a Vmax plate reader
(Molecular Devices).

Immunoblotting
Gel samples were diluted in SDS-PAGE loading buffer to a final concentration of
20 mM Tris-HCl (pH 6.8), 0.5% (w/v) SDS, 5% (v/v) glycerol, 0.005% (w/v)
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bromophenol blue, and 5% (v/v) β-mercaptoethanol and heated for 4-5 min at 100°C.
Samples were run on 8% (w/v) acrylamide/bis(acrylamide) (29:1) SDS-PAGE mini-gel
and electrotransfered to Immobilon-P polyvinylidene difluoride membrane (Millipore) at
125 V for 90 min in 25 mM Trizma base, 192 mM glycine, and 20% (v/v) methanol.
After an overnight incubation in 5% non-fat dry milk, 20 mM Trizma base, pH 7.5, 150
mM NaCl, 0.1% (v/v) Tween-20, blots were probed with primary and secondary
antibodies listed in the Supplemental Information. Protein complexes were detected using
chemiluminescent detection (Pierce ECL Western Blotting Substrate, Thermo Scientific).

Results
Effect of Purα and Purβ Overexpression on Myocd Coactivation of Acta2
To determine whether Purα and Purβ have a functional effect on Myocd
coactivation, expression vectors encoding each protein were transiently co-transfected
with reporter vectors containing full-length (VSMP8) and minimal length (VSMP4)
promoters of Acta2 upstream a luciferase reporter in AKR-2B mouse embryonic
fibroblast cells. Control experiments showed that cells transfected with an expression
vector encoding either Purα or Purβ had limited reporter activity when compared to cells
transfected with reporter vectors only (Figure 4-1A). As expected, Myocardin expression
induced potent co-activation of the Acta2 promoter. The addition of Purα had virtually
no effect on Myocd coactivation of either promoter-reporter. However, co-expression of
Myocd and Purβ resulted in over 2 fold repression of both promoters of Acta2.
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Subsequent Western blot analysis confirmed the stable expression of both Purα and Purβ
in AKR2B cell extract (Figure 4-1A, inset).
To evaluate whether Pur protein repression of Myocd coactivation was
concentration dependent, VSMP8 promoter-luciferase reporter assays were performed
using constant concentrations of Myocd vector and titrating the amount of the vector
encoding Pur protein. As shown in Figure 1B, Purα and Purβ shared similar activity at
concentrations ≤100 ng, both appearing to minimally enhance Myocd coactivation of
Acta2. However, at concentrations exceeding 100 ng, Purβ strongly repressed Myocd
coactivation, while Purα appeared to have no repressor activity. Western blot analysis
confirmed that each of the proteins was stably expressed in each experimental condition.
(Figure 4-1B, inset).
To confirm that the differences in Purβ and Purα activity were not the result of
dissimilar trafficking to the nucleus, subcellular fractionation was performed using
HEK293 cells that were transiently transfected with combinations of vectors encoding
HA-Myocd, Myc-SRF, His-Purα and His-Purβ. Western blot analysis revealed that HAMyocd, Myc-SRF, and His-tagged Pur proteins were comparably expressed in the
nucleus (Figure S4-1). GAPDH was used as a loading control, as expression is typically
confined to the cytoplasm, except for in cells undergoing apoptosis.

Functional Characterization of Purβ Repression of Myocd Coactivation
The preceding experiments have focused on evaluating Purβ repression of Myocd
V4 and V5. However, there are five tissue-specific isoforms of Myocd that result from
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Figure 4- 1. Pur Protein Repressor Activity with Myocd Coactivation of the Acta2
Promoter.
(A) AKR2B mouse embryonic fibroblast cells were transiently cotransfected with
combinations of expression vectors encoding NHis-Purα, NHis-Purβ, HA-Myocd V5,
and a control vector pCI, as well as a reporter vector containing either the full-length
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(VSMP8) or truncated (VSMP4) forms of the Acta2 promoter upstream of a luciferase
reporter gene. Following 48 hour incubation, cells were harvested and lysates were
evaluated for reporter activity and adjusted based on protein concentration. Western blot
analysis confirmed Purβ and Purα expression using an antibody against the His-tag.
Blots were re-probed with GAPDH antibody as a loading control. (inset) (B) AKR2B
cells were transfected with a fixed concentration of VSMP8-Luciferase reporter and HAMyocd V4. Vectors encoding Purα and Purβ were transfected at varying amounts from
50-500 ng. After a 48 hour incubation, cells were harvested and lysates were measured
for reporter activity and adjusted based on protein concentration. Data is reported as fold
induction by Myocd. Cell lysate was analyzed using Western blotting in which His-Pur
proteins and HA-Myocd were detected using antibodies against the respective protein tag.
(inset)
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alternative splicing (21, 22). To determine whether Purβ repression is specific to Myocd
V4 and V5, VSMP8 promoter-luciferase reporter assays were performed in fibroblast
cells transiently co-transfected with expression vectors encoding Purβ and each isoform
of Myocd (V1, V2, V3, V4, V5). As anticipated each isoform induced the activity of
VSMP8 (Figure 4-2A). Importantly, Purβ was able to repress the activity of each Myocd
isoform with greatest effect in isoforms Myocd V4 and V5.
Myocd activates various contractile proteins and has been described as the master
regulator of smooth muscle gene expression (15). Therefore, to evaluate whether Purβ is
capable of repressing Myocd coactivation of contractile protein genes, cell-based assays
were performed. Smooth muscle contractile protein promoters upstream of a luciferase
reporter were cotransfected with expression vectors encoding Myocd V5 and Purβ in
AoSMCs. Myocardin expression induced transcriptional activity in the promoters of
smooth muscle contractile genes; smooth muscle myosin heavy chain (SM-MHC),
smooth muscle alpha acitn (SMAA), calponin (SM-CALP), and transgelin (SM22a)
(Figure 4-2B). Similarly, Purβ co-expression with Myocd diminished transcriptional
activity at each of the promoters, with repression most notable in the SMAA gene
promoter and MHC gene promoter.

Direct binding of Purβ to CArG boxes
A common feature in the promoters of smooth muscle contractile protein genes is
the presence of multiple degenerate CArG boxes. To determine if direct binding of Purβ
to CArG boxes may mediate Purβ repression, DNA binding assays were performed.
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Figure 4- 2. Functional Characterization of Purβ Repression of Myocd Coactivation.
(A) AKR-2B cells were transiently transfected with VSMP8 promoter – luciferase
reporter and expression vectors encoding His-Purβ and the five isoforms of Myocd (V1,
V2, V3, V4, V5). After 48 hours, cells were harvested and lysate was analyzed for
luciferase activity. Luciferase activity was adjusted based on protein concentration in
lysates. (B) Primary smooth muscle cells were transiently transfected with reporter
vectors containing the promoter of various smooth muscle contractile proteins; smooth
muscle myosin heavy chain (SM-MHC), smooth muscle alpha actin (SMAA), smooth
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muscle calponin (SM CALP), transgelin (SM22a), and an empty vector pGL3. After
cotransfecting with Purβ and Myocd containing vectors, cells were incubated for 48
hours and were harvested and analyzed as previously described.
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DNA probes included single-stranded and double-stranded CArG2 from Acta2, PE-32 - a
single-stranded purine-rich sequence from Acta2 involved in high affinity binding to
Purβ, and PE-32 3I5T7 - a mutated version of PE-32 in which purines were substituted
with thymidylate. Biotinylated DNA probes were immobilized on strepravidin coated
wells at concentrations ranging from 0.082 to 60 nM (Figure 4-3A). Purified Purβ was
applied to wells and nucleoprotein complexes were immunodetected to generate binding
profiles (Figure 4-3A, B). The relative binding affinity of Purβ for the reverse singlestranded CArG2 probe (Kd = 4.982 ± 0.7113 nM) was 5.6 fold lower than Purβ binding to
ssPE32 (Kd = 0.8832 ± 0.1636 nM) and equivalent to the non-specific control PE-32
3I5T7 (Kd = 5.042 ± 0.8819 nM). The relative binding of Purβ to the forward singlestranded and double-stranded CArG2 probes was more than 24 fold lower than Purβ
binding to PE-32(Kd = 25.94 ± 4.866 nM, Kd = 21.97 ± 2.579 nM, respectively).
Collectively these experiments suggest that Purβ binds to CArG2 with low affinity
suggesting that repression is mediated by other mechanisms.

Effect of Purβ Overexpression on Myocd-SRF association with CArG boxes from
Acta2
To investigate whether Purβ influences Myocd-SRF association with CArG
boxes, DNA pulldown assays were performed using nuclear extract from HEK cells
transiently transfected with HA-Myocd and Myc-SRF and biotinylated double-stranded
(ds) CArG2 DNA (Figure 4-4A). Control experiments of nuclear lysate and streptavidincoated beads were performed to evaluate nonspecific binding of nuclear protein to the
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Figure 4- 3. Purβ binding to single and double-stranded CArG2 from the Acta2
promoter.
(A) The Acta2 promoter contains multiple CArG boxes and the CArG2 box is important
for transcriptional activity. Another key sequence in the Acta2 promoter is PE-32 which
surrounds the MCAT cis-element is PE-32 and has three purine rich regions to which
Purβ binds with high affinity. (B) DNA binding ELISAs were used to evaluate the
binding of purified Purβ to varying concentrations of immobilized DNA probes (PE-32,
CArG2, or PE-32 3I5T7-a mutated version of PE32 in which purine rich stretches were
mutated to thymidylate). Protein-DNA complexes were immunodetected with an
antibody against Purβ 302-324 and read at A405. A rectangular hyperbola (B) was used
to fit the data or a sigmoidal 4-parameter curve (C).
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Figure 4- 4. Effect of Purβ on Myocd-SRF association to CArG boxes.
(A) DNA Pulldown Assays were performed using biotinylated dsCArG2 probes. (B)
Probes incubated with nuclear lysate from HEK293 cells containing transiently
transfected HA-Myocd and Myc-SRF and purified His-Purβ. Control lanes contained
nuclear extract and streptavidin coated beads, but no DNA. (C) Subsequent DNA
pulldowns utilized a long probe containing multiple CArG boxes as well as other ciselements. (D) DNA pulldown assays were performed using nuclear lysate in which all
three proteins had been transiently transfected. Numbers indicate the migration and
weight (kDa) of the molecular weight ladder.
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beads (Figure 4-4B). With the inclusion of dsCArG2 probes extending 30 bp, Myocd and
SRF associate with the DNA. The addition of purified Purβ protein failed to disrupt
Myocd-SRF association with dsCArG2 DNA, rather Purβ associated with the
nucleoprotein complex. Similar results were obtained when nuclear lysate from HEK293
cells transfected with HA-Myocd, Myc-SRF, and His-Purβ was incubated with the
dsCArG2 probes (Figure S4-2), though background binding to A/G magnetic beads was a
problem in both experiments.
To determine whether multiple CArG boxes effect protein binding to DNA, a
longer probe containing three CArG boxes and a well-reported binding site of Purβ
proximal to the MCAT cis- element was used in DNA pulldown assays (Figure 4-4C).
Similar to previous pulldown assays, nuclear HA-Myocd and Myc-SRF bound to the long
probes (Figure 4-4D). When Purβ was transfected into cells, all three proteins associated
with the DNA having no noticeable effect on either Myocd or SRF binding. Experiments
containing lysate but no DNA, revealed that there was no nonspecific binding of proteins
to streptavidin coated beads.

Purβ binding to nuclear Myocd and SRF
To evaluate whether Purβ binds to the Myocd-SRF complex in the absence of
DNA, immunoprecipitations were performed using nuclear extract from HEK cells that
were transiently transfected with HA-Myocd, Myc-SRF, and His-Purβ. Using an antiHA antibody, HA-Myocd, Myc-SRF, and His-Purβ co-precipitated (Figure 4-5A).
Similarly, Myc-tag immunoprecipitations, precipitated HA-Myocd, Myc-SRF, and His-
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Figure 4- 5. The effect of Purβ on Myocd-SRF complex formation.
(A) Immunoprecipitations were performed using nuclear lysate containing HA-Myocd,
Myc-SRF, and His-Purβ and antibody against the HA-tag. Following overnight
incubation at 4°C, A/G beads were added for 1 hour. After washing the beads, proteins
were eluted and proteins were later detected using Western blot analysis. To control for
nonspecific binding some reactions were composed of nuclear lysate and A/G beads with
no antibody. (B) Immunoprecipitations were also performed using an antibody against
the Myc-tag.
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Purβ (Figure 4-5B). To control for non-specific binding, both experiments included
reactions with A/G beads, nuclear lysate, and no antibody.
As previous studies have indicated that Purβ associates with SRF (23), additional
immunoprecipitation assays were performed to determine if Purβ association with the
Myocd-SRF complex is mediated by binding to SRF. Nuclear lysate from HEK 293 cells
transiently transfected with Myc-SRF and His-Purβ, revealed that both proteins, coprecipitate using an antibody against the Myc-tag (Figure 4-6A). To evaluate whether an
interaction between Purβ and Myocd may exist, immunoprecipitations were performed
using nuclear lysate in which HA-Myocd and His-Purβ were overexpressed. Antibody
with an epitope against the His-tag showed that HA-Myocd and His-Purβ co-precipitate
(Figure 4-6B). Similarly immunoprecipitation with an antibody against the HA-tag,
precipitated the Myocd-Purβ complex (Figure 4-6C). Collectively, these experiments
suggest that a direct interaction may exist between Myocd-Purβ and Purβ-SRF.

Effect of Specific Subdomains and Amino Acids in Purβ on Repression of Myocd
Coactivation
Previous experiments have shown that the inter- and intra-molecular domains of
Purβ are both necessary for full repression of the Acta2 promoter. To assess whether
each domain is important in the repression of the Myocd cofactor activity, transient
transfections were performed in a similar manner using three additional Purβ constructs
encoding a functional core region of the protein containing three regions of internal
homology termed repeats (Purβ I-II-III), the intramolecular domain of Purβ (Purβ I-II)
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Figure 4- 6. Purβ association with excess Myocd or SRF.
(A) Immunopreciptions were performed as previously described using nuclear extract
from HEK 293 cells containing Myc-SRF and His-Purβ. Complexes were
immunoprecipitated with an anti-Myc antibody. (B) Similarly immunoprecipitations with
extract containing His-Purβ and HA-Myocd were performed with antibodies against the
His-tag or (C) HA-tag. Control conditions contained nuclear extract and A/G beads but
no antibody.
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and the intermolecular domain of Purβ (Purβ III). Purβ I-II-III was comparable to full
length Purβ in repressor activity suggesting that Purβ subdomains contribute to the
repression of Myocd-SRF coactivation. (Figure 4-7A). Accordingly, Purβ I-II was
mildly impaired compared to both the full length and core proteins, demonstrating that
Purβ I-II is involved in repression and suggesting that Purβ III contributes to Purβ
repression of the Myocd cofactor activity. Previous study has shown that the
intermolecular domain fails to localize to the nucleus, therefore it is no surprise that
transfection with the intermolecular domain of Purβ had no effect. Western blot analysis
confirmed the stable expression of Myocd and Purβ constructs (Figure 4-7B). To
evaluate Purβ III contribution to Purβ repression of Myocd coactivation, previously
characterized mutants and variants primarily localized to Purβ III were evaluated in the
promoter-reporter system. This included variants originally identified by the National
Heart Lung and Blood Institute Exome Sequencing Project. Interestingly all but one of
the variants seemed impaired in repressor activity compared to Purβ (Figure 4-8A).
Mutants were originally selected on the basis of positive charge and positional
conservation. An evaluation of the mutants ability to repress Myocd cofactor activity
revealed that mutation of an arginine (R267A) in the third repeat was the most impaired
followed by a triple mutant containing additional positionally conserved mutations in
repeats I and II. Interestingly, a double mutant containing mutations to the third repeat
and the second repeat resulted in an enhancement of Myocd coactivation(Figure 4-8C).
Western blot analysis was used to confirm the stable expression of each variant and
mutant (Figure 4-8B, D).
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Figure 4- 7. Purβ Subdomain Repression of Myocd Coactivation.
(A) Promoter-reporter assays were performed using VSMP4 promoter-luciferase
reporters or VSMP8 promoter-luciferase reporters and expression vectors encoding HAMyocd and truncated forms of His-Purβ; the functional core (I-II-III), an intramolecular
domain (I-II) and an intermolecular domain (III). (B) To ensure that proteins were stably
expressed, Western blot analysis was performed on soluble lysate, using antibodies
against the HA-tag for Myocd expression, the His-tag for Purβ expression, and GAPDH
as a loading control. Numbers are indicative of the molecular weight of standards in
kDa.
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Figure 4- 8. Evaluation of the Role of Specific Residues in Purβ on the Repression
of Myocd coactivation.
(A)

Previously characterized variants of Purβ were analyzed in the context of Myocd

coactivation. Expression vectors containing His-Purβ variants and HA-Myocd along
with reporter vector VSMP8-Luc were transiently cotransfected into AKR2B cells. After
48 hours, cells were harvested and lysates were analyzed for luciferase activity. Activity
levels were adjusted based on total protein concentration in lysates and normalized to
Myocd and Purβ using feature scaling. (Mean ± SEM, n= 6-15). (B) Similarly promoterreporter assays were performed using previously-characterized single, double, and triple
mutants of Purβ. (Mean ± SEM, n= 3-15) (C, D) Purβ protein in cell lysate was detected
through Western blot analysis with an antibody against the His-tag. Antibodies against
GAPDH served as a loading control.
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Discussion
Myocd is a potent coactivator of smooth muscle contractile genes and has been
described as a master regulator of differentiated VSMCs. The mechanistic basis of this
activity is in the formation of Myocd-SRF complexes at degenerate CArG boxes in the
promoters of smooth muscle contractile protein genes. As individual transcription
factors, SRF is a weak activator of CArG boxes and Myocd is thought to be unable to
bind to DNA, yet in combination transcription far exceeds baseline activity (16). In the
promoter-reporter assays reported here overexpression of Myocd in combination with
endogenous SRF, results in transcription almost 5x greater than baseline. This finding
corresponds with studies in the literature that report a high level of transcriptional activity
with Myocd and SRF expression. To date a variety of mechanisms for this interaction
have been suggested and each account for indirect interaction between Myocd and the
degenerate CArG boxes unique to SM contractile protein genes (24, 25).
In this study 2 members of the purine-rich element binding protein family are
characterized in respect to Myocd-SRF activity. These proteins, namely Purα and Purβ,
have been well-characterized in the context of Acta2 for their repressor activity, which is
attributed to Purα/β high affinity binding to purine-rich DNA and protein-protein
interactions (18, 19). Studies from this paper, show that at low concentrations both
proteins may slightly enhance promoter activity, but at higher concentrations only Purβ is
capable of repressing Myocd activation. While Purα and Purβ are 71% identical and
share similar affinity for purine rich DNA, this discrepancy is not entirely surprising as
both loss of function and gain of function studies have shown that Purβ is the dominant
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repressor (19). Subcellular fractionation experiments suggest that both Purα and Purβ
localize to the nucleus suggesting that differences in repressor ability are directly related
to differences in function. An alignment of the Purα and Purβ suggests that Purβ has
longer flexible regions linking functional domains of the protein, which may suggest that
structural limitations in Purα prevents protein interactions from occurring and prevents
repression of Myocd. Another hypothesis that cannot be entirely dismissed is that Myocd
influences Purα expression levels through an indirect mechanism.
Purβ repression of Myocd coactivation at high concentrations, mirrors the
dynamic regulatory processes that control Acta2 expression. In addition to potent
expression at high concentrations Purβ repressor activity is widespread in nature,
effecting each isoform of Myocd, although repression is most notable in smooth muscle
cell isoforms. As additional experiments have shown that Purβ represses Myocd
coactivation of other contractile protein promoters, it may suggest that at high
concentrations Purβ acts as a master repressor of the expression of smooth muscle
contractile genes.
To identify the mechanism of repression, Purβ binding to DNA and other proteins
was analyzed. DNA bindings assays showed that Purβ had low relative affinity for the
independent single-stranded and double stranded (ds) CArG2 element. In fact binding to
CArG2 was less than or equal to the PE-32 3I5T7 DNA probe, in which purine stretches
from PE-32 were mutated to thymines for low affinity binding of Purβ. This suggests
that Purβ repression of the Myocd cofactor activity is not mediated by direct binding to
CArG elements. Interestingly, DNA pulldown assays show that Purβ associates with
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Myocd, SRF, and CArG2. Furthermore, Purβ binding does not limit Myocd and SRF
association to CArG2. This may suggest that complex formation mediates a
conformational change in protein structure of the Myocd or SRF, changes DNA
conformation, or blocks association and binding of other proteins necessary for
transcription. Experiments using the long probe, may suggest that Purβ is capable of
binding to purine-rich regions upstream of CArG elements and repressing activation by
interacting with DNA bound Myocd-SRF complexes, though additional experiments are
needed to confirm this theory.
One may suggest that gene repression is mediated by Purβ sequesteration of
Myocd or SRF. However, this does not appear likely as binding of Myocd and SRF to
the DNA is not effected by Purβ protein presence. This is somewhat suprising as other
studies have identified multiple proteins that regulate Myocd-SRF activation through
sequesteration of SRF effectively preventing the formation of Myocd and SRF
complexes. These proteins include ACTR5 (26), FOXO4 (27), HMGXB1 (28), JUN (29),
KLF15 (30), RELA (31), RUNX2 (32), SOX9, TDG, TSHZ3, YAP1 (33). Although
other proteins repress Myocd coactivation through alternative mechanisms. IRF8 and
IRF9 displaced p300 from binding and thereby limit Myocd activity (16). Additionally,
another protein GSK3B mediates repression through the phosphorylation of Myocd (16).
To determine whether Purβ repression is linked with protein-protein interactions,
immunoprecipitations were performed using nuclear lysate containing HA-Myocd, MycSRF, and His-Purβ. This revealed that all three proteins form a complex in the absence
of excess DNA. Further evaluation showed that Purβ associates with SRF in the absence
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of Myocd, an expected finding as Purβ-SRF interactions are well-reported in the
literature (34). Similarly, overexpression of Purβ and Myocd also results in complex
formation, though additional studies are needed to confirm whether this interaction is
direct or if another protein mediates association. Collectively, these experiments suggest
that Purβ is capable of binding to the Myocd-SRF complex and suggests that Purβ may
bind to the individual proteins Myocd and SRF.
After assessing truncated forms of Purβ, it appears that each subdomain
contributes to repression of the Myocd cofactor activity. Previously characterized
variants and mutants primarily localized to the dimerization domain were used to identify
amino acids involved in repression. Previous studies have shown that Purβ variants
P223L and R297Q are deficient in their repression of the Acta2 promoter. Biochemical
characterization revealed that these variant proteins were comparable to the wild type
Purβ in protein structure and DNA binding and suggested that both variant residues
effected Purβ ability to bind to other proteins. As these variant proteins are also impaired
in their ability to repress Myocd-SRF coactivation, it supports the idea that Purβ
repression of Myocd-SRF coactivation is mediated by protein-protein interactions.
Additionally, a mutant R267A, and triple mutant (K82A, R159A, R267A) were impaired
in their ability to repress the Myocd coactivation. Previously, these proteins were
reported to be impaired in their ability to bind to purine-rich DNA and also were altered
in their ability to bind to a corepressor, MSY1. These experiments also support the idea
that repression is mediated through protein interactions, but they do not eliminate the
hypothesis that Purβ protein could be binding upstream from CArG elements at purine-
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rich sites and also binding to proteins bound to CArG boxes to mediate repression (Figure
4-9).
Collectively, this study reports that the purine-rich element binding protein family
has 2 members with differential repressor activity towards potent Myocd coactivation.
Overexpression of Purβ, facilitates the repression of all isoforms of Myocd, especially
smooth muscle specific isoforms. Furthermore, Purβ repression of multiple smooth
muscle contractile gene promoters in the presence of Myocd, suggests that Purβ may be a
master repressor of smooth muscle contractile protein expression. This repression does
not appear to be mediated by direct competitive interaction between Purβ and DNA, nor
through sequesteration mechanism as shown by DNA pulldown assays. Instead, given
Purβ association with the Myocd-SRF complex, repression appears to be primarily driven
through a protein-protein based mechanism.
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Figure 4- 9. A hypothetical mechanism by which Purβ represses Myocd cofactor
activity.
Purβ may mediate repression of Myocd cofactor activity by binding to purine-rich DNA
upstream of CArG boxes and binding to Myocd and SRF.
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Supplemental Tables and Figures
Table S4- 1. Primary and secondary antibodies used to detect Purβ-protein
complexes.
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Table S4- 2. Synthethic DNA Probes Used in Binding Assays and DNA Pulldown
Assays.
DNA Probes are oriented in the 5’ to 3’ direction and each probe is biotinylated at the 3’
end.
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Figure S4- 1. Subcellular localization of HA-Myocd, Myc-SRF, and His-Pur
proteins.
HEK293 cells were transiently cotransfected with expression vectors encoding NHisPurα, NHis-Purβ, HA-Myocd, and Myc-SRF. Following 48 hour incubation, cells were
harvested using a buffer-based subcellular fractionation protocol. Cytoplasmic and
nuclear extract at concentrations of 100 μg were run on 8% SDS-PAGE gels for Western
blot analysis. Antibodies against the HA, Myc, and His-tag were used to detect HAMyocd, Myc-SRF, and His-Purβ respectively. GAPDH was used as a marker of
cytosolic fractions. Numbers depict the migration of molecular weight standards and
report their weigh in kDa.
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Figure S4- 2. Effect of HEK 293FT-derived Purβ on Myocd and SRF binding to
DNA.
(A) DNA Pulldown assays were performed using CArG2 boxes and nuclear extract from
cells transfected with HA-Myocd, Myc-SRF, and His-Purβ. Briefly, following 45 minute
incubation of Nuclear Extract and DNA, streptavidin coated magnetic particles were
added for 30 minutes. Complexes were washed and protein was eluted with the addition
of SDS-PAGE loading buffer and an incubation at 60°C. Elutions were run on an 8%
SDS-PAGE gel and transferred to PVDF. Proteins were detected using antibodies
against the given tag.
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CHAPTER FIVE: SUMMARY AND FUTURE DIRECTIONS
A previous study has shown that the third repeat of Purβ is essential for repression
of smooth muscle alpha actin gene (Acta2) expression and has demonstrated that Purβ
repeat III binds to purine-rich regions in proximity to the MCAT cis-element with higher
affinity than repeats I-II (1). In this dissertation, we show that the binding of both fulllength Purβ and Purβ repeat III to purine-rich DNA is mediated by ionic and hydrophobic
interactions. Accordingly, mutation of three positively-charged and positionallyconserved amino acids in full-length Purβ impaired Purβ repression of Acta2 expression
and Purβ ability to bind to DNA. Analysis of each of the individual mutations revealed
that an arginine mutation in Purβ repeat III had the greatest effect on Purβ repressor
activity. Similarly, Purβ variants identified by the NHLBI Grand Opportunity Exome
Sequencing Project (GO-ESP) primarily reside in Purβ repeat III and are impaired in their
ability to repress Acta2 expression (2). Further evaluation of two of the variants in Purβ
repeat III suggested that diminished repression is the result of changes in Purβ binding
affinity for other nuclear proteins. Lastly, experiments in this dissertation suggest that
Purβ mediates the repression of Myocd cofactor activity primarily through proteinprotein interactions and suggests that the third repeat contributes to Purβ repression.
Collectively, these studies demonstrate that Purβ III is involved in full-length Purβ
repression of Acta2 expression through both protein-DNA and protein-protein
interactions.
To elucidate the specific molecular mechanism by which Purβ represses Acta2
expression, studies have focused on identifying structural features of Purβ. In the
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absence of a crystal structure alternative techniques have been used and have identified
1°, 2°, 3°, and 4° structural features. Most notably, these findings include the shape of
the protein, the functional core protein, and the subdomains of Purβ. In combination with
crystal structures of Purα, web-based homology modeling servers have generated
hypothetical structural models. The recent crystal structure of Purα repeat III has enabled
a revised homology model of Purβ (3). The revised model uses the crystal structure of
Purα repeat III as a template for Purβ repeat III and the dimerization of the two
monomers. This is opposed to the previous model which used repeats I-II as a template
for both repeat III and the dimerization domain. As the crystal structures of the Purα
intermolecular domain and intramolecular domain both form a PUR domain, there are
only slight changes in the revised model, namely deviations in beta strands and alpha
helices. Comparison of the model dimensions to those reported by Ramsey et al.
revealed that the shape of purified Purβ is much longer and the “height” is substantially
smaller than the model dimensions (4). This difference may be due to programming
features in the modeling server, which appear to preferentially group residues together,
presumably trying to minimize contact of hydrophobic residues in the protein with water.
This feature may be impacting both the linking region and flexible termini regions. In this
regard, an extended conformation may be observed in the model with the unfolding of a
flexible glycine-rich linking region that connects the intra- and inter-molecular
subdomains. Additionally, discrepancies in the “height” of the protein may be the result
of subdomain “breathing,” or may be reflective of differences in structure of Purα and
Purβ PUR subdomains.
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While these models are of use in generating hypothesis-driven aims, it must be
remembered that they are only models, not actual structures. Predicted secondary
structure and the formation of classical PUR domains has not been confirmed in Purβ.
Given the functional differences between Purα and Purβ, there is a possibility that the
structure may not be identical to Purα. Acta2 promoter reporter studies in fibroblasts and
VSMCs have shown that Purβ is the dominant repressor protein in both loss-of-function
and gain-of-function studies (5). Additionally, biochemical analysis has shown that Purβ
has the ability to displace and limit the binding of other proteins to the Acta2 promoter
(6). However, Purα functions as a strong destabilizer of dsDNA, an activity that is only
partially shared with Purβ (7). Studies evaluating the PUR subdomains, have reported
that Purα repeat III has virtually no DNA binding affinity compared to Purα repeats I-II
while Purβ repeat III has higher DNA binding affinity than Purβ repeats I-II (1, 8).
Given these differences in function, it would be advantageous to the field to determine if
there are differences in Purβ PUR domain structure compared to Purα. Crystallization
studies may provide insight as to whether these functional differences are due to
differences in PUR domain conformation, differences in the length of loop and linking
regions, differences in primary sequence structure, or a combination of these factors. As
recent studies have solved a crystal structure of Purα repeats I-II with DNA, similar
conditions may also stabilize and facilitate crystallization of Purβ subdomains (3).
However, given that previous attempts in crystallization have been problematic, studies
using small angle x-ray scattering may also provide additional structural information in
regards to protein shape. This should be feasible as early studies of Purα structure used
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small angle x-ray scattering to delineate the shape of the intramolecular domain and fulllength protein (8).
In this dissertation we report on the repressor activity of 7 variants identified by
the NHLBI GO-ESP (2). Functional analysis revealed that 5 of the 6 missense variants
affected Purβ repression of Acta2 expression in fibroblast cells, and each of the variants
were impaired in repressor activity in VSMC. Given these results, one may question
whether these variants also affect the transcription of other contractile protein genes.
Studies have shown that Purβ is capable of repressing the expression of smooth muscle
myosin heavy chain, smooth muscle transgelin, and smooth muscle calponin gene
promoters, therefore an investigation of variant Purβ repression of these promoters may
provide insight into the biological significance of these variants. Regardless, the clinical
phenotype of these individuals is of interest, especially in regards to the premature stop
variant Q64*. Functional analysis shows that this variant is essentially non-functional
and Western blot analysis suggests that this protein is not stably expressed. Therefore
Q64* would induce a hemizygous-like Purβ state, similar to genotypes observed in some
forms of cancer (9). As heterozygous patients with single point mutations of Purα have
clinical manifestations, evaluation of the other variants may also be of interest (10). If
symptoms are observed it may provide insight to the biological role of Purβ in humans,
though additional study would be needed to confirm this.
Similarly, other approaches that delineate the biological role of Purβ would
benefit the field. In addition to analysis in animal models, chromatin
immunoprecipitation assays would be helpful in identifying Purβ binding sites and
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indicating which genes are regulated by endogenous Purβ expression. Furthermore, ChIP
assays performed in several cell types under varying conditions may provide a more
extensive profile of Purβ binding in the cell. Previous studies have shown that Purβ
associates with bases +58 to -322 in the Acta2 promoter during growth arrest of mouse
embryonic fibroblast cells (11). Additional studies would also evaluate Purβ binding to
the promoter of multiple contractile protein genes in fibroblasts and vascular smooth
muscle cells. Both fibroblasts and VSMCs are of particular interest, given the
hypothetical role of Purβ in both fibrosis and atherosclerosis.
Additional experiments with the purified variant proteins may help to further
delineate the molecular mechanism by which Purβ represses the expression of Acta2.
Obtaining specific purified protein and antibodies would enable thorough evaluation of
Purβ variant-protein interaction as binding profiles could be generated using ELISAs.
Previous cell-lysate-Purβ variant assays have suggested that P223L is deficient in binding
Smad 2/3, 4. However, background signal was high making conclusions tentative. A
binding assay using purified protein would confirm or negate these findings. Another
limitation of the cell lysate- Purβ variant assay is the low detection of complexes due to
low concentrations of transcription factors and weak antibody detection. As a result
subtle binding differences between Purβ WT and variants may not be detected, but may
be detected in an ELISA format using purified protein. Among such factors are Sp3,
TEF1, SRF, and Myocd. Previous attempts to immunoprecipitate variant-transcription
factors were unsuccessful due to both low protein concentration and weak antibody
recognition, therefore antibodies with higher affinity for a given transcription factor may
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detect and immunoprecipitate protein complexes. Alternative explanations for impaired
repression of Acta2 by Purβ variants include failure to displace activators from DNA and
impaired destabilization of dsDNA, both of which would be best addressed with purified
protein.
Similarly, purified Myocd and SRF would enable additional characterization of
Purβ-protein interactions. It may not be possible to evaluate purified Myocd as it is an
intrinsically unstable protein. However purified versions of truncated Myocd and
Myocd-related-factors have been reported and would also be of use. Specifically,
binding ELISAs between Myocd and Purβ would reveal whether a direct interaction
exists between both proteins. An ELISA with SRF and Purβ would also provide a means
to compare binding affinities of Purβ to each of the proteins. Purified protein would also
enable the lab to test whether Purβ interaction with Myocd and SRF is mediated by the
binding of a fourth protein. These experiments could be performed with PUR
subdomains, variants, and mutants to further characterize Myocd-SRF-Purβ complex
formation.
Additional DNA pulldown assays may elucidate the role of Purβ bound to
Myocd-SRF. Probes containing CArGB-CArGA of the Acta2 promoter, should recruit
more SRF to CArG sites and stabilize Myocd binding, providing a stronger signal. As
there are no purine-rich regions in this sequence, Purβ binding would hypothetically be
mediated by interaction with Myocd-SRF. Comparison of the long probe to the long
probe with mutations at PE-32 would demonstrate whether Purβ is able to bind to purine-
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rich DNA and Myocd-SRF complexes. Control experiments in which CArG boxes are
mutated should also be performed to confirm the absence of Myocd-SRF-Purβ binding.
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